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Introduction: Lupus nephritis (LN) is one of the most serious and significant chronic 
complications of juvenile-onset systemic lupus erythematosus (JSLE) affecting up to 
80% of patients. The renal glomerulus is severely affected in LN leading to chronic 
inflammation and glomerulonephritis (GN). GN can affect all parts of glomeruli, 
including the glomerular endothelial cells (GEnCs), which together with podocytes and 
their shared glomerular basement membrane (GBM), form the glomerular filtration 
barrier (GFB).  
Aims: It was hypothesised that human GEnCs are not just passive bystanders but are 
actively involved in the perpetuation of renal inflammation in LN. Thus, the main aim 
of this project was to elucidate the pro-inflammatory involvement of human GEnCs in 
LN, utilising in vitro models of conditionally immortalised human GEnCs (ciGEnCs).  
Materials and Methods: The ciGEnCs were treated with cytokines known to be 
involved in LN pathogenesis (TNF-α, IL-1β, IFN-α, IFN-γ, IL-6, IL-13, VEGF) and 
LPS. Subsequently, ciGEnC expression, secretion and production of various pro-
inflammatory proteins were tested via real-time PCR, ELISA and flow cytometry. 
Activation of the pathways involved were investigated via Western blotting and 
immunofluorescence. To assess the role of the renal microenvironment, ciGEnCs were 
treated with JSLE (active/inactive LN) and paediatric healthy control sera and with 
conditioned media from cytokine-/LPS-stimulated mesangial cells, podocytes, human 
neutrophils, macrophages and THP-1 cells; mRNA expression and protein secretion of 
pro-fibrotic and pro-inflammatory genes/proteins was tested. The effect of the novel 
urinary LN biomarkers (AGP, CP, TF, L-PGDS, MCP-1, NGAL) on ciGEnC pro-
inflammatory gene expression and ciGEnC viability was tested, following treatments 
with each biomarker alone, or all in combination. 
Results: The ciGEnCs were found to significantly upregulate (p ≤ 0.05) the production 
of most pro-inflammatory proteins tested including cytokines, chemokines and cell 
adhesion molecules (CAMs) following cytokine stimulation confirming a role for 
GEnCs in perpetuating the inflammatory response. The cytokines found to have a 
robust effect on ciGEnC activation (p ≤ 0.05) were TNF-α, IL-1β, and IFN-γ (IL-13 
was only able to significantly induce surface VCAM-1 and sVCAM-1 production), 
therefore these three cytokines were further assessed in terms of pro-inflammatory 
transcription factor activation. TNF-α and IL-1β induce their effects through NF-κB 
activation; while IFN-γ acts via STAT-1 activation. The JSLE sera exerted a moderate 
to low effect compared to cytokines but were able to upregulate the expression of 
certain pro-fibrotic and pro-inflammatory genes. THP-1 cell conditioned media induced 
significant changes in ciGEnC pro-inflammatory proteins secretion suggesting 
macrophage involvement in the pathogenesis of LN. The novel urinary biomarkers 
were not found to affect ciGEnC pro-inflammatory activation and ciGEnC viability. 
Conclusion: This study identified the human GEnCs as important pro-inflammatory 
players in LN-associated renal disease. The GEnCs can actively respond to pro-
inflammatory stimuli and are involved in immune cell activation and recruitment 
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1. Chapter 1: Introduction 
1.1. Renal physiology and function. 
The kidneys are two bean-shaped organs, approximately the size of a human fist, 
located in the upper abdominal area, with a fundamental role in the maintenance of pH 
and whole-body fluid homeostasis1. They are also essential for the control of blood 
pressure, osmotic regulation, maintenance of electrolyte and acid-base balance, bone 
mineralisation, vitamin D synthesis, production of hormones such as calcitriol and 
erythropoietin, and enzymes such as renin1. 
In adults, each kidney is approximately 10.9 to 11.2 cm long2 -the size of a human 
fist- with the left kidney being larger that the right kidney. In an observational study of 
437 children aged between 0 and <13 years, the size of each kidney was assessed via 
sonography and each kidney was found to be approximately 5.3 to 8.5 cm long (with 
the left kidney again being larger than the right kidney)3. These findings also agree with 
other studies, worldwide4. In study of 947 children aged between 6 and 17 years, the 
size of each kidney was assessed via sonography and was found to be between 7.15 to 
8.77 cm for the right kidney, and between 7.33 to 9 cm for the left kidney5.  
One of the most important homeostatic functions of the kidneys is blood filtration 
which leads to excretion of the body’s metabolic waste products into the urine. Each 
adult human kidney is able to generate on average 1-2 liters of urine every day1. 
Compared to adults, children produce smaller volumes of urine per day and the amount 
of urine produced depends on age. In adults, the normal urine output (that is often used 
to assess renal function and it is age-dependent) is approximately 0.5 ml/kg/hour, 
whereas in newborns and infants up to 1 year it is 2 ml/kg/hour, in toddlers it is 1.5 
ml/kg/hour and in older children and adolescents it is approximately 1 ml/kg/hour6. 
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Urine filtration and concentration occur within the nephrons, the structural and 
functional renal units1. There are approximately 1x106 nephrons in each kidney; each 
nephron consists of a glomerulus where initial blood plasma filtration takes place and 
a reabsorption tubular system (made up of the proximal convoluted tubule, the loop of 
Henle and the distal convoluted tubule) for urine concentration leading finally to a 
collecting duct which leads to the ureter1 (Figure 1.1). 
 
Figure 1.1  Nephron structure. 
Each nephron, part of which is located in the renal pyramid (medulla) and part of which is 
located in the renal cortex, consists of a glomerulus (found in the renal cortex) and a series of 
connected tubules starting from the proximal convoluted tubule (attached to the glomerulus) 
and continuing to the U-shaped Loop of Henle and the distal convoluted tubule which empties 
the urine into the collecting duct.  
 
The glomeruli are highly vascularised, tortuous tuft-like structures formed by 
parietal epithelial cells (PECs) consisting of a network of capillaries into which blood 
enters and exits via the afferent and efferent arterioles respectively. Each capillary is 
lined with glomerular endothelial cells (GEnCs) on its luminal side and with a 
specialised type of epithelial cells with interdigitating foot processes, the podocytes, 
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covering its exterior surface7. The GEnCs and podocytes contribute to a common 
extracellular matrix (ECM), known as the glomerular basement membrane (GBM)7. 
The mesangial cells (MCs) are found central to the capillaries forming a stalk-like 
structure, the mesangium. MCs contribute to the GBM by producing ECM, they provide 
structural support to the glomerular microvasculature and are responsible for the 
regulation of the blood flow through the capillaries (Figure 1.2).  
 
Figure 1.2 The glomerulus.  
The glomerulus is a tuft-like structure formed by parietal epithelial cells (PECs), which are the 
constituents of the Bowman’s capsule. Inside the Bowman’s capsule are enclosed the 
glomerular capillaries. Blood enters and exits the glomeruli via an afferent and an efferent 
arteriole, respectively. 
 
The GEnCs, the podocytes, and the GBM between them constitute the tri-layered 
glomerular filtration barrier (GFB). This is a biological semi-permeable sieve that 
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functions as a whole unit and selectively filters blood in order to generate the primary 
urinary filtrate. GEnCs are fenestrated and, together with the podocytes that 
interdigitate to form slit diaphragm junctions between neighboring foot processes, these 
form a physical barrier that permits only molecules of appropriate size/charge to cross 
the barrier1. The GBM and the GEnC glycocalyx (layer of glycoproteins surrounding 
the cells) form a highly negatively charged barrier that permits only positively charged 
molecules to pass through the sieve. Therefore, under physiological conditions the GFB 
permits only the passage of water and other small molecules (e.g. glucose, urea, amino 
acids and mineral ions) to the Bowman’s capsule, whereas red blood cells 
(erythrocytes) and proteins (e.g. albumin) remain restricted inside the lumen and return 
to the circulation8,9 (Figure 1.3).  
 
Figure 1.3 The renal glomerular capillary.  
Each capillary consists of GEnCs lining the luminal side and podocytes covering its outer 
surface. These two cell types together with their common basement membrane form the GFB. 
The MCs provide structural support and regulate the blood flow.  
 
The glomerular capillary tuft is enclosed by PECs forming the Bowman’s capsule. 
The blood enters the glomerulus via an afferent arteriole, and it gets filtered through 
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the GFB. Subsequently, the proteins and erythrocytes return to the circulation through 
an efferent arteriole (Figure 1.2). At the same time, the primary urinary filtrate 
composed mainly of water and small solutes, collects inside the Bowman’s capsule and 
passes through the continuous renal epithelial tubular compartment starting from the 
proximal tubules, the U-shaped loop of Henle and the distal tubules to finally reach the 
collecting duct1 (Figure 1.1).  
The majority of substances necessary for the normal function of the human body 
(e.g. water, electrolytes, amino acids and glucose) which are initially filtered through 
the glomerulus are reabsorbed by the renal tubules into the interstitial space and 
eventually back into the blood1. Waste products such as hydrogen, creatinine, ions and 
some drugs are secreted into the collecting duct where they form the urine which is 
excreted out of the body through the ureter. Both the reabsorption and excretion 
processes occur through a number of ion and water channels as well as transporters 
expressed by the renal tubules and collecting ducts, therefore both processes can either 
be active or passive1. 
 GEnCs and their contribution to the GFB. 
The GEnCs are characterised by the presence of transcellular pores or fenestrations 
of 60–80 nm in diameter occupying 30–40% of the cell surface, which allow for 
efficient and rapid filtration of large amounts of water across the endothelium 10,11. The 
fenestrations are not just empty holes but are covered with a polyanionic gel-like fibrous 
mesh consisting of glycoproteins, proteoglycans (which consist of core proteins 
covalently bound to negatively charged heparan or chondroitin sulphate) and sialic 
acids anchored on the luminal side of the GEnC membrane12,13. Furthermore, blood 
plasma components such as hyaluronan, albumin, lumican and α-1-acid glycoprotein 
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(or orosomucoid 1; ORM1) are adsorbed into the glycocalyx13. The glycocalyx layer in 
combination with the adsorbed plasma components make a thicker filamentous coat 
(200nm) with strong negative charge which lines the luminal side of the glomerular 
endothelial microvasculature, known as the endothelial surface layer (ESL)8,13. The 
ESL is responsible for formation of the negative charge of the GFB that is important 
for limiting the passage of negatively charged solutes into the urine.  
As the GEnCs are found in the blood plasma-renal tissue interface, they are the 
first GFB component to block passage towards the Bowman’s capsule1.  The ability of 
the glomerular endothelium to provide a first-line barrier inside the glomerulus was 
first demonstrated in 1976 by immunolabelling of albumin to track its location within 
glomeruli under physiological conditions14. This showed that during normal filtration 
and regular blood flow, albumin does not pass freely through the fenestrated glomerular 
endothelium but remains restricted inside the lumen. Furthermore, albumin density 
notably decreased at the endothelium compared to the capillary lumen, a finding that 
provided evidence for the pivotal role of GEnCs in albumin sequestration. 
In vitro studies using conditionally immortalised human GEnCs (ciGEnCs) which 
have a 200nm glycocalyx,15  as well as ex vivo and in vivo studies using cooled isolated 
perfused murine kidneys16 and mice17,18 respectively, have since provided evidence for 
the important role of ESL in albumin handling. Enzymatic removal of certain 
glycocalyx and ESL constituents such as heparan sulphate removal by heparinase in 
ciGEnCs15 led to increased albumin permeation through the ciGEnC monolayers19. In 
addition, heparan sulphate removal by heparinase or hyaluronan removal by 
hyaluronidase in murine kidneys16–18,20  led to higher albumin excretion ex vivo due to 
significant reduction of ESL anionic sites and thickness16,20. Moreover, this led to 
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higher urine protein excretion levels and albumin translocation to the podocyte space 
in vivo due to loss of glycocalyx volume 17,18. Furthermore, in patients with type 1 
diabetes mellitus, a decrease in the size of systemic endothelial glycocalyx volume has 
been correlated with increased levels of urinary protein excretion21.  
These data together suggest a pivotal ESL role in GFB albumin handling and 
sequestration inside the lumen and highlights the importance of normal glomerular 
endothelium function in the prevention of proteinuria.  
 Glomerular cell crosstalk  
The formation and establishment of a fully functional GFB largely depends on the 
proper development of resident renal cells, as well as on the maintenance of the 
physiological crosstalk among them.  
During the development of the glomerular vasculature, growing podocytes secrete 
Vascular Endothelial Growth Factor (VEGF) A (VEGFA). VEGFA has trophic and 
chemoattractant properties that promote the migration of endothelial precursor cells 
(angioblasts) which express on their surface the VEGFA cognate receptors, namely 
VEGFR1, VEGFR2 and neuropilin-122 to the area to begin angiogenesis. Furthermore, 
the podocytes and MCs secrete angiopoietin-1 (Ang-1) whereas the GEnCs express its 
respective receptor, Tie223,24. Ang-1 is an endogenous endothelial growth factor that 
promotes glycocalyx synthesis as well as ESL thickening in the systemic endothelium, 
enhancing its barrier properties and leading to reduced albumin permeability24,25 . 
In addition, the GEnCs produce platelet-derived growth factor subunit B (PDGF-
B) and MCs express its receptor PDGFR-β26–28. The interaction of PDGF-B with 
PDGFR-β is necessary for MC proliferation and the development of the glomerulus29. 
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Finally, the development of an in vitro conditionally immortalised GEnC-podocyte co-
culture model has provided evidence that the GEnCs have the ability to modulate the 
podocyte barrier properties through the induction of Kruppel-like factor 2 as a response 




Figure 1.4 Schematic representation of glomerular cell interactions.  
Glomerular cell crosstalk is achieved via several modes of interaction. The podocytes secrete VEGFA which can bind its cognate receptors VEGFR1, VEGFR2 
and neuropilin-1, expressed by the GEnCs. Fluid laminar flow shear stress induces the production of the Kruppel-like factor 2 by the GEnCs that can modulate 
the podocyte barrier functions. Furthermore, the GEnCs can secrete PDGF-B that binds onto the MCs-expressed PDGFR-β and is involved in MC proliferation. 
Finally, both the podocytes and MCs secrete Ang-1 which, via binding to Tie2 expressed by the GEnCs, modulates the endothelium’s barrier properties. 
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1.2. Systemic Lupus Erythematosus: A multifactorial autoimmune disease 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with 
multiple clinical and immunological characteristics. A UK retrospective study from 
1999 to 2012 was conducted using the Clinical Practice Research Datalink (CPRD), 
which provided evidence with regards to the incidence and prevalence of adult SLE32. 
This study demonstrated that SLE incidence (new cases every year) declined annually 
and was reported to be 4.91/100,00032. In contrast, SLE prevalence (number of cases in 
any given year) increased, perhaps because of improved disease management leading 
to significantly increased SLE patient survival, from 64.99/100 000 in 1999 to 
97.04/100 000 in 2012, with women being predominantly affected32. SLE develops as 
a result of the combination of several confounding factors such as genetics, hormones 
and environmental factors. SLE pathogenesis involves aspects of both the innate and 
adaptive immune system33–40. SLE is the archetypal systemic autoimmune disease, 
characterised by multi-organ involvement, including the skin, blood, brain, lungs and 
kidneys41,42. A number of candidate genes, among them those encoding early 
components of the classical complement pathway such as C1q and C443, as well as 
genes involved in regulation of the interferon-alpha (IFN-α) pathway44,45, have been 
defined as contributors to the onset of SLE. However, candidate genes themselves are 
not enough to initiate the disease alone. Furthermore, certain ethnic groups such as 
individuals of Black African or Asian heritage have a greater risk of developing SLE46, 
potentially due to shared gene variations. Environmental agents such as a viral 
encounter, exposure to ultraviolet rays and certain medications (including IFN-α used 
for treatment of viral infections) can trigger the disease in a susceptible individual47. 
The complex interaction among the above-mentioned factors can lead to a variety of 
innate and adaptive immune responses. Some of the most important immunological 
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features of SLE include: increased production of anti-nuclear and anti-DNA 
autoantibodies by autoreactive B cells (the hallmark of SLE)35, increased expression of 
type I IFN signature genes37,38  and increased production of pro-inflammatory 
cytokines. Furthermore, increased neutrophil apoptosis and NETosis (NET: neutrophil 
extracellular trap) which, in combination with the imperfect phagocytosis observed in 
SLE, result in prolonged autoantigen exposure and breakdown of tolerance33,34,39. 
 Comparison between adult- and juvenile-onset SLE. 
SLE occurs less frequently in children compared to adults and data from different 
populations worldwide indicate that the incidence of juvenile-onset SLE (JSLE) is 
between 0.36–0.9 per 100,000 children per year32,48–51. Approximately 15-20% of SLE 
patients develop their first symptoms in childhood or adolescence (before 18 years 
old)52,53. JSLE is more common in girls, with the female:male ratio being approximately 
4:3 before puberty suggesting a role for the X-chromosome;  however, pubertal 
female:male ratio increases up to about 5:154 suggesting an important role for sex 
hormones and particularly oestrogens54,55. The sex differences increase even more in 
adulthood, with the female:male ratio being 9:152 . Higher incidence of JSLE has been 
reported in patients of Black African or Asian origin and these patients have earlier 
disease onset, generally more severe disease and increased nephritis incidence46.  
Data from studies where direct comparisons were made between adult-onset SLE 
(ASLE) and JSLE patients indicate that JSLE is generally more severe and aggressive 
and it presents with more acute disease features compared to ASLE56,57. There is also 
an associated increase in the medication burden (e.g. greater need for corticosteroid 
usage and immune-suppressive agents). Comparison of the clinical manifestations 
characteristic in adult-onset and childhood-onset disease has demonstrated that both 
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ASLE and JSLE patients have similar frequency of skin, joint, and central nervous 
system (CNS) damage58. However, ASLE patients are more frequently affected by 
cardiovascular disease, whereas in JSLE patients, haematological and renal 
complications are more commonly occurring52,58.  
In JSLE the levels of anti-double stranded DNA (anti-dsDNA) antibodies are 
higher compared to ASLE59. As with ASLE, changes in the levels of anti-dsDNA 
antibodies are monitored in order to determine disease activity in JSLE60. Children and 
adolescents generally have higher mortality rates directly attributable to SLE disease 
and suffer from greater disease damage than adults with SLE52,56. In both JSLE and 
ASLE, the major causes of death include renal disease, severe disease flares, and 
infections61,62.   
A study using data from the UK JSLE Cohort Study and Repository for both 
childhood-onset (diagnosis before 12 years old) and juvenile-onset (diagnosis between 
12 and 17 years old) SLE as well as from the University College London Hospitals 
(UCLH) SLE cohort for both ASLE (diagnosis between 18 and 49 years old) and 
mature-onset (diagnosis after the age of 50 years old) SLE, assessed phenotypic and 
disease severity differences among different age groups 63. The study demonstrated that 
lupus nephritis had a significantly higher prevalence in JSLE patients (44%) compared 
to both adult- and mature-onset SLE patients (33%) and confirmed female 
predominance, especially at puberty and adult ages. No age group differences were 
observed for patients with rashes or photosensitivity but JSLE patients were reported 
to be affected more by alopecia and oral ulcers whereas ASLE patients were more likely 
to be affected by arthritis and serositis. No significant differences were observed for 
neurological disease among age groups, however mature-onset SLE patients had 
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markedly lower presence of neurological involvement. JSLE patients had significantly 
higher immunological (anti-dsDNA antibodies, anti-RNP, anti-Sm autoantibodies) and 
haematological (thrombocytopenia and haemolytic anaemia) involvement, however 
leucopenia increased with advanced ages. This study supported the finding of previous 
studies that JSLE is more aggressive and with worse outcome than ASLE and although 
mortality rates have been decreasing during recent decades, they still are higher than 
the general population in both JSLE and ASLE 63. 
In conclusion, from all the studies between JSLE and ASLE patients it is evident 
that although JSLE and ASLE share many common characteristics, they have also 
distinct features with different clinical phenotypes. Therefore, studying JSLE and 
ASLE as one continuum based just on age, and treating the JSLE patients just as “young 
ASLE patients”, could potentially miss significant differences and invaluable insights 
into the pathophysiological mechanisms and potential therapeutic implications of 
childhood-onset disease. For this reason, it is vital to study both ASLE and JSLE, 
allowing for the development of more effective and targeted therapies. 
1.3. Lupus Nephritis 
In JSLE, between 50% and 75% of patients will develop kidney involvement64 and 
10 to 50% of these individuals will eventually progress to end-stage renal failure65,66. 
The most common clinical manifestations of lupus nephritis include: microscopic 
haematuria (79%), and proteinuria (55%)67. Decreased glomerular filtration rate (GFR) 
and hypertension are also observed (50% and 40%, respectively)67. 
Due to the severity and aggressiveness of LN, there is a pressing need to gain a 
much deeper understanding of the pathophysiological mechanisms underpinning the 
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development of lupus nephritis in order to identify better and potentially novel 
treatments and therapies.   
 Dysregulated apoptosis and imperfect cell clearance 
SLE can develop in individuals bearing gene mutations which compromise those 
immunoregulatory mechanisms that under physiological conditions impede the 
presence of high levels of self-antigens (such as chromatin) in the extracellular spaces 
of the human body. Such mechanisms include: apoptosis,68,69 complement opsonisation 
of dead cells, as well as effective phagocytosis of apoptotic cells70. In SLE imperfect 
phagocytosis of apoptotic cells leads to the increased presence of circulating apoptotic 
material, such as nucleosomes and cell membrane components71. These circulating 
autoantigens can potentially stimulate autoreactive T- and B cells, and promote immune 
complex formation72.   
Neutrophils are also able to undergo NETosis, which results in the release of 
nuclear material into the extracellular space (NETs) in order to trap extracellular 
pathogens and during homeostasis these would be cleared by incoming phagocytes39,73. 
However, in SLE delayed removal of dead cells due to imperfect phagocytosis leads to 
the sustained exposure of their components (e.g. nucleosomes and cell membrane 
components) to the immune system as well as to their gradual degradation74,75. This 
nuclear component degradation could lead to the loss of epigenetic modifications such 
as DNA and RNA methylation that normally aid the immune system to distinguish 
between self and foreign antigens and consequently trigger the induction of anti-viral 
immunity against autoantigens via type one interferon (IFN I: IFN-α and IFN-β) 
release74–76. In SLE, nuclear autoantigens are recognised as viral-like particles (for 
example U1snRNP ligation to TLR-7 or nucleosomal DNA ligation to TLR-9 
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expressed by pDCs). Plasmacytoid dendritic cells (pDCs) exhibiting a strong IFN type 
I gene signature, can initiate an anti-viral immune response, leading to SLE symptoms, 
namely fatigue, fever, myalgia and arthralgia69,76–78. 
 Formation of immune deposits in LN 
Lupus nephritis initiation is triggered by the production and deposition of anti-
double-stranded DNA (dsDNA) antibodies (and other, less abundant autoantibodies) 
and/or the formation of in situ immune complexes in the renal parenchyma including 
the glomerulus, the vasculature, and the mesangium as well as the tubular interstitium 
of the kidney79–82 .  
In healthy individuals, anti-dsDNA autoantibodies of the IgM isotype class belong 
to the normal antibody (Ab) repertoire and display weak reactivity and low affinity for 
the self-antigens83. However, in SLE patients, these anti-dsDNA IgM antibodies 
undergo an isotype change to IgG class antibodies (probably due to increased presence 
of autoreactive B cells) with increased pathogenic potential, as they can fix complement 
by promoting the binding of the C1-complex to their Fc (fragment crystallisable) 
regions84–86.  Furthermore, these pathogenic IgG autoantibodies display high affinity 
for self-antigens87,88 as well as cross-reactivity with non-DNA self-antigens expressed 
on native kidney cells including α-actinin89 , heparan sulfate proteoglycans90,91 , 
laminin91, collagen91  and annexin II 92.  
Apart from deposition of autoantibodies in the renal compartments, passive 
entrapment of preformed circulating immune complexes can occur in the glomerulus 
although this event is not the most significant mechanism of the formation of immune 
deposits in LN93.  The imperfect clearance of apoptotic cells in lupus nephritis can lead 
to the release of nucleosomes from apoptotic intraglomerular cells94 and subsequently 
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to nucleosome capture within the GBM where they serve as platforms for the indirect 
autoantibody binding to the GBM95–97 . 
Immune complex deposition can occur in different renal compartments 
(mesangium, subendothelial, subepithelial, and tubulointerstitial spaces) depending on 
the type of autoantibodies, the duration, and severity of LN98,99. Therefore, there is a 
clear association of histological classification and severity of LN renal injury with the 
presence of immune complexes in different renal spaces. Immune complex deposition 
in the mesangium is characteristic of 2003 International Society of Nephrology 
(ISN)/Renal Pathology Society (RPS) class I (minimal mesangial) and II (mesangial 
proliferative) glomerulonephritis (GN), subendothelial immune deposits are associated 
with class III (focal) and IV (diffuse) GN, and subepithelial immune complexes 
characterise class V (membranous) GN98. 
 Activation of glomerular cells by immune deposits 
Immune complexes can activate glomerular renal cells such as the MCs, by 
glomerular renal cell-expressed Fc receptor (FcR) ligation to the Fc regions of 
autoantibodies100.  Furthermore, anti-DNA antibodies can activate endothelial and MCs 
through autoantibody internalisation by the renal cells following receptor binding101,102. 
There is evidence from in vitro studies that anti-dsDNA antibodies can bind to 
MCs, podocytes, endothelial cells, and proximal tubular cells79,80,102,103 and that this 
event can promote functional changes in the intra-renal cells80,104–107. 
Anti-dsDNA antibodies can bind to the mesangium through attachment to 
chromatin103 or via direct binding to cross-reactive antigens including α-actinin and 
annexin II89,92,108. The autoantibody binding promotes functional changes in MCs 
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including increased production of pro-inflammatory cytokines and pro-fibrotic 
mediators such as hyaluronan, interleukin-1β (IL-1β), IL-6, tumour necrosis factor-α 
(TNF-α), transforming growth factor-beta 1 (TGF-β1), and fibronectin92,109,110. 
Glomerular endothelial cell activation and injury is a common event observed in 
severe proliferative lupus nephritis98,111. Activation of GEnCs leads to upregulated 
surface expression of adhesion molecules such as Intercellular Adhesion Molecule-1 
(ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1)112, which promotes 
stabilisation and adhesion of infiltrating leukocytes to the sub-endothelial and 
mesangial kidney regions and results in immune-mediated renal injury. 
Incubation of human umbilical vein endothelial cells (HUVECs) with human 
polyclonal anti-dsDNA antibodies from lupus patients can stimulate the expression of 
VCAM-1, ICAM-1, and von Willebrand factor; these have been correlated with 
increased expression levels of the inflammatory cytokines IL-1, IL-6, and IL-8, which 
play an important role in lupus nephritis105,106,113. However, these data have not be 
validated using glomerular endothelial cells. 
 Chemokines, cytokines, soluble inflammatory mediators, and Toll-like 
receptors (TLRs) 
Type I interferons (IFNs) play a significant role in the pathogenesis of lupus 
nephritis114,115. Both infiltrating and intra-renal immune cells as well as GEnCs can 
synthesise pro-inflammatory IFN alpha and gamma (IFN-α and IFN-γ)116. Increased 
levels of type I-IFNs (IFN-α and IFN-β) can stimulate dendritic cells which in turn can 
activate T- cells to cause tissue damage and B cells to produce more autoantibodies117. 
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Immune complex deposition stimulates the production of numerous inflammatory 
mediators inside the nephritic kidneys, with the inflammatory mediator production 
being further enhanced as disease progresses118,119. CC-chemokine ligand 2 or 
monocyte chemoattractant protein-1 (CCL2 or MCP-1 respectively), is a chemokine 
expressed early in GN development, while tumor necrosis factor-α (TNF-α), is 
expressed upon initiation of proteinuria120,121 suggesting a temporal release of cytokines 
is occurring. Nephritic kidneys are also characterised by a type I IFN signature which 
can cause vascular damage and PEC and podocyte injury122–124. The injured renal 
GEnCs release a number of soluble mediators such as nitric oxide (NO) which can 
damage podocyte foot processes, leading to podocyte loss125. 
Furthermore, the nucleic acids which are part of the immune complexes can 
promote intra-renal inflammation via immune complex endocytosis and nucleic acid 
recognition by toll-like receptors (TLRs) which are expressed by intra-renal 
macrophages and dendritic cells126. TLRs are involved in anti-microbial immunity127 
and therefore self-nucleic acids can be falsely recognised as foreign antigens (for 
example a virus), leading to an initiation of immune response against them. 
 Disruption of cell-cell communication among glomerular renal cells 
Cell-cell interaction is of utmost importance for the maintenance of the GFB as 
well as of the nephron structure128. Direct contact of the GEnCs with the MCs ensures 
the protection of the GEnCs from transforming growth factor (TGF)-β-mediated 
damage, as the MCs sequester TGF-β on αvβ8 integrin expressed on the MC 
surface129,130. 
 In LN as well as other renal pathologies, in both human renal diseases and animal 
models, expression of certain PDGF isoforms by MCs  is upregulated, triggering 
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excessive proliferation of MCs, ECM deposition, cytokine and chemokine release, and 
renal fibrosis28. More specifically, abnormal PDGF isoform expression involves 
PDGF-A in rat models and human renal vascular rejection, PDGF-C and PDGF-B in 
rat models131–134 and PDGF-C in human renal biopsies and rat models 131 135.  
Loss of VEGFA which is necessary for GEnC survival and is secreted by podocytes 
is a feature of LN both in SLE patients but also in mouse models of the disease. 
Furthermore, affected GEnCs and podocytes in LN release endothelin-1 which 
aggravates glomerular injury by triggering a mitochondrial stress response136. Mature 
podocytes are terminally differentiated and have a limited proliferative capacity making 
regeneration and replacement of injured podocytes very difficult after cumulative 
damage in LN. This has as a consequence the development of glomerulosclerosis and 
loss of nephrons137. 




Figure 1.5 Schematic representation of impaired glomerular cell interactions in LN.  
Upon renal disease, abnormal glomerular cell crosstalk can occur, leading to LN exacerbation. Different isoforms of PDGF can be produced in the glomerulus 
by the MCs leading to MC hyperproliferation, lack of VEGFA production can affect the survival of GEnCs whereas endothelin-1 production by podocytes and 
GEnCs can further aggravate the renal disease. 
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 Chronic Kidney Disease (CKD) 
If lupus nephritis is left untreated, or an abrupt decline in kidney function (leading to low 
GFR and to a rise of serum creatinine, known as acute kidney injury (AKI)), is not completely 
reversed, severe renal parenchyma injury occurs. Damage to renal cells initiates fibrotic 
processes such as increased extracellular matrix production and deposition by PECs and MCs 
and replacement of the renal parenchyma with fibrous tissue138. The accumulation of fibrotic 
tissue causes reduced renal function and thus develops into CKD which will require renal 
replacement therapy (dialysis or transplantation).  
It is important to note that AKI  and CKD are closely associated and interlinked, and can 
initiate one another, as accumulating evidence suggests that not only unresolved AKI can lead 
to CKD but also underlying CKD can promote AKI139,140. In LN, patients with AKI (that could 
be resulting from a renal flare) can suffer from significantly higher occurrence of 
thrombocytopenia and anemia, serositis and nephrotic syndrome, a condition characterised  by 
heavy proteinuria, oedema and low albumin serum levels; they are furthermore characterised 
by decreased levels of serum C3 and by a poorer renal outcome141. In another study with a 
cohort of children with glomerulonephritis-related AKI, haematuria, heavy proteinuria and 
lipiduria are linked to AKI142. 
 In contrast to AKI, which is commonly reversible, CKD is permanent, resulting in an 
irreversible decline in the number of functional nephrons and eventually leading to irreversible 
kidney failure143. In CKD caused by LN, renal damage is associated with proteinuria, 
haematuria, low GFR143,144 and hypertension as well as an inability to achieve complete 
remission in the first year of treatment145. CKD can be categorised into 5 stages, from mild to 
moderate to severe CKD, with the latter requiring kidney replacement therapy144. Among the 
key molecular events contributing to CKD development, are inflammation involving -among 
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others- NF-κB activation and production/release of pro-inflammatory proteins at the sites of 
injury, renal fibrosis characterised by impaired scarring processes, extracellular matrix 
deposition and TGF-β-mediated epithelial-to-mesenchymal transition and accumulation of 
uremic toxins leading to endothelial cell dysfunction146.  
In LN, immune complex formation, abnormal function and TGF-β-mediated damage of 
the glomerular endothelial cells, TNF-α secretion at onset of proteinuria, kidney infiltration of 
macrophages, T cells (such as Th17 cells) and B cells and loss of intra-glomerular renal cell 
interactions as well as renal fibrosis are key contributors to CKD development147. 
 
 Summary of LN pathogenic factors 
LN pathogenesis involves both extra-renal and intra-renal factors. The extra-renal factors 
include specific combinations of genetic predeterminant variants for certain individuals that 
compromise immune tolerance for autoantigens as well as environmental factors and 
medications which lead to the production of anti-nuclear antibodies, the immunological 
hallmark of SLE. Furthermore, defective clearance of NETing or apoptotic neutrophils results 
in long-term exposure of nuclear particles that bind TLR-7 and TLR-9 and trigger a pseudo 
anti-viral immune response, orchestrated by IFN-α. As a result, the expansion of autoreactive 
dendritic cells, T helper cells, B cells and plasma cells is stimulated, and high levels of 
polyclonal autoantibodies are produced. 
Renal damage in lupus nephritis begins with the formation of immune deposits in the 
kidney which trigger the activation of the complement cascades, influx of acute and chronic 
inflammatory cells inside the glomerulus, generation of inflammatory or fibrotic mediators 
from resident renal cells and infiltrating cells and activation of the coagulation cascade.  
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1.4. Pro-inflammatory proteins in lupus nephritis  
Several studies have explored the differences in the expression of both systemic and intra-
renal levels of pro-inflammatory factors and cytokines in patients with active LN148–150. 
Through these studies, it has become clear that LN patients exhibit a CD4+ T-helper (Th) 1 
(Th1) cytokine profile (IFN-γ, TNF-α, IL-1β) 151 152. However, specific CD4+ Th2 cytokines 
(IL-4, IL-13, IL-10) can also play an important role in LN. 
Th1 and Th2 cytokines as well as pro-inflammatory molecules which have been shown to 
be involved in SLE and renal disease are presented below. The combined action of these 
molecules during renal flares or the action of different subsets of these pro-inflammatory 
factors during different stages of LN inflammation could lead to the promotion and 
sustainability of a highly inflammatory environment inside the nephritic kidney. 
 Tumour necrosis factor-α (TNF-α)  
The role of TNF-α in LN is ambiguous as conflicting data have emerged from various 
studies.  
Both protective  153 and detrimental 154 TNF-α effects have been reported in NZBxNZW 
and MRL-Faslpr lupus-prone mouse strains respectively, and the underlying mechanisms 
leading to this beneficial TNF-α response in NZBxNZW mice have not been clarified. For the 
NZBxNZW mice it was reported that complete TNF-α signalling depletion using anti-TNF-α 
Ab had deleterious effects on renal function whereas for the MRL-Faslpr mice, the 
administration of a TNF-α inhibitor or anti-TNF-α Ab reduced autoantibody production, TNF-
α serum levels and inflammatory arthritis. Different studies have clearly demonstrated that 
NZBxNZW mice are characterised by TNF-α deficiency which drives lupus-like autoimmunity 
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155–157. On the other hand, in MRL-Faslpr mice TNF-α is found in abnormally high amounts in 
both serum and renal tissue and has been associated with the degree of inflammation in the 
diseased organs 158 159. Nevertheless, even in NZBxNZW mice, when TNF-α was administered 
in low doses during later stages of disease progression, renal injury was accelerated 160. These 
data could suggest that low, basal levels of TNF-α expression are necessary for a normal, 
healthy state but neither TNF-α overexpression nor total TNF-α ablation are protective against 
autoimmunity. Furthermore, the time of TNF-α administration, even in low doses, can play a 
crucial role in renal disease amelioration. 
In human LN, serum levels of circulating TNF-α have been linked to glomerular protein 
expression of ICAM-1 which has been correlated with renal glomerular capillary damage in 
biopsy samples 161. TNF-α gene polymorphisms leading to excessive TNF-α production can 
predispose patients to LN development and TNF-α protein levels have been found to be 
upregulated in the plasma of active lupus nephritis patients 162. Additionally, in paediatric LN, 
podocyte cytoplasmic TNF-α overexpression has been reported 163. A study comparing 60 
serum samples from JSLE patients, found that TNF-α serum levels were significantly higher 
in patients with active LN compared to those without LN 164. 
Results from two case studies have shown that patient TNF-α blockade treatment using 
infliximab (a chimeric monoclonal antibody targeting TNF-α) led to LN amelioration and 
improved long-term renal function for 9 out of 12 patients, 165 as well as mitigated proteinuria 
and improved SLE activity for 6 out of 8 patients 166. However, other groups reported that anti-
TNF-α treatments used in rheumatic diseases not only led to autoantibody production but also 
induced SLE as well as LN development 167 168. Therefore, LN patients may be able to be 
categorised into ‘good’ and ‘bad’ anti-TNF-α responders, suggesting a potential application for 
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individualised anti-TNF-α therapy. However, it is currently unclear how patients should be 
stratified for this treatment.  
 Interleukin-6 (IL-6)  
IL-6 is a cytokine with pleiotropic effects expressed by diverse cell types, including 
macrophages, dendritic cells, B cells and T cells as well as fibroblasts, mesangial and 
endothelial cells 169. A number of pro-inflammatory factors such as interleukin-1 (IL-1), TNF-
α and lipopolysaccharide (LPS) induce high amounts of IL-6 production by different cell types 
including fibroblasts, keratinocytes and epithelial cells 169 170. Among the main IL-6 functions 
are B- and T cell differentiation as well as the stimulation of acute phase protein production by 
human hepatocytes 171. 
In human LN, peripheral blood mononuclear cells (PBMCs) from patients produce 
elevated IL-6 levels compared to healthy control patients 172 and high amounts of urinary IL-6 
have been correlated with diffuse (class IV) active LN 173. Furthermore, in a pristane-induced 
murine model for lupus, lower levels of anti-dsDNA antibodies were observed in IL-6 deficient 
mice compared to wildtype mice 174 suggesting IL-6 might play an important role in renal flares 
174. Data from Phase I trials have provided evidence that a monoclonal high-affinity anti-IL-6 
Ab, sirukumab, could be a promising treatment for both SLE and LN patients by regulating the 
levels of abnormal  B- and T cell populations and by acting locally in the inflamed kidney, 
respectively 175. 
 Interferons 
Th1 cells are potent producers of both IFN-α and IFN-γ 176. IFN-α and IFN-γ have been 
correlated with the presence of anti-dsDNA antibodies as well as with proteinuria in SLE 
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whereas murine LN models have also exhibited preponderance of IFN-γ–producing Th1 cells 
compared TNF-α-producing Th1 cells and a shift towards Th1-type response was observed177. 
1.4.3.1.IFN-α 
IFN-α is predominantly produced by plasmacytoid dendritic cells (pDCs) 178 and has 
several functions including induction of IFN-γ production, monocyte differentiation into 
antigen-presenting dendritic cells, activation of natural killer (NK) T cells and promotion of B 
cell differentiation, as well as initiation of apoptosis, leading to further accumulation and 
exposure of cellular debris to the immune system117,179 . Circulating IFN-α levels have been 
correlated to serological activity of SLE 180 whereas studies using PBMCs from SLE patients 
have confirmed an association between IFN-α signature gene expression and disease activity 
181 182. Furthermore, a local IFN-α signature has been detected in biopsies from LN patients 183. 
A study using a new single-molecule array (Simoa) digital ELISA technology which is 5,000-
fold more sensitive than commercial ELISAs 184 enabled for the first time the accurate 
measurement and direct quantification of IFN-α in the serum of patients with ASLE and JSLE 
(as well as patients with interferon abnormalities caused by other diseases, such as diabetes 
mellitus and type I monogenic interferonopathies) compared to healthy controls even in 
attomolar (fg/ml) concentrations. The ASLE patients in this study displayed a 250-fold increase 
and the JSLE patients displayed a 750-fold increase in serum IFN-α levels compared to healthy 
controls. This assay could assist clinicians towards better disease monitoring and diagnosis of 
patients suffering from aberrant type I IFN regulation. 
1.4.3.2.IFN-γ 
The effect of IFN-γ in SLE disease activity has been studied in several murine models 
showing that recombinant IFN-γ administration promoted disease advancement, an effect 
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abrogated by monoclonal Ab treatment against IFN-γ 185. Furthermore, different models of 
IFN-γ-depleted mice exhibited reduced GN 186 and were protected from premature death 186 
and renal disease 187. 
Contradicting outcomes for the role of IFN-γ in SLE and LN have emerged from different 
clinical studies; IFN-γ serum levels have been associated with SLE activity and IFN-γ has been 
correlated with the severity of renal disease as it was shown to upregulate protein production 
of the co-stimulatory molecule CD40 by cultured MCs 188. On the other hand,  decreased IFN-
γ protein production by PBMCs of patients with LN has been demonstrated 189. However, 
another study provided evidence for IFN-γ upregulated glomerular expression in patients with 
segmental diffuse (class IV) LN but not global diffuse proliferative (Class IV) LN150. For the 
same patients, an association between IFN-γ expression and anti-dsDNA antibodies as well as 
serum complement levels was found. These data might suggest that IFN-γ might be mainly 
involved in LN and not in systemic SLE. 
 Interferon gamma-inducible protein 10 (IP-10)  
IP-10 is a chemokine produced by IFN-γ-activated monocytes, fibroblasts, and endothelial 
cells. IP-10 mediates T cell accumulation to the inflamed tissues where it has been shown to 
have an anti-angiogenic effect 190 191. IP-10 serum levels have been found to be significantly 
upregulated in LN patients 192 and subsequent studies have highlighted urinary IP-10 mRNA 
as a reliable indicator of class IV (diffuse proliferative) LN as well as a potential biomarker for 
treatment effectiveness (lower IP-10 levels signified better response to treatments) 193. 
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 Interleukin-10 (IL-10) 
IL-10 is a pleiotropic cytokine, mainly produced by monocytes and Th2 cells.  IL-10 has 
been known to have anti-inflammatory properties, however in SLE mouse models, IL-10 has 
been shown to promote anti-dsDNA autoantibody production from B cells which subsequently 
bind to the glomerular compartments promoting the development of GN 194, a phenomenon 
that suggests a potent role for IL-10 in B cell activation. 
A human study demonstrated that unstimulated cultured PBMCs from SLE patients 
secreted 33-fold higher levels of IL-10 compared to controls. 195. Furthermore, a human LN 
study reported a significant correlation between intra-glomerular IL-10 expression (as well as 
of IL-12, IL-18 and MCP-1 expression) and histological activity index150. 
 Interleukin 1-beta (IL-1β) 
IL-1β is a leukocyte-produced prototypical inflammatory cytokine. IL-1β has been shown 
to promote the expression of the adhesion molecules ICAM-1 and VCAM-1 in kidney, lung, 
heart, and brain endothelial cells 196 as well as B cell autoantibody production 197 in lupus-
prone mice. Furthermore, in human LN, IL-1β has been detected in the renal tissue of patients 
with diffuse (class IV) GN whereas intra-renal IL-1β mRNA was predominantly synthesised 
by infiltrating macrophages and monocytes 198.  
 Interleukin-8 (IL-8) 
IL-8 is a potent neutrophil chemokine, produced by monocytes and other cell types such 
as the endothelial cells where IL-8 is stored in the Weibel-Palade bodies (WPBs) 199 200. In LN 
patients of African-American origin, a certain IL-8 gene polymorphism (IL-8-845C) which 
could potentially influence IL-8 expression (as hypothesised by the authors) has been 
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associated with more severe renal injury suggesting a potential for development of 
individualised immunosuppressive therapy 201. 
 Macrophage-Colony Stimulating Factor (M-CSF) and Granulocyte Macrophage-
Colony Stimulating Factor (GM-CSF) 
M-CSF (or CSF-1) and GM-CSF (or CSF-2) are produced by various cell types including 
macrophages, lymphocytes, fibroblasts and endothelial cells 202 203 204. GM-CSF promotes the 
maturation and differentiation of macrophages, neutrophils, eosinophils and basophils 205 
whereas M-CSF mediates the growth, survival, differentiation and chemotactic activity of 
monocytes and macrophages 206. 
In murine GN models the production of GM-CSF by both renal and immune cells was 
necessary for the development of renal glomerular injury 207 208. Furthermore, M-CSF–deficient 
lupus-prone mice exhibited amelioration of renal disease, suggesting an important role for M-
CSF in lupus nephritis pathophysiology 209 210. In human LN, urinary M-CSF  levels were 
found to be predictors of renal flares in diffuse (Class IV) GN patients 211 whereas serum and 
urine M-CSF could prove to be a reliable and sensitive biomarker for LN 212. In addition, GM-
CSF and M-CSF protein levels have been shown to be increased in human GN 213. 
 Macrophage Inflammatory Protein-1 alpha (MIP-1a) 
MIP-1α (or CCL3) is a chemokine mainly produced by macrophages, dendritic cells, and 
lymphocytes 214 which activates neutrophils, eosinophils and basophils promoting acute 
neutrophilic inflammation.  In human crescentic GN, MIP-1α together with MCP-1 has been 
shown to promote macrophage recruitment and activation in the kidneys 215. Furthermore, in a 
human SLE study MIP-1α serum levels were strongly correlated with discoid lupus 216. 
58 
 
 Interleukin-13 (IL-13) 
IL-13 is a Th2 cytokine and is involved in allergic inflammation and IgE secretion by 
activated human B cells 217.  In SLE, IL-13 has been found in increased levels in the plasma, 
serum and PBMCs of patients with active LN 218 219 220. In murine models of AKI, IL-13 has 
been shown to be necessary for the polarisation of the renal macrophages and dendritic cells 
towards an M2a phenotype (induced by IL-13 or IL-4 and characterised by macrophages TGF-
β and arginase production), in order to achieve recovery from AKI 221. 
 VEGF 
VEGF plays an important role in the preservation of glomerular endothelial cell functions, 
including their viability, growth, and permeability 222. In childhood LN, plasma VEGF and its 
soluble receptor VEGFR1 were shown to be significantly increased in patients with active renal 
disease compared to patients in remission or healthy controls 223. Therefore, although VEGF 
has an important beneficial role for endothelial cell survival, the increased plasma levels of 
VEGFR1 which binds VEGF with higher affinity than VEGFR2 (although it is VEGFR2 which 
mainly mediates the biological effects of VEGF)224 sequesters VEGF from binding to VEGFR2 
expressed on endothelial cell surfaces and initiates the signaling cascades leading to 
preservation of endothelial viability. In proliferative LN decreased intra-renal VEGF mRNA 
expression has been correlated with worse disease prognosis and deterioration of renal 
function225.  
1.5. From traditional to novel urinary LN biomarkers 
The traditional clinical biomarkers used for LN monitoring such as measurement of 
proteinuria levels, the estimated GFR, blood pressure and hypertension as well as examination 
of the urinary sediment, have significant limitations in effectively identifying disease activity 
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in certain cases. Proteinuria can remain high for up to one year following renal flare while the 
urinary sediment (the deposit of cells derived from the centrifuged urine specimen which 
contains red cells, white cells or urinary casts in the urine collection) from patients with active 
LN could appear normal. It lacks specificity, whereas the monitoring of GFR has proved to be 
timely and costly and therefore unsuitable for routine use226–228. A summary of some of the 
advantages and limitations of traditional biomarkers for LN are shown in Table 1.1. 
 
Table 1.1 Traditional urinary biomarkers, their advantages and limitations. 
Several cross-sectional and longitudinal studies have taken place in order to identify easily 
accessible, non-invasive LN biomarkers in the urine of JSLE patients. Two novel urinary 
biomarkers, MCP-1 and neutrophil gelatinase associated lipocalin (NGAL), which were shown 
to distinguish between histological classes and predict deterioration of renal disease activity in 
adult disease, lacked specificity in JSLE229–233.  
Work from our group234 as well as others235 has provided strong evidence that the 
combination of four novel urinary biomarkers which are significantly increased in the urine of 
patients with LN are useful markers of disease activity in juvenile-onset LN. Those four 
biomarkers are: Alpha-1-acid glycoprotein (AGP), Lipocalin-type prostaglandin D synthase 
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(L-PGDS), transferrin (TF) and caeruloplasmin (CP), with AGP being the most consistent 
solitary indicator of renal flare. 
Finally, urinary VCAM-1 has been shown to be significantly upregulated in JSLE patients 
with active lupus nephritis and therefore, it might be able to serve as an important indicator of 
renal disease activity234,236. 
 Novel urinary biomarkers in LN 
AGP is an acute phase plasma protein with drug-binding properties237 mainly synthesised 
in the liver and secreted by hepatocytes.  However, extra-hepatic production of AGP has been 
described: human breast epithelial cells as well as human microvascular endothelial cells 
(HMECs) can actively synthesise AGP238,239. 
The serum concentration of AGP increases rapidly several-fold upon inflammatory 
stimuli. AGP gene expression in hepatic tissues is regulated by the combined action of IL-1β, 
IL-6, TNF-α and glucocorticoids; this may also be important in extra-hepatic tissues240. 
AGP is a natural anti-inflammatory and immunomodulatory factor, due to its anti-
neutrophil and anti-complement activity241; hence it might have a protective role for the kidney. 
Upon a LN flare, local and systemic upregulation of AGP could act as a signal against 
inflammation. Furthermore, circulating AGP could exert its anti-neutrophil and anti-
complement properties in renal tissues, promoting the remission of flares. 
L-PGDS is an enzyme which catalyzes the isomerisation of prostaglandin (PG) H2 (PGH2) 
to PGD2, which act as endogenous regulators of sleep and pain242. L-PGDS is mainly expressed 




A study in which the localisation of L-PGDS in Macaca fascicularis or Cynomolgus 
Macaques primate kidney was examined by in situ hybridisation and immunohistochemistry, 
revealed that L-PGDS was synthesised de novo in the kidney244.  
TF is an iron-binding plasma glycoprotein that transports iron to all tissues and controls 
the free iron levels in biological fluids245. TF is principally synthesised in the liver and enters 
the cells through receptor-mediated endocytosis245. TF is an acute phase response protein. As 
kidneys express the TF receptor246, TF uptake might be involved in the regulatory mechanisms 
of kidney homeostasis. 
CP is a ferroxidase enzyme synthesised in the liver. It is the major copper-carrier in the 
blood (contains over 95% of the copper found in healthy plasma), and it also has a role in iron 
metabolism247. 
MCP-1 is a chemokine with the ability to promote kidney infiltration by inflammatory 
cells in lupus nephritis. MCP-1 is expressed by MCs, podocytes and monocytes in response to 
pro-inflammatory cytokines, such as TNF-α248 . MCP-1 expression within the glomerulus can 
be predictive of poor renal outcomes in JSLE patients with lupus nephritis229. MCP-1 can also 
be found anchored in the surface of endothelial cells. 
Neutrophil gelatinase-associated lipocalin (NGAL) is a member of the lipocalin family of 
proteins and plays a key role in the growth and differentiation mechanisms of renal tubular 
epithelial cells, and of epithelial cells in general249. It can also act as a bacteriostatic agent, by 
impeding the bacterial iron-acquisition mechanisms. NGAL has proved to be an efficient non-
invasive biomarker as it is upregulated by the kidney in a number of acute renal injury 
conditions, such as urinary tract infection250,251. It has also displayed the ability to accurately 
predict renal flares in JSLE patients in cross-sectional cohort trials252,253. 
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VCAM-1 is a cell-surface protein involved in the migration and adhesion of inflammatory 
cells such as lymphocytes, monocytes, eosinophils, and basophils to the vascular endothelium 
through which they can be recruited to inflammatory sites254. VCAM-1 promotes the 
recruitment and adhesion of inflammatory cells through its interaction with an integrin (very 
late antigen-4 or VLA-4) expressed by infiltrating leukocytes. VCAM-1 expression as well as 
VCAM-1 serum and urinary levels have been shown to be significantly upregulated in adult-
onset SLE patients and especially, in LN255,256. Furthermore, in patients with active LN and 
more specifically Class III and Class IV GN, the levels of soluble VCAM-1 (sVCAM-1) were 
shown to be significantly elevated compared to LN patients in remission 257. 
1.6. The glomerular endothelium in inflammation and biomarker production 
As the role of the glomerular endothelial cells (GEnCs) in renal diseases has not been 
widely studied and limited data are available regarding their exact role in the renal 
inflammatory cascade, a general overview on the role of endothelial cells in inflammation is 
provided below.  
Experiments presented here using human conditionally immortalised GEnCs (ciGEnCs) 
were designed based on both the general knowledge about the role of different endothelial cell 
types in inflammation (as described by previous studies and summarised below), but also 
according to research findings regarding the specific role of GEnCs in inflammation in general 
or in LN specifically. The human ciGEnCs were developed and kindly donated for our research 
by our collaborators at the University of Bristol, who used donated healthy human kidneys to 
isolate via differential sieving (described in more detail in section 2.2.2) primary human 
GEnCs, podocytes and MCs258–260. Using the same method for all three cell types, the primary 
GEnCs, podocytes and MCs were conditionally immortalised via a process that is described in 
more detail in section 2.2.2. Conditional immortalisation allowed for prolonged survival of the 
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conditionally immortalised GEnCs, podocytes and MCs in culture, overcoming the early 
senescence barrier of their primary counterparts, whilst also maintaining the same functional 
properties as the primary cells258–260. 
 The endothelium under physiological conditions 
Under homeostatic conditions the vascular endothelium performs specific basal functions, 
such as control of blood flow, maintenance of blood fluidity and coagulation inhibition as well 
as regulation of the capillary wall permeability and impeding leukocyte binding261–266. 
In non-inflamed tissues, the resting endothelial cells utilise different mechanisms to 
prevent interaction with leukocytes. Under physiological conditions endothelial cells express 
low levels of adhesion molecules including ICAM-1, VCAM-1 and E-selectin on their cell 
surfaces 266. In addition, they store P-selectin as well as chemokines restricted inside secretory 
vesicles, the Weibel-Palade bodies (WPBs) ready for rapid release in response to injury or 
noxious stimuli 267 199. Furthermore, shear stress-induced nitric oxide (NO) production by the 
endothelial cells can suppress the expression of pro-inflammatory factors 268 and hinder the 
WPB fusion to the cell membrane 269 contributing to the overall leukocyte recruitment 
inhibitory environment.  
Inability of the endothelial cells to exert these vital functions, leads to endothelial cell 
dysfunction, blood vessel compression and increased leukocyte binding onto the endothelium 
resulting in endothelial cell activation and initiation of the inflammatory cascade. 
 The stages of acute inflammation of the endothelium 
Acute inflammation ensues within hours following a stimulus and is characterised by the 
recruitment of large numbers of neutrophils to the site of the activated endothelium. 
Endothelial cell activation occurs in two stages, known as type I activation or stimulation 
and type II activation. Type I activation does not require new gene expression and leads to 
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rapid cell responses whereas type II activation necessitates new gene expression and therefore 
the cells elicit slower responses compared to type I activation 270. Both types of activation result 
in local increases in blood flow, release of plasma fluid in the surrounding tissue and infiltration 
of circulating leukocytes which release mediators able to induce pain through interaction with 
specialised nerve fibres. Furthermore, factors released by the leukocytes can promote 
vasodilation and induce changes in the physiological functions of the resident cells of the 
invaded tissue by stimulating their activation.  
1.6.2.1.Type I activation 
Type I activation is induced by ligand binding, such as leukocyte-released histamine, to 
the extracellular part of G-protein-coupled receptor (GPCRs) histamine H1 receptors, that are 
expressed by the endothelial cells. 270 As a result, the endothelial cells are activated to secrete 
PGI2 and produce nitric oxide (NO) 
271 which synergistically promote vascular dilation leading 
to increased blood flow and enhanced circulating immune cell recruitment. Furthermore, 
endothelial cell cytoskeleton reformation can occur, leading to creation of gaps in the tight 
junctions between neighbouring endothelial cells which, in turn, allow for plasma protein 
leakage 272 and circulating neutrophil 273 and monocyte transmigration through interactions 
between platelet-endothelial cell adhesion molecule-1 (PECAM-1; also known as cluster of 
differentiation 31;CD31) expressed on endothelial cells and CD99 expressed on circulating 
leukocytes 274. In addition, increased WPB exocytosis can result in P-selectin emersion to the 
luminal surface of the endothelium 275; P-selectin, in turn, can promote the recruitment and 
tethering of both neutrophils and lymphocytes to the endothelial cells. 
Type I activation does not require new gene expression and it approximately lasts for 10-
20 minutes 276. After their initial activation, GPCRs become desensitised in order to prevent 
continuous inflammation and further neutrophil and leukocyte recruitment 276. 
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Another example of Type I activation commonly observed in LN, is the glomerular 
invasion of pathogenic microorganisms such as bacteria, through the glomerular capillaries. 
There, substances released by the bacteria or expressed in the bacterial wall (for example LPS) 
could activate resident and/or infiltrating macrophages, which in turn, would secrete cytokines 
and chemokines leading to vasolidation, changes in GEnC permeability, PGI2 secretion and P-
selectin emergence to cell surface. 
1.6.2.2.Type II activation 
Type II activation requires the induction of gene expression and therefore promotes the 
formation of a more persistent inflammatory microenvironment. The prototypic pro-
inflammatory cytokines orchestrating this response are TNF-α and IL‑1β which are produced 
by activated leukocytes 270. 
TNF-α and IL-1β bind to their receptors expressed by the endothelial cells (TNFR-
1/TNFR-2 and IL1-RI respectively) and initiate different cascade pathways which all converge 
at the activation of the nuclear factor-κB (NF-κB) transcription factor 277 278 279. Furthermore, 
signaling through TNFR-1 and IL1-RI leads to the activation of another transcription factor, 
activator protein-1 (AP-1). NF-κB is heavily involved in the overall  pro-inflammatory 
response of the endothelial cells by inducing the expression of multiple downstream target 
genes responsible for neutrophil, monocyte, macrophage and T cell recruitment and binding, 
including; IL-6, IL-8, IL-1β, RANTES, MCP-1, MIP-1α, IP-10, GM-CSF, M-CSF, IFN-γ, 
TNF-α, VCAM-1, ICAM-1, E-selectin and P-selectin280,281. In addition, the endothelial cells 
produce higher levels of PGI2, due to cyclooxygenase-2 (COX-2) expression via NF-κB 
activation 280. Both TNF-α and IL-1β can promote changes in the endothelial cytoskeleton 
through reorganisation of the actin and tubulin structures, resulting in gap formation between 
neighbouring cells and plasma protein leakage 282 283. 
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Type II endothelial activation is characterised by a temporal switch from the expression of 
the adhesion molecule E-selectin to the expression of the adhesion molecules VCAM-1 and 
ICAM-1 and of the chemokine MCP-1 which allow the gradual predominance of a 
mononuclear cell infiltrating population over the initial neutrophil accumulation in a time 
interval of 6-24 hours after the endothelial stimulation by TNF-α and IL-1β 284 285. Factors 
produced by the leukocytes will eventually cause endothelial cell injury and plasma leakage 
through the capillaries, therefore enhancing the inflammatory response 286. In addition, TNF-α 
and IL-1β in combination with IFN-γ (a cytokine known to be prevalent in LN) can further 
aggravate endothelial cell injury by inducing apoptosis287.  
 Chronic inflammation 
Failure of resolution of acute inflammation can lead to a more chronic adaptive immune 
response, where specialised effector T- and B- cells become key inflammatory players.  The 
endothelial cells have been hypothesised to be involved in this process by antigen presentation 
to the circulating effector and memory T cells288–290. Furthermore, under chronic inflammatory 
conditions the endothelial cells can support the sustainability of either a CD4+ Th1 or Th2 cell 
response, by differential production of chemokines and adhesion molecules291,292. 
Prolonged periods of inflammation without resolution through effector cell action 
subsequently lead to angiogenesis; the endothelial cells migrate to the surrounding tissues and 
new capillary networks are generated in order to sustain the viability of the accumulated 
inflammatory cells293, as observed in both rheumatoid arthritis (RA) and atherosclerosis294. 
Finally, chronically inflamed tissues can promote the formation of tertiary lymphoid 
organs (TLOs) which consist of naïve and memory T cells as well as B cells295. The endothelial 
cells support the sustainability of the TLO-structures by changing their shape as well as by 




Often, the mediators of acute and chronic inflammation can have overlapping activities; 
therefore, it might not be simple to distinguish between the two processes. For instance, TNF-
α signaling through TNFR-1 and TNFR-2 can induce type II acute inflammatory responses via 
NF-κΒ activation but TNFR-2 signaling can also have a pro-angiogenic effect, indicative of 
chronic inflammation, through vascular endothelial growth receptor factor receptor-2 
(VEGFR2) activation297. 
 The glomerular endothelium in inflammation 
Biopsies of LN patients have been found to exhibit upregulated protein expression and 
activation levels of NF-κB in GEnCs (and also MCs), which correlated with increased 
production of pro-inflammatory cytokines and cell adhesion molecules such as TNF-α, IL-1β, 
IL-6 and ICAM-1 298 299.  
Furthermore, IL-1β treatment was shown to promote permeability in cultured primary 
human GEnCs 300, an effect that could lead to GFB disruption and subsequent increase in 
proteinuria levels whereas kidney injury induced by LPS and TNF-α was shown to promote 
renal heparenase expression and subsequent damage of the GEnCs’ ESL in a mouse model of 
AKI sepsis  301. In both human and murine cultured GEnCs, TNF-α was also shown to increase 
albumin permeability, alter the size of fenestrations, induce changes in the actin cytoskeleton, 
create gaps between adjacent GEnCs, decrease the levels of occludin (a tight junction protein) 
and cause glycocalyx degradation, via the Rho and myosin light chain kinase (MLCK) 
signalling pathway 302. 
Therefore, NF-κΒ, together with TNF-α and IL-1β, seems to have a prominent role not 
only generally in endothelial cell inflammation but also specifically in GEnC inflammation. 
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 Glomerular endothelial cell function and role in biomarker expression 
As the GEnCs line the interior surface of the glomerular capillaries, they come in direct 
contact with circulating blood and serum components in the lumen. Therefore, under renal 
pathogenic situations such as in lupus nephritis, the formation of a pro-inflammatory 
microenvironment (e.g. cytokine expression by circulating inflammatory cells) in the 
glomerular capillaries, will eventually promote the increased expression of adhesion molecules 
on the surface of the GEnC. The increased expression of adhesion molecules will in turn lead 
to increased binding of leukocytes to endothelial cells and initiation of leukocyte kidney 
infiltration112 . 
Inflamed endothelial cells such as cytokine-activated HUVECs, express both E-selectin 
and P-selectin, which promote leukocyte rolling and binding to the vascular endothelium via 
glycosylated ligands303,304 . Subsequently, leukocyte arrest and stable binding to the vascular 
endothelium are mediated through interaction of leukocyte integrins with immunoglobulin 
superfamily members expressed by the endothelial cells, such as ICAM-1 and VCAM-1305,306. 
Several prototypical cytokines, among them TNF-α, IL-1β, IL-4 and IFN-γ have been 
shown to upregulate the expression of adhesion molecules on vascular endothelial cells in 
culture and thereby to increase the binding of leukocytes258,307–309. 
Under the highly inflammatory environment of LN, the activated endothelial cells might 
produce elevated levels of biomarkers including AGP, L-PGDS, TF, CP, MCP-1, NGAL and 




1.7. Summary  
Unraveling the mechanisms underpinning lupus nephritis inflammation and renal damage 
is of utmost importance in order to develop new, more effective treatments and improve the 
quality of life of JSLE patients. There is a great need not only to investigate the changes 
occurring in the structure and function of the GFB in lupus nephritis, but also find novel non-
invasive biomarkers with high specificity and sensitivity for early LN diagnosis and 
monitoring. Although kidney biopsy is the gold standard for investigation of renal involvement 
and diagnosis of LN, it is an invasive and painful procedure, especially as some JSLE patients 
require a general anaesthetic. 
Therefore, studying the role of the resident renal cells in the development of inflammation 
in LN could open new avenues for the development of novel and more targeted therapeutic 
approaches. The human GEnCs are an integral GFB component and at the same time are 
located at the interface between the blood microcirculation and the glomerular renal tissue. 
They could therefore be involved in the perpetuation of renal inflammation in LN through 
several different mechanisms including structural and functional changes (such as accelerated 
apoptosis), activation by the blood plasma and serum components and by pro-inflammatory 
cytokines. Furthermore, they could be actively involved in the production of the novel urinary 
biomarkers, secretion of pro-inflammatory chemokines and cytokines and surface expression 
of adhesion molecules and receptors, aberrant interactions with infiltrating and resident 
immune cells as well as with the podocytes and the MCs. 
In this project, the human GEnCs were tested for their ability to produce various pro-
inflammatory proteins under appropriate stimuli. These proteins and their involvement in lupus 





Proteins induced by  
TNF-α, IL-1β, IL-
13, IFN-γ and LPS 
Involvement in SLE and renal disease 
MCP-1 
  
MCP-1 expression within the glomerulus can be predictive of poor 
outcomes in JSLE patients with LN229. 
VCAM-1 VCAM-1 serum and urinary levels have been shown to be upregulated 
and associated with active LN255,257. 
ICAM-1 ICAM-1 urinary levels are upregulated in with class III, IV and V LN310. 
IL-6 High IL-6 levels have been detected in the urine of active LN patients311.  
IL-8 High IL-8 levels have been detected in the urine of active LN patients311. 
IL-10 Plasma IL-10 has been found to be significantly elevated in JSLE 
patients with active disease312. 
M-CSF Serum and urine M-CSF levels have been shown to be a reliable and 
sensitive biomarker for LN211,212. 
GM-CSF Increased mRNA levels of GM-CSF are expressed by in vitro cultured 
human renal tubular cells derived from interstitial fibrotic kidneys 
compared to tubular cells derived from non-fibrotic kidneys313. 
MIP-1α Together with MCP-1, promotes macrophage recruitment and activation 
in the kidneys of patients with crescentic glomerulonephritis215. 
IP-10 IP-10 serum levels are upregulated in LN patients192. 
TNF-α TNF-α gene polymorphisms leading to excessive serum TNF-α 
production can predispose patients to LN development314.  
IFN-γ Significantly increased IFN-γ positive immune-histochemical staining 
has been observed in biopsies from juvenile-onset LN patients compared 
to HCs315. 
PD-L1 In JSLE, decreased PD-L1 expression by antigen-presenting cells has 
been associated with active disease316. 
ICOS-L ICOS-L plasma levels are increased in patients with active SLE 
compared to those with inactive SLE317. 




1.8. Scope of the thesis 
 Hypothesis 
The human GEnCs are not just passive bystanders but are actively involved in the perpetuation 
of renal inflammation in LN. 
 Aims 
The hypothesis will be addressed using the following aims and objectives (Figure 1.6): 
• Aim-1: To assess the pro-inflammatory profile of the human GEnCs using an in vitro 
model of human ciGEnCs (Chapter 3). 
-Objective 1: To determine the effects of inflammatory cytokines involved in LN in ciGEnC 
expression of novel urinary biomarkers for LN and pro-inflammatory protein production, and 
to determine which of these cytokines have the most prominent effect. 
-Objective 2: To test whether the pro-inflammatory stimulated ciGEnCs activate important 
pro-inflammatory transcription factors. 
-Objective 3: To assess the viability of ciGEnCs after pro-inflammatory stimulation. 
• Aim-2: To investigate the effect of the glomerular renal microenvironment on GEnC 
pro-inflammatory profile using multiple in vitro ciGEnC models (Chapter 4). 
-Objective 1: To assess whether ciGEnC treatments with JSLE patient and paediatric healthy 
control sera can modify their fibrotic and pro-inflammatory phenotype. 
-Objective 2: To determine whether glomerulus-infiltrating immune cells such neutrophils and 




-Objective 3: To determine whether GEnC-neighbouring renal cells, podocytes and MCs have 
a paracrine effect on the pro-inflammatory activation of GEnCs. 
• Aim-3: To investigate the effect of the novel urinary biomarkers for LN on GEnC pro-
inflammatory profile using an in vitro ciGEnC model (Chapter 5). 
-Objective 1: To assess whether treatments with human recombinant urinary biomarker could 
promote the expression and/or production of novel urinary biomarkers for LN and pro-
inflammatory proteins. 
-Objective 2: To determine whether the human recombinant urinary biomarker treatments can 
affect the ciGEnC viability. 
Figure 1.6 summarises the approaches that will be taken to investigate the role of GEnCs in 
the development and perpetuation of inflammation in LN. 
 
Figure 1.6 Summary diagram for the study of the role of human GEnCs in the development and 




2. Chapter 2: Materials and Methods 
This chapter provides an overview of key methodological techniques used for the design and 
development of experimental assays used to address this thesis’ key hypothesis, aims and main 
objectives (see section 1.8).  
2.1. Materials 
The specific materials used in the different methodological assays are summarised below. 
 Whole blood processing 
In order to process blood samples, HetaSep, an erythrocyte aggregation agent aiding 
separation of red blood cells from white blood cells, was purchased from StemCell whereas 
Histopaque 1077, a density gradient cell separation Ficoll-based medium aiding separation of 
neutrophils from PBMCs, was purchased from Sigma-Aldrich. A red blood cell lysis buffer 
containing ammonium chloride, potassium carbonate and ethylenediaminetetraacetic acid 
(EDTA) was also used (Sigma-Aldrich). 
 Cell culture 
All cell types were washed using Phosphate Buffered Saline (PBS, Sigma-Aldrich). For 
the ciGEnCs 0.25% trypsin (59428C, Sigma-Aldrich) was used. Bovine Serum Albumin (BSA) 
was purchased from Sigma-Aldrich (A9418). 
Human macrophages and neutrophils isolated from whole-blood samples with the use of 
HetaSep and Histopaque were cultured in Roswell Park Memorial Institute (RPMI) medium-
1640 (RPMI-1640) that was purchased from Sigma-Aldrich, with 10% Fetal Bovine Serum 
(FBS), purchased from Gibco. Human recombinant M-CSF (R&D Systems, 216-MC) was used 
for monocyte differentiation into macrophages. For the culture of THP-1 cells RPMI medium 
1649-GlutaMAX and L-glutamine were purchased from Gibco and antibiotic/antimycotic was 
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purchased from Sigma-Aldrich. Phorbol 12-myristate 13-acetate (PMA) was purchase from 
Abcam (ab120297). 
For the culture of the human ciGEnCs, Endothelial growth medium 2-microvascular was 
purchased from two companies; Lonza (EGM2-MV Bulletkit, CC-3202) and PromoCell (MV-
2 media kit, C-22121). For the culture of human ci podocytes and MCs RPMI-1640 (+L-
glutamine, Lonza) with 10% FBS and 1% insulin transferrin selenium (ITS, Sigma-Aldrich) 
was used. 
When necessary, cells were frozen using Dimethyl sulfoxide (DMSO) purchased from 
Sigma-Aldrich (D2650) and FBS. 
 Cytokines and lipopolysaccharide (LPS) used in assays 
The human recombinant cytokines and the bacterial LPS used in this study, and their source, 
are presented on Table 2.1 below: 
 




 Human recombinant novel urinary biomarkers investigated 
The human recombinant biomarkers used for ciGEnC treatments, and their source, are 
presented on Table 2.2 below: 
 
Table 2.2 List of the human urinary biomarkers used for ciGEnC treatments. 
 RNA extraction, cDNA conversion and SYBR-Green real-time PCR kits used 
In order to undertake RNA extraction, the Qiagen RNeasy Mini Kit was used and Trizol 
reagent was purchased from Invitrogen. RNase-free DNase sets (79254) and nuclease-free 
water were purchased from Qiagen. cDNA synthesis and qRT-PCR kits from Agilent and 
Primerdesign were utilised for all experiments. 
 Antibodies used for flow cytometry 
The antibodies and isotype control antibodies utilised for the detection of the adhesion 
molecules as well as the isotype control antibodies which were included in all experimental 




Table 2.3 List of antibodies for FC. 
 
Table 2.4 Isotype control antibodies. 
 Materials used for flow cytometry-based assessment of apoptosis/necrosis 
The apoptosis kit utilised was purchased from Sigma-Aldrich (APOAF). Hank’s Balanced 




 Materials used for enzyme-linked immunosorbent assay (ELISA) 
R&D Systems DuoSet ELISA kits were utilised to identify potential treatment-induced 
changes in the secretion levels of human TNF-α (DY210) and IL-1β (DY201) by THP-1 cells 
and of human MCP-1 (DY279) and sVCAM-1 (DY809) by ciGEnCs. 
A custom-synthesised Magnetic Luminex multiplex ELISA custom kit (LXSAHM) was 
purchased from R&D Systems and was used to detect 24-hour cytokine- and LPS-induced 
differences in the secretion levels by ciGEnCs of the following pro-inflammatory proteins; 
macrophage MIP-1α, IP-10, IL-6, IL-8, GM-CSF, M-CSF, TNF-α and IFN-γ.  
 Materials used for Western blotting (WB)  
RIPA buffer (R0278) and protease inhibitor cocktail (P8340) were purchased from Sigma-
Aldrich. Pierce™ BCA (Bicinchoninic acid) Protein Assay Kit (23225) was purchased from 
Thermo Fisher Scientific. 4x NuPAGE LDS Sample buffer was purchased from Invitrogen and 
dithiothreitol (DTT) from Sigma-Aldrich. Bio-Rad precast SDS-PAGE gels (4561044) and 
Bio-Rad vertical electrophoresis cells were used. 10x Running buffer was prepared as follows; 
25 mM Tris-Base (Sigma-Aldrich), 190 mM glycine (Sigma-Aldrich), 0.1% SDS (Sigma-
Aldrich). 
Sample buffer at a final 1x concentration with 50μM DTT, as a reducing agent. The 
proteins were boiled for 5 minutes at 90oC and were loaded in 12% 50μl 10-well precast SDS-
PAGE gels (4561044, Bio-Rad) and protein gel electrophoresis took place into vertical 
electrophoresis cells (Bio-Rad) filled with 1x running buffer prepared from water-diluted 10x 
running buffer (25 mM Tris-Base, 190 mM glycine, 0.1% SDS). Polyvinylidene difluoride 
(PVDF) membranes and the Trans-Blot Turbo Transfer System from Bio-Rad Gels were used. 
5% non-fat dry milk from Marvel was used. 10x Tris-buffered saline (TBS) with Tween-20 
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(TBS-T) stock solution (pH: 7.5) was prepared as follows: 100 mM Tris-Base (Sigma-Aldrich), 
1.5 M NaCl (Sigma-Aldrich), 0.1 % Tween-20 (Sigma-Aldrich), 500 ml of ddH20. Enhanced 
chemiluminescence (ECL) reagents (WesternSure ECL Substrate, 926-80100) for protein 
detection were purchased from Li-COR. Li-COR software was used for protein band 
densitometry. Mild stripping buffer (pH:2.2) was prepared as follows; 200 mM glycine (Sigma-
Aldrich), 3.5 mM SDS (Sigma-Aldrich), 0.01 % Tween-20, (Sigma-Aldrich) and 500 ml of 
ddH20. 
The primary antibodies and secondary antibodies utilised for the assays are shown on 
Table 2.5. 
 
Table 2.5 WB primary and secondary antibodies.  
 Materials used for immunofluorescence (IF) assays 
Formaldehyde solution and Triton-X-100 were purchased from Sigma-Aldrich. DAPI (4',6-
diamidino-2-phenylindole) was purchased from Thermo Fisher Scientific (D1306). 




Table 2.6 IF primary and secondary antibodies. 
2.2. Methods 
All methods reported here were carried out in accordance with relevant guidelines and 
regulations of the University of Liverpool. All experimental protocols were reviewed and 
approved by either the North West – Liverpool East Research Ethics Committee (UK JSLE 
Cohort Study and Repository) (REC: 06/Q1502/77) or the University of Liverpool Committee 
of Research Ethics (Adult Healthy Control samples) (Research Ethics Approval Number: 
RETH000773). Paediatric healthy control whole-blood samples were obtained pre-surgery, 
from young patients being admitted to Alder Hey Children’s Hospital to undergo non-
emergency surgery and who, at the time of the sample acquisition, presented with no 
autoimmune or inflammatory conditions that could affect experimental results. Informed 
consent was obtained from all subjects or, if subjects are under 18, from a parent and/or legal 
guardian. 
 Isolation of neutrophils and PBMCs from whole blood 
Human blood was obtained from adult healthy volunteers using a 21-gauge needle and 
transferred to a collection tube containing heparin-coated beads to prevent clotting. The blood 
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was transferred to a 10mL tube and immediately HetaSep was added to the blood at a volume 
5-fold lower than that of the whole blood. Whole blood and HetaSep were gently mixed and 
left at room temperature for 30 minutes for erythrocyte sedimentation to occur (Figure 2.1). 
The top plasma layer containing neutrophils and Peripheral Blood Mononuclear Cells 
(PBMCs: lymphocytes, monocytes and dendritic cells) was collected, placed in a new tube and 
diluted with sterile PBS at a volume 4-fold higher than that of the plasma layer. The PBS-
plasma solution was centrifuged at 200 xg for 10 minutes. The supernatant was discarded and 
the cell pellet consisting mainly of leukocytes (neutrophils and PBMCs) was re-suspended in 
1 ml of RPMI 1640 medium. Subsequently, this was layered onto 2 ml of Histopaque in a new 
10 ml tube and centrifuged at 300 xg for 20 minutes, leading to neutrophil and PMBC 
separation, with neutrophils forming a pellet on the bottom of the tube and PBMCs forming a 
cloudy ring at the interface between Histopaque and RPMI (Figure 2.1). The PBMCs were 
collected, placed into a new 10 ml tube and diluted with PBS. The neutrophil pellet was re-
suspended in 1 ml of RPMI and 9 ml of 1x red blood cell lysis buffer (containing 155mM 
ammonium chloride, 10 mM potassium carbonate and 0.1 mM EDTA). This was gently 
inverted for 3 minutes at room temperature to ensure all erythrocytes were lysed. Finally, the 
PBMC- and neutrophil- suspensions were pelleted by centrifuging for 5 minutes at 300 xg and 




Figure 2.1 Neutrophil and PBMC isolation from whole blood.  
HetaSep is initially added to whole blood to separate leukocytes from red blood cells. Leukocytes, 
present on the plasma layer, are then separated into neutrophils and PBMCs via Histopaque 
sedimentation. 
2.2.1.1. Primary macrophage culture from PBMC-derived monocytes 
Isolated PBMCs from healthy adult donors were re-suspended in RPMI with 10% FBS. 
The re-suspended PBMCs were equally distributed onto 4-wells of a 24-well plate (different 
plates for different donors) and were incubated at 37oC at 5% CO2 for 2 hours. Subsequently, 
the supernatants containing non-adherent lymphocytes were discarded and the adherent 
monocytes were washed twice with PBS. After complete removal of PBS, RPMI with 10% 
FBS and 50 ng/ml human recombinant M-CSF (to aid monocyte differentiation to 
macrophages) was added to each well and the monocytes were incubated at 37oC at 5% CO2 
for 6 days (without media change). Macrophage differentiation was confirmed via light 




2.2.1.2. THP-1 cell culture 
The human monocytic THP-1 cell line has also been utilised to determine the effects of 
treatments of macrophages without the variation seen in human primary cells. THP-1 cells are 
non-adherent before differentiation is induced and were cultured in RPMI medium 1649 
GlutaMAX supplemented with 10% FBS and 1% L-glutamine and 1% antimycotic/antibiotic 
in 75 cm2 flasks which were placed vertically in a humidified chamber at 5% CO2 at 37
oC. 
Upon confluence, the cells were counted and subsequently 750,000 cells per well were 
distributed into 6-well plates. 100 ng/ml PMA was added to each well for 4-5 days at 37oC to 
promote attachment of the THP-1 cells to the bottom of the wells and differentiation towards 
macrophages (determined via light microscopy). Following completion of PMA incubation, 
PMA-containing media was discarded, and the THP-1 macrophages were incubated for 24 
hours at 37°C at 5% CO2 in PMA-free medium before being used for cytokine treatments and 
downstream experiments. (Figure 4.2, section 4.4.1) 
 Conditionally immortalised human GEnCs (ciGEnCs) culture 
A cell line of human conditionally immortalised GEnCs (ciGEnCs) was developed and 
kindly donated by Professor Moin Saleem and Dr Simon Satchell (Academic Renal Unit, 
Bristol Royal Hospital for Children)258. Primary human GEnCs were obtained from healthy 
human glomeruli from donated children’s kidney tissue, as previously done with human 
podocyte conditionally immortalised cell line development, which preceded the development 
of ciGEnCs259. The kidney tissue was transported and kept at all times prior to human glomeruli 
isolation at cool conditions259.  
 For the development of conditionally immortalised podocytes, human glomeruli were 
isolated via differential sieving (using different sizes of sieves) up to 24 hours post-
nephrectomy and sieved glomeruli were collected in a sterile container259. Subsequently, the 
83 
 
cortex which contains the glomeruli was isolated from the medulla, was chopped into small 
pieces using disposable scalpels and the cortex pieces were sieved again259. The isolated 
glomeruli were finally transferred onto culture-treated flasks or Petri dishes and were incubated 
at 37oC259. After 7-10 days, the podocytes have sufficiently grown, and patches of podocytes 
are formed and reach confluence; at this stage the podocytes can be isolated from the cultured 
glomeruli via trypsinization and passing through a 40μM cell strainer259.  
The primary podocytes can then be plated into 25 or 75cm2 flasks and they can now be 
transfected with vectors containing the temperature sensitive mutant of the Simian virus 40 
large T-antigen (SV40LT) and the essential catalytic subunit of the human telomerase reverse-
transcriptase (hTERT) gene for conditional immortalisation318. The SV40LT allowed for 
podocyte growth/proliferation at a permissive temperature (33oC) in a non-differentiated state 
and subsequent maturation and differentiation after thermoswitching to a non-permissive 
temperature leading to SV40LT inactivation (37oC)319 whereas the hTERT gene aided 
prolonged ci podocyte culture, overcoming the common issue of early senescence of primary 
podocytes in culture320. To ensure that ci podocytes were indeed generated, podocyte-specific 
markers (such as nephrin and podocin) were tested and compared between primary and ci 
podocytes and no significant differences were observed259. 
 Prior to conditional immortalisation, primary human GEnCs were isolated from donated 
human glomeruli. The glomeruli were isolated via differential sieving and subsequently were 
grown in cell culture treated flasks or Petri dishes259. Outgrowth of endothelial and epithelial 
cells (podocytes) was daily monitored and approximately after three to eight days, the 
endothelial cells were purified and detached from the epithelial cells via selective trypsinisation 
and further filtration via sieving, cells were pelleted and incubated with anti-PECAM-1 
monoclonal antibody and finally glomerular endothelial cells were selectively isolated via 
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magnetic separation beads; the glomerular endothelial cells were then plated and cultured 
again258,321. The ciGEnCs  were transfected with vectors for SV40LT and hTERT258.  
When thermo-switched to 37°C the ciGEnCs stop proliferating, terminally differentiate 
after approximately 5 to 7 days of culture and express at levels similar to primary human 
glomerular endothelial cells and in contrast to podocytes, endothelial cell-specific markers, 
such as PECAM-1, ICAM-2, VEGF receptor 2 (VEGFR2), and von Willebrand factor 
(vWF)258. This approach successfully overcomes the limited proliferative ability of primary 
GEnCs in culture and permits scientists to use ciGEnCs in various experiments, as it allows 
successful culture of ciGEnCs up to passage 40258. 
 A similar approach has also been used for the generation of conditionally immortalised 
(ci) mesangial cells (MCs)260. After successful generation of the ci MCs, the mesangial cells 
were tested for expression of GEnC-specific and podocyte-specific markers and were found to 
be negative for these markers260. The ci MCs were able to express MC-specific markers (alpha-
smooth muscle actin, PDGFR-β and fibronectin) and similarly to the primary MCs260.  
The ciGEnCs were cultured at 33oC at 5% CO2 in endothelial growth medium 2-
microvascular  containing 5% FBS  and the following growth factors supplied together with 
FBS and the basal endothelial media; hydrocortisone, ascorbic acid, human endothelial growth 
factor (h-EGF), fibroblast growth factor (h-FGF) and insulin growth factor (h-IGF).VEGF was 
excluded as it was utilised for ciGEnC stimulation in certain experiments but also because the 
developers of the cell line excluded VEGF addition to the media so as to prevent ciGEnC 
hyperproliferation. The concentrations of the growth factors added in the media were not 
disclosed by the manufacturing companies for reasons of proprietary. 
The ciGEnCs were grown in 25cm2 culture flasks with media changed every 3-4 days as 
required. Upon confluence, the flasks were trypsinised with 0.25% trypsin for 10 minutes until 
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detached from the bottom of the flasks and at least a 3-fold higher amount of media compared 
to the total amount of trypsin was added in order to inactivate the trypsin. The ciGEnCs from 
each flask were separately added into 10 ml tubes, were pelleted by centrifuging at 200 xg for 
5 minutes and were equally distributed in 6-well, 12-well or 24-well plates according to 
experimental needs and were incubated at 33oC until 50% confluent. At that point, the plates 
were thermoswitched to 37oC for 5-7 days until complete ciGEnC differentiation was achieved. 
Differentiation of ciGEnCs was confirmed via observing a change into a cobblestone, 
fibroblast-like morphology via light microscopy (Figure 2.2). Subsequently, the ciGEnCs were 
treated at 37oC for specific amounts of time with pro-inflammatory factors, sera or culture 
media from other cell types, according to experimental needs. At the end of the treatments, the 
conditioned ciGEnC culture media were collected and the ciGEnCs were used for downstream 
experiments. 
For all experiments, ciGEnCs between passage 29 and 36 have been utilised with a 
minimum of 3 consecutive passages to ensure reproducibility and to allow for appropriate 
statistical analysis of the data. Untreated ciGEnCs cultured in medium without addition of any 
other factors were included in all experimental repeats to enable comparison of any treatment-





Figure 2.2 Cultured ciGEnCs at 33oC and 37oC.  
At 33oC (A, C) ciGEnCs continuously proliferate. Once thermoswitched at 37oC for 5-7 days, 
proliferation ceases, the ciGEnCs differentiate and morphological changes (acquisition of a 
cobblestone, fibroblast-like morphology) can be confirmed by light microscopy. Similar morphology 
was seen between Lonza and PromoCell media. Scale bars: 400μm. 
 
2.2.2.1.Serum treatments of ciGEnCs 
The ciGEnCs were cultured in 25 cm2 flasks and were seeded for 7 days at 37oC onto 12-
well plates using the Lonza media supplemented with 5% FBS. Subsequently, the differentiated 
ciGEnCs were washed three times with PBS and were treated for 4 and 24 hours in Lonza 
medium free of FBS and supplemented instead with 5% serum from JSLE patients with active 
LN (renal BILAG; British Isles Lupus Activity Group: A or B, N=10), inactive LN (renal 
BILAG: D or E, N=10) as well as with 5% serum from age- and sex-matched healthy controls 
(N=10). Following incubation, the ciGEnCs were washed twice with PBS and RNA was 
collected for real-time PCR assays. 
The BILAG index is an important tool that monitors disease activity via using the BILAG 
score. The BILAG score does not take into account immunological data but it consists of both 
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renal and haematological assessments, including; assessment of blood pressure, evaluation of 
proteinuria (urine dipstick, 24-hour quantification) and active urine sediment, presence of 
nephrotic syndrome, evaluation of renal function via creatinine/creatinine clearance 
measurement and GFR) and histological manifestation of active LN322. The renal BILAG score 
can effectively distinguish active from inactive LN and thus, is a very useful tool for accurate 
assessment of lupus renal disease activity322. 
Renal BILAG scores were previously assessed by experienced clinicians and were readily 
available for this study. However, although some factors included in the scoring (such as 
albumin:creatinine ratio) are quantitative values some are subject to inter- and intra-observer 
bias. For instance, one of the criteria is evidence of damage on renal biopsy and this requires 
the clinician to have requested a biopsy based on the evidence they have seen in the clinic; this 
level of evidence may differ based on the examining clinician (inter-observer bias) and it has 
to be noted that even when one specific clinician is examining a material more than once or on 
different days, a degree of variation may be observed (intra-observer bias). Furthermore, once 
a biopsy has been performed, it is analysed by histopathologists and a recent paper in childhood 
LN  has demonstrated that the inter-observer variability is significant323. In an attempt to 
minimise bias, I selected active LN samples based, along with the BILAG score, on records of 
biopsy-proven lupus nephritis where the biopsy had taken place within 3 months of sample 
acquisition. 
2.2.2.2.Cytokine and LPS treatments with ciGEnCs 
Differentiated ciGEnCs were seeded in 6-well or 12-well plates for flow cytometry assays, 
in 6-well plates for WB experiments, in 12-well plates for SYBR Green real-time PCR and 
ELISA assays and in 24-well plates for mRNA dose response SYBR Green real-time PCR 
assays. Subsequently, the cells were incubated at 37 oC for 15 minutes, 30 minutes, 4 hours, 24 
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hours and 4 days with 10 ng/ml of seven human recombinant cytokines (IFN-α, IFN-γ, TNF-
α, IL-1β, IL-6, IL-13, VEGF) either individually or in a combined cytokine treatment and with 
1 μg/ml of LPS. A 24-hour dose response experiment for the cytokines found to have a robust 
effect on ciGEnCs in vitro activation (TNF-α, IL-1β, IFN-γ and IL-13) was performed using 
10-fold serial cytokine dilutions (10 pg/ml – 10 ng/ml). 
2.2.2.3.Urinary biomarker treatments 
The effect of six previously determined novel urinary biomarkers for LN (AGP, CP, TF, 
L-PGDS, MCP-1 and NGAL) 324–326 on the ciGEnCs was tested after either individual 
biomarker treatment or combined treatment of all six biomarkers together. The biomarkers 
were added in high and low concentrations, reflecting their concentrations as detected in the 
urine of patients with active LN (high concentration) or inactive LN (low concentration)327, as 
specified in section 5.5.1.1. 
 SYBR-Green real-time PCR principles 
Polymerase Chain Reaction (PCR) is a technique utilised to create multiple copies of a 
target DNA sequence (in this case, complementary DNA (cDNA) derived from reverse 
transcription (RT) of messenger RNA (mRNA)).328 Amplification of the double-stranded target 
DNA occurs with the use of a solution containing a DNA polymerase enzyme, a mix of all four 
nucleotides and a pair of single-stranded primers (forward and reverse) complementary to the 
target DNA sequence. When mixed with the DNA polymerase and nucleotide solution, the 
target DNA is amplified as follows: initially the mixture is heated up to 95oC to induce 
denaturation of the double-stranded DNA (ds-DNA) and subsequently the temperature is 
reduced to 55oC to promote annealing of the primers to the target DNA strands. Following the 
annealing step, the temperature is increased to 75oC to promote extension of the DNA sequence 
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of interest and amplification of the specific DNA target through repeated cycles of the 
annealing and extension steps. 
The SYBR-Green method can be used for real-time PCR analysis of the amplified DNA 
target. 329 It is based on the ability of the SYBR-Green dye to preferentially bind to the minor 
groove of ds-DNA, leading to formation of a DNA - SYBR-Green complex which absorbs blue 
light and emits green light (Figure 2.3). The more ds-DNA products accumulate over time, the 
more the SYBR-Green dye fluorescence signal will increase and become more intense. 
Therefore, the more highly expressed the DNA target is, the higher levels of fluorescence will 




Figure 2.3 SYBR Green real-time PCR.  
Forward and reverse primers bind the target DNA sequence and through repeated cycles of the annealing and extension steps multiple copies of the target 
DNA are produced. SYBR Green dye is incorporated into the double-stranded DNA. 
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2.2.3.1.RNA extraction  
Following completion of treatment periods according to the requirements of each 
experimental set-up, the ciGEnCs in cell culture plates were washed twice in PBS and 1 ml of 
Trizol reagent was added into each well for a minimum of 10 minutes at room temperature. 
The lysed cells were then briefly scraped from the bottom of the wells and the Trizol cell lysate 
was transferred into 1.5 ml tubes. 200 μl of chloroform was added into each of the tubes and 
shaken by hand to mix for 15s. Following this the tubes were left at room temperature to settle 
for 2-3 mins and then centrifuged at 12,000 xg for 15 minutes at 4oC to aid separation of RNA 
from DNA and protein. Subsequently, the upper aqueous phase containing RNA was removed 
(leaving the lower organic phase with DNA and proteins) and added into new 1.5 ml tubes, to 
this 500 μl isopropanol was added. At this point, the isopropanol-precipitated RNA was frozen 
at -80oC for future utilisation or was left to precipitate for a minimum of 10 minutes at room 
temperature and subsequently samples were centrifuged at 12,000 xg for 30 minutes at 4oC. 
The pelleted RNA was then re-suspended in 500 μl of 70% ethanol and was centrifuged at 
12,000 xg for 15 minutes at 4oC to aid further precipitation and concentration of the RNA. The 
ethanol was removed, and the samples were left to air-dry for 1 minute at room temperature 
before re-suspension into 100 μl of nuclease-free water followed by addition of 250 μl of 
absolute ethanol (100%).  
Subsequently, RNA on-column clean-up and on-column DNase digestion were performed 
using the Qiagen RNeasy Mini Kit as follows; 350 μl of Buffer RLT (lysis buffer) were added 
into each nuclease-free water and ethanol- diluted sample and samples were thoroughly mixed 
to ensure complete lysis of any remaining cell fragments. The mixture (approximately 750 μl) 
was then transferred into columns placed on supplied collection tubes. The columns were 
centrifuged at 8,000 xg for 15 seconds at room temperature and placed into new collection 
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tubes. Each column was then washed with 350 μl RW1 wash buffer, the columns were 
centrifuged at 8,000 xg for 15 seconds and after emptying the collection tubes DNase digestion 
was performed by adding a mixture of 80 μl of RNase-free DNase diluted 8x into RDD buffer 
(RNase-free DNase set - Qiagen) directly onto the membrane of each column. The columns 
were then incubated with the DNase/RDD mix for 15 minutes at room temperature and at the 
end of this incubation 350 μl of RW1 buffer were added into each column followed by a 15-
second centrifugation at 8,000 xg. Following thorough emptying of the collection tubes, 500 
μl of buffer RPE (supplied with ethanol to aid washing of membrane-bound RNA and ensure 
removal of residual salts) were added into each column and columns were centrifuged at 8,000 
xg for 2 minutes. This process was repeated twice. Following completion of RPE washes, the 
columns were placed into clean and sterile 1.5 ml tubes and purified RNA was eluted by adding 
40 μl of nuclease-free water into each column and centrifuging at 8,000 xg for 2 minutes.  
The extracted RNAs’ concentrations as well as 260/280 (RNA purity ratio, indicating 
potential presence of protein, phenol or other contaminants that strongly absorb at 280 nm) and 
260/230 (RNA purity ratio, indicating potential presence of contaminants such as phenol and 
guanidine that absorb at 230 nm) ratios were determined using Nanodrop (ND-1000 
Spectrophotometer, Thermo Fisher Scientific). 
2.2.3.2. cDNA conversion and real-time PCR for relative quantification of mRNA expression 
Quantitative SYBR Green real-time PCR was used to assess mRNA levels of different 
genes expressed by the ciGEnCs.  
2.2.3.3. Agilent kit used for reverse transcription and real-time PCR 
RT was initiated from 100ng or 200ng of total RNA diluted in nuclease-free water to equal 
concentration per experiment using 15ng/ml of random primers (initial concentration: 100 
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ng/ml) per sample. The samples were vortexed briefly, centrifuged and incubated at 65oC for 
5 minutes to enable denaturation of the RNA secondary structures.  
Subsequently, the mastermix was prepared as per manufacturer’s instructions: 1X 
affinityScript RT buffer (initial concentration: 10x), 4mM of deoxy-ribonucleotides (dNTP) 
mix (initial concentration: 100mM, 25mM each), 1U/μl of RNAse inhibitor (initial 
concentration: 40U/μl) and 1 μl of affinityScript reverse transcriptase (RTase). The final 
volume of each reaction was 20 μl. Three RNA samples were randomly chosen as negative 
controls and RTase was replaced with nuclease-free water for these reactions. All samples were 
thoroughly mixed and centrifuged and were incubated in the thermal cycler using the following 
programme: 25°C for 10 minutes- 42°C for 60 minutes-72°C for 15 minutes. 
For the real-time SYBR Green PCR, all cDNAs and primers were diluted 1:10 in nuclease-
free water. The Mastermix (Brilliant SYBR-Agilent Kit) for each sample was prepared as per 
manufacturer’s instructions: 0.2μl of sterile H2O, 5μl of SYBR Green qPCR mastermix, 0.3μl 
of ROX dye (reference dye), and 0.25μl of 10x diluted forward and reverse primers were 
thoroughly mixed, vortexed and centrifuged. 
Following Mastermix preparation, 6μL of Mastermix and 4μL of diluted cDNA were 
loaded in duplicates onto 96-well plates (final volume: 10 μl per well). For the negative control 
samples, the cDNA was replaced with 4μl of sterile H2O. All samples were thoroughly mixed 
and centrifuged before qPCR runs. 
Real-time PCR took place using Stratagene MX thermal cycler and MxPro software under 
the following conditions:   95°C for 3 minutes (initial denaturation) followed by 40 cycles at 
95°C for 20 seconds (denaturation) and then 60°C for 20 seconds (annealing/extension) with 
fluorescence reading after each cycle. For the generation of the dissociation curve, the 
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temperature was increased to 95°C for 1 minute followed by a decrease to 55°C and finally the 
temperature was ramped up to 95°C (0.2°C/cycle) while constant fluorescence was collected. 
2.2.3.4. Primerdesign kit used for reverse transcription and real-time PCR 
RT was initiated from 100ng or 200ng of RNA. RNA was added onto PCR tubes 
previously loaded with 20 μl RT premix (Precision nanoScriptTM 2 RT kit). All samples were 
vortexed briefly and were spun down and subsequently they were incubated in the thermal 
cycler using the following programme: 42oC for 20 minutes (RT step) and 72oC for 10 minutes 
(heat inactivation for reverse transcriptase).  
The cDNA was subsequently diluted using nuclease-free water and real-time PCR 
reactions (which took place onto 96-well plates) were prepared as follows: 1x Precision®PLUS 
qPCR Master Mix (initial concentration: 2x) were mixed with 6 pmols of forward and 6 pmols 
of reverse primers and with nuclease-free water up to a volume of 7 μl per well (a premix was 
prepared according to the total number of cDNA samples which were loaded on the 96-well 
plates in duplicates). Subsequently, 3 μl of diluted cDNA were added into each well reaching 
a total volume of 10 μl per well.  
Real-time PCR took place using Stratagene MX3000P thermal cycler and MxPro software 
under the following conditions:   95°C for 2 minutes (initial denaturation) followed by 40 
cycles at 95°C for 10 seconds (denaturation) and then 60°C for 1 minute (annealing/extension) 
with fluorescence reading after each cycle. For the generation of the dissociation curve, the 
temperature was increased to 95°C for 1 minute followed by a decrease to 55°C and finally the 
temperature was ramped up to 95°C (0.2°C/cycle) while constant fluorescence was collected. 
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2.2.3.5.Relative quantification of transcripts 
Relative quantification of transcripts was determined using Delta Ct (cycle threshold) 
values (ΔCt). mRNA expression for each gene was normalised to one or more housekeeping 
(HK) genes by calculating the ΔΔCt values.  For the calculation of the ΔΔCt values, the mean 
(for one HK) or the geometric mean (for more than one HKs) of the most suitable of the 
following HK gene(s) was used: beta-actin (ACTB), TATA-binding protein (TBP), beta-
tubulin (TUBB) and 14-3-3 protein zeta/delta (YWHAZ). Suitability of the HK gene was 
determined each time by comparing all the treatment groups of each experiment to each other, 
using the same non-parametric statistical analysis that was eventually utilised for statistical 
analysis of the target genes. Only the HK gene(s) having the most similar expression levels 
among groups without displaying any statistically significant differences in mRNA expression 
were used for each experiment. For some experiments, only one HK gene could meet these 
criteria and thus, for these cases, target genes were compared to the mean of this HK gene 
instead of the optimal comparison to the geometric mean of at least three HK genes. 
The equation utilised for the ΔΔCt values is the following:  
ΔΔCt= 2-(Mean [target gene] – (Geo)Mean [HK gene(s)]) 
2.2.3.6.Design of primer pairs and calculation of efficiencies 
Initially, through PubMed’s “Gene” search categories, the “mRNA-protein” accession 
number of the human genes of interest was collected and was used to design the primer pairs 
of the target genes through the Primer-BLAST tool. The following options were chosen for 
optimal design of the forward-reverse primer pairs; PCR product size had to be between 85-
200 base pairs (bp), the G-C content of primers and melting temperature (Tm) had to be 50-
60% and 50oC-65oC respectively, whereas the primers should preferentially cross an exon-
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exon junction. Furthermore, targets with 2 or more mismatches were ignored and primers with 
four or more repeats of the same nucleotide were avoided. Quality scores and primer dimer 
formation of all the potential primer pairs generated from Primer-BLAST were determined 
using the Amplifx software. Only primers that did not form any dimers and with a quality score 
higher than 70 and generally marked as “Good” were purchased.  
ACTB primers were purchased from Invitrogen whereas the rest of the primers used for 
SYBR-Green real-time PCRs were purchased from Eurofins (100 μM). Primers are illustrated 
on Table 2.7. Primer efficiencies were calculated by using 1:10 diluted cDNA (neat cDNA) 
from 3 random ciGEnCs samples as a stock and by performing serial dilutions (1:2, 1:5, 1:7 
and 1:10). All samples of neat and serially diluted cDNA were loaded onto 96-well PCR plates 
as triplicates and real-time PCRs for all candidate primer pairs were performed. Results were 
analysed via linear regression using the GraphPad Prism 4.0 software and the slope of the linear 
regression curve was used to calculate the primer efficiencies using the Thermo Fisher 
Scientific software. Only pairs of primers with efficiencies within the range 80%-120% were 




Table 2.7 List of primers used for real-time PCR experiments. 
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 Flow cytometry (FC) 
2.2.4.1. Basic principles of FC 
FC allows for the measurement of optical features and fluorescence characteristics of 
single cell suspensions 330. Different cell populations can be distinguished with FC according 
to their size (illustrated by the forward scatter or FSC) and granularity/internal complexity 
(illustrated by the side scatter or SSC). (Figure 2.4)  
Depending on the aims of the assay, cells can be labelled with DNA- or RNA-
binding/intercalating dyes or with fluorochrome-conjugated antibodies against target proteins, 
either membrane–bound or intracellular. Propidium iodide (PI) is an example of a commonly 
used DNA-intercalating dye, which cannot penetrate the cell membrane and is therefore very 
useful in distinguishing between viable, early and late apoptotic cells. Furthermore, among 
fluorochromes commonly utilised for Ab conjugation are Fluorescein isothiocyanate (FITC), 
allophycocyanin (APC), phycoerythrin (PE) and Alexa Fluor 488 (A488). Multiple staining of 
the same cell sample with antibodies against more than one target protein conjugated with 
fluorochromes emitting light of non-overlapping or partially overlapping wavelengths, can aid 
simultaneous detection of changes in the levels of these target proteins. 
Once inside the flow cytometer, the suspended cells are focused into a laminar stream flow 
generated by an isotonic sheath fluid which allows each cell to pass separately through an 
“inspection point” (Fluidic System, Figure 2.4). The Merck Guava flow cytometer that was 
specifically used for this thesis’experiments however, uses a patented microcapillary system 
without sheath fluid to create a single cell suspension to allow each cell to pass separately 
through an “inspection point”. There, a monochromatic light beam of a certain wavelength –
usually from a laser source- excites the fluorochromes to a state of higher energy. Upon return 
to their normal energy state, the excited fluorochromes will emit light of a higher wavelength 
than that of the monochromatic laser light beam. Light that passes straight through the cell 
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(FSC) and light that is scattered 90° (SSC) are collected with the help of an optical system 
consisting of filters allowing for only certain wavelengths to be directed forward (filters can 
also act as dichroic mirrors able to disperse light at a 90o angle) and different light detectors 
able to capture light emitted from fluorochromes or fluorescent dyes (FL1, FL2, FL3) (Figure 
2.4).  
The light signals are finally amplified by photomultiplier tubes and are digitalised to allow 




Figure 2.4 Flow Cytometry.  
A flow cytometer consists of three interconnected systems; the microcapillary system (which focuses cells into a single stream), the optical system (consisting 
of a monochromatic laser beam which “interogates” each cell separately, a series of optical filters and dichroic mirrors and FS, SS and fluorescence detectors) 




2.2.4.2.Basic principles of apoptosis assay using FC 
Apoptosis is a type of genetically programmed cell death characterised by successive and 
distinct morphological alterations eventually leading to loss of cell viability331. As apoptosis is 
a tightly regulated process and each event leading to gradual cell fragmentation occurs in a 
specific order, changes in plasma cell membrane polarity take place early in the apoptotic 
procedure and precede changes in membrane integrity332,333. Therefore, early and late apoptotic 
events such as phosphatidylserine (PS) translocation from the inner to the outer surface of the 
cell membrane and increased membrane permeability to otherwise non-permeable DNA-
intercalating dyes respectively, can be utilised to distinguish among  different apoptotic stages. 
332,333 Annexin V is a protein able to bind phospholipids such as PS and once conjugated to 
fluorochromes such as FITC, can aid sensitive detection of cells at early stages of apoptosis. 
333  Furthermore, PI is not able to penetrate the plasma membranes of viable cells but once the 
membranes lose their integrity during later apoptotic stages, PI can enter the cells and bind 
their DNA333. Therefore, a combination of Annexin V – FITC and PI staining can help 
distinguish over time between viable (Annexin V/PI negatives), early (Annexin V positives/PI 




Figure 2.5 Annexin V- FITC and PI staining for distinction between viable, early and late apoptotic 
cells.  
As PS is found on the inner side of the membrane of viable cells, annexin can bind phosphatidylserine 
only in early and late apoptotic cells. Furthermore, only late apoptotic cells are PI-positive. Therefore 
Annexin/PI staining can distinguish among viable, early and late apoptotic cells. 
 
2.2.4.3. Fluorescence FC 
For the FC assay, the ciGEnCs were treated for 4 and 24 hours with 10 ng/ml of TNF-α, 
IL-1β, IL-1 and, IFN-γ and 1μg/mL LPS. Subsequently, the effect of these cytokines and of 
LPS were investigated regarding potential changes on surface expression of ICAM-1, Vascular 
Cell Adhesion Molecule 1 (VCAM-1), E-/P-selectin, Programme Death-Ligand 1 (PD-L1) and 
Inducible Costimulator-Ligand (ICOS-L). Isotype controls were each time added at the same 
concentration as the antibodies against the target proteins. 
At the end of 4- and 24-hour treatments, the ciGEnCs were washed twice with warm PBS 
and were subsequently trypsinised by adding 0.25% trypsin for 10 minutes at 37oC. The 
trypsinised ciGEnCs were centrifuged at 300 xg for 5 minutes. Sample labelling took place 
using 96-well round bottom well plates. Each sample of ciGEnC treatments was re-suspended 
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in 50 μl of PBS with 0.1% BSA and was then transferred into a well of the 96-well plate. 
Subsequently, the antibodies were added in appropriate dilutions and the samples were 
incubated on ice and in the dark for 30 minutes to prevent photobleaching. Double or triple Ab 
staining was performed based on the wavelength of the light emitted from each fluorochrome 
upon excitation. After the 30-minute incubation the 96-well plates were centrifuged at 300xg 
for 30 seconds, supernatants were discarded, and the samples were washed by adding 200 μl 
of PBS-0.1% BSA in each well. The samples were subsequently centrifuged at 300xg for 30 
seconds and a total of three similar washes were performed. Finally, the samples were re-
suspended in 200 μl of PBS-0.1% BSA, were transferred into new 1.5 ml tubes and were 
directly run through the flow cytometer (Guava, Merck). Acquisition of geometric mean 
fluorescence intensity values for the fluorescence FC adhesion molecule and cytokine receptor 
assays and diagrams were generated using the FlowJo 10.3 Software.   
2.2.4.4. Apoptosis Assay with FC 
For the apoptosis assay, following 24-hour TNF-α, IL-1β, IL-13, IFN-γ and LPS 
treatments, the ciGEnC samples were trypsinised, centrifuged at 300 xg and resuspended in 
100 μl HBSS and were transferred onto round bottom 96-well plates. The samples were stained 
with Annexin V-FITC at a 1:100 dilution on ice/dark for 15 minutes and subsequently, with PI 
at a 1:1000 dilution in dark and room temperature for 3 minutes. Following completion of 
Annexin V/PI incubation, the cells were further resuspended into 100 μl HBSS, were 
transferred back into 1.5 tubes and were directly run through the flow cytometer. Dot plots for 




2.2.5.1.Basic principles of sandwich ELISA 
A sandwich ELISA is a technique utilised for detection and quantitative measurement of 
the concentration of a target protein in any sample containing proteins (such as cell lysates, 
supernatants, conditioned media, blood serum or plasma samples etc.) without requiring 
previous protein purification334. The target protein is quantified as it is sequestered between 
two different layers of antibodies, the capture and the detection Ab which are both specific to 
the target protein but bind different epitopes of the protein. The capture Ab is diluted in PBS 
and added overnight to coat the bottom of the wells. Subsequently, a solution containing a 
blocking protein such as bovine serum albumin (BSA) is added to prevent non-specific binding. 
The sample is loaded onto the plate and incubated for 2h at room temperature for binding to 
occur. Following this the plate is washed in PBS + 0.05% Tween-20 and this step is followed 
by the addition of the detection Ab which is conjugated to streptavidin, with horseradish 
peroxidase (HRP) being used as a streptavidin substrate. This leads to the target protein being 
“sandwiched” between the capture and the detection Ab. Subsequently, addition of a 
chromogenic substrate for HRP such as Tetramethylbenzidine (TMB), causes a concentration-
dependent colour change that can be quantified by comparison to a standard curve of known 
concentrations. Once the reaction has finished a stop solution is added (5% sulfuric acid diluted 
in ddH2O) and the reaction is immediately measured at 450nm using a microplate reader 
(Figure 2.6). For the measurement of the unknown concentrations of the target protein in 
different samples, a standard sample of known concentration is serially diluted and added onto 
the 96-well plate to create a standard curve (Figure 2.7). The equation of the standard curve 
(the R-square value of the standard curve should ideally range between 0.9-1.) allows for 
calculation of the unknown concentration of the target protein within different samples. All 
standards and samples are added onto the plates in duplicates to ensure better reproducibility 
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of the experiments whereas blank samples (consisting only of reagent diluent) are added as 







Figure 2.6 Sandwich ELISA.  
A capture Ab is added on the bottom of the wells of the 96-well plates followed by addition of standards and samples and then addition of a detectionAb, often 
conjugated to an enzyme, such as HRP. Supplementation of chromogenic enzyme substrate such as TMB can lead to a chromogenic reaction and colour 
formation (HRP-TMB reaction: blue colour). Subsequent addition of a stop solution can lead to change of blue to yellow colour which can be easily processed 




Figure 2.7 Example of a sandwich ELISA standard curve. 
 
2.2.5.2.Protocol for sandwich ELISA 
The secretion of MCP-1 and sVCAM-1 by ciGEnCs and secretion of TNF-α and IL-1β by 
THP-1 cells was assessed using single ELISA kits. All steps were followed as per 
manufacturer’s instructions and as presented on this thesis’s “Basic principles of sandwich 
ELISA” (section 2.5.1). A 2-fold dilution of all samples was performed before addition on 96-
well plate. Plates were read directly at 450 nm using a Microplate Reader (Spectrophotometer).  
2.2.5.3.Luminex multiplex ELISA principles 
Unlike conventional ELISAs, a Luminex ELISA allows for simultaneous detection of 
multiple analytes of interest within the same sample. 
Colour-coded magnetic microparticles pre-coated with analyte-specific capture antibodies 
are pipetted onto the 96-well plate of the Magnetic Luminex® Assay multiplex kit (Figure 
2.8). Subsequently, Luminex assay standards and samples are added onto the plates and the 
capture antibodies specifically bind the multiple analytes of interest (Figure 2.8). Following 
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thorough washes for removal of non-bound substances, a biotin-conjugated Ab cocktail 
specific to the target analytes is pipetted into the wells of the plate and the plate is washed again 
(for the washes the plate is placed on top of the magnet to prevent microparticle loss) (Figure 
2.8). Finally, Streptavidin conjugated to PE is added onto each well and as streptavidin binds 
biotin, PE fluorescence can lead to a light emission where intensity is proportional to the 
concentration of the analytes of interest within each sample (Figure 2.8). After a final wash 
following Streptavidin-PE addition, a buffer is added onto each well to re-suspend the 
microparticles and the plate is read using the Luminex® MAGPIX Analyzer. The Analyzer 
contains a magnet which focuses the microparticles onto a monolayer and a dual laser dissects 
the microparticles, utilising two Light Emitting Diodes (LEDs) which display differential 
spectrum patterns (Figure 2.8). The two LEDs have distinct roles which are identification of 
the detected analyte and determination of the intensity of PE-signal (Figure 2.8). Each well of 
the 96-well plate is scanned with a CCD camera. For this thesis’ experiments, the Luminex® 





Figure 2.8 Luminex multiplex ELISA.  
A Luminex ELISA allows for simultaneous detection of more than one analyte within the same sample. This technique utilises colour-coded magnetic 
microparticles which are pre-coated with analyte-specific capture antibodies. The microparticles are pipetted first on the wells of the 96-well plates and then 
the standards and samples are added followed by analytes-specific biotin-conjugated antibodies and subsequent addition of streptavidin-conjugated PE. The 
beads are then measured through a dual-laser flow-based instrument. 
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2.2.5.4.Protocol for Luminex multiplex ELISA assay 
MIP-1α, IP-10, IL-6, IL-8, GM-CSF, M-CSF, TNF-α and IFN-γ secretion by the ciGEnCs 
was assessed via Luminex multiplex ELISA. All steps were followed as per manufacturer’s 
instructions and as presented on this thesis’s “Luminex multiplex ELISA principles” (section 
2.5.3). A 2-fold dilution of all samples was performed before addition on 96-well plate. Each 
plate was analysed within 20 minutes using the Luminex® MAGPIX CCD Imager. 
 Western blotting 
2.2.6.1. Basic principles of WB 
WB is a semi-quantitative analysis technique allowing for Ab-based detection of a target 
protein within a mixture of various proteins335.  
In WB, biological samples of extracted proteins are initially loaded onto a polyacrylamide 
gel. The proteins are then separated according to their molecular weight (MW) via gel 
electrophoresis, with the proteins of higher MWs moving more slowly from the top to the 
bottom of the gel compared to those of lower MWs, when the electrical current is stably applied 
to the gel. A WB protein ladder consisting of recombinant proteins of a known range of MWs 
is always loaded onto the gel to aid accurate identification of the target protein. At the end of 
the electrophoresis, the separated proteins are transferred onto a PVDF membrane and the 
membrane is blocked for a specific amount of time to avoid non-specific binding of antibodies 
to its surface (Figure 2.9). 
Following blocking, a primary Ab specific for the target protein is added and binds the 
target protein on the surface of the membrane, Subsequently, a secondary Ab conjugated to an 
enzyme such as HRP is also added to specifically bind the primary Ab (the secondary Ab is 
specific to the host species of the primary Ab). When the appropriate substrate is provided for 
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the enzyme such as luminol for HRP, then HRP with the help of hydrogen peroxide (H2O2) 
will catalyse the oxidation of luminol, a process resulting into light emission (known as 
enhanced chemiluminescence or ECL) 336 (Figure 2.9). 
The emitted light is then detected, and the results of the WB chemiluminescent signal can 
be captured -among other ways- utilising digital imaging methods and instruments, leading to 
visualisation of the protein bands. Higher band intensity indicates higher protein expression 




Figure 2.9 Western Blotting.  
The protein lysates are loaded onto a gel and following gel electrophoresis the gel is transferred onto a membrane (nitrocellulose or PVDF) and after successful 
transfer a primary Ab specific to the target protein is added followed by addition of a secondary HRP-conjugated Ab which binds the primary Ab and an ECL 
reaction which leads to production of light and target protein detection through visualisation of the protein bands. Thorough washes are performed between 
each step of Ab and ECL addition. 
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2.2.6.2. Protein extraction and WB protocol 
For the WB assays, the ciGEnCs were seeded into 6-well plates and were treated for 
15 and 30 minutes (37oC, 5% CO2) with 10 ng/ml of TNF-α, IL-1β, IL-13 and IFN-γ and 
with 1 μg/ml of LPS. Following completion of treatments, the ciGEnCs were washed 
twice in 1 ml of cold PBS and were subsequently lysed for 10 minutes on ice, in 180 μl 
of RIPA buffer including 1% protease inhibitor cocktail. The samples were scraped, 
collected into 1.5 ml tubes and were sonicated for 10 minutes to ensure complete lysis. 
Subsequently, the protein samples were centrifuged at 11,000 xg for 10 minutes, the 
supernatants were collected and transferred into new 1.5 ml tubes. 
The protein concentration of each sample was determined using the Pierce™ BCA 
Protein Assay Kit. The BCA assay is a biochemical method for colorimetric protein 
detection and quantitation337. It is based on the creation of an alkaline environment 
promoting the chelation of cupric ions (Cu2+) with peptides of the protein samples 
leading to Cu2+ reduction to cuprous ions (Cu1+), followed by BCA reaction with Cu1+ 
inducing the generation of an intense purple colour337. The assay was carried out in 96-
well plates. The BSA protein standards starting from 2 mg/ml of stock BSA (8 standards, 
range: 2000 μg/ml – 125 μg/ml) were prepared as shown on the table below (Table 2.8), 




A (2000 μg/ml) 300 μl stock BSA 
B (1500 μg/ml) 375 μl stock BSA + 125 μl RIPA buffer 
C (1000 μg/ml) 325 μl stock BSA + 325 μl RIPA buffer 
D (750 μg/ml) 325 μl B + 175 μl RIPA buffer 
E (500 μg/ml) 325 μl C + 325 μl RIPA buffer 
F (250 μg/ml) 325 μl E + 325 μl RIPA buffer 
G (125 μg/ml) 100 μl G + 400 μl RIPA buffer 
Blank RIPA buffer 
 
Table 2.8 BCA assay BSA standards. 
 
All standards and protein samples were added in duplicates (10μl per well) on the 
96-well plates and subsequently 200 μl of the BCA reagent (consisting of 50 parts of 
reagent A and 1 part of reagent B) were added on each well. The plates were then placed 
on a plate shaker for 30 seconds and were incubated at 37°C for 30 minutes. Following 
completion of the 30-minute incubation, the plates were immediately read on a plate 
reader at 562 nm. The standard curve (Figure 2.10) was generated by plotting the 
average absorbance values (y axis) against the standard protein concentrations (x axis) 
and the unknown concentrations of the protein samples were interpolated from the 




Figure 2.10 Example of BCA standard curve. 
For the WB experiments, 15 μg of protein were diluted in NuPAGE LDS Sample 
buffer at a final 1x concentration with 50μM DTT, as a reducing agent. The proteins 
were boiled for 5 minutes at 90oC and were loaded in 12% 50μl 10-well precast SDS-
PAGE gels and protein gel electrophoresis took place into vertical electrophoresis cells 
filled with 1x running buffer prepared from water-diluted 10x running buffer. Gels were 
run at 95 V and at the end of the electrophoresis, were transferred into PVDF membranes 
using the Trans-Blot Turbo Transfer System. At the end of the transfer, each PVDF 
membrane was blocked for at least 1 hour in 5% non-fat dry milk diluted in 1x TBS-T. 
1x TBS-T was prepared via diluting in water the 10x TBS stock solution and adding 
0.1% Tween-20. 
All antibodies were diluted in 1x TBS-T and 5% non-fat dry milk. At the end of 1-
hour blocking, the primary antibodies were added onto the membranes overnight, at 4oC 
and after completion of the primary Ab incubation each membrane was washed with 
TBS-T three times, with a duration of 5 minutes each. The membranes were then 




TBS-T washes, protein detection was achieved using ECL reagents (5-minute 
incubation). Li-COR software was used for protein band densitometry. 
Each membrane was used for multiple protein detection, therefore, after the end of 
each ECL detection procedure the membranes were washed twice for 20 minutes each 
time with mild stripping buffer followed by two 10-minute washes with PBS and three 
5-minute washes TBS-T. By the end of the stripping process, the membranes were ready 
to be re-blocked for detection of a different protein. Beta-actin (β-actin) was used as a 
loading control for reference on each gel.  
 Immunofluorescence (IF) 
2.2.7.1. Basic principles of IF and indirect IF 
IF is a cell imaging technique utilising fluorochrome-conjugated antibodies to detect 
an antigen of interest in a fixed sample and to assess its cellular abundance and 
distribution; visualisation and detection of the antigen of interest subsequently occurs 
via utilisation of a fluorescent microscope (such as a confocal or epifluorescence 
microscope)338,339.  
IF can be either direct or indirect depending on whether the primary Ab against the 
target-antigen is directly conjugated to a fluorophore (direct IF), or whether a secondary 
fluorophore-conjugated Ab is bound to the primary Ab which, this time, is unconjugated 
(indirect IF)338,339. (Figure 2.11). Compared to the direct IF method, indirect IF can 
further enhance the fluorescent signal although it adds further complexity to the assay. 
When an intracellular protein or antigen of interest needs to be detected via IF, the cells 




Figure 2.11 Immunofluorescence (IF).  
Schematics of direct (fluorophore-conjugated primary Ab) versus indirect IF (fluorophore-
conjugated secondaryAb against the primary Ab). 
 
2.2.7.2. IF protocol 
Transcription factor activation and subsequent nuclear translocation was assessed 
using IF. Following 30-minute incubations with 10 ng/ml of TNF-α, IL-1β and IFN-γ 
and with 1 μg/ml of LPS in 12-well plates, ciGEnC plates were placed on ice and cells 
washed three times (3x) with ice-cold PBS and were fixed in 4% formaldehyde for 30 
minutes. Subsequently, ciGEnCs were washed 3x with PBS (at room temperature) and 
were permeabilised using 0.4% Triton-X-100 for 10 minutes. The cells were washed 
with PBS (3x, room temperature) and then, non-specific binding was blocked using 
PBS-1% BSA for 1 hour at room temperature. By the end of 1-hour incubation in PBS-
BSA the cells were washed with PBS 3x (room temperature). Primary antibodies against 
human NF-κΒ, Signal transducer and activator of transcription (STAT)-1 and STAT-2 
were added into plate wells and incubated at 4oC overnight on a plate rocker. Following 
overnight incubation, ciGEnCs were washed 3x with PBS (room temperature) and were 
incubated with fluorescence-conjugated secondary antibodies and 1 μg/ml of DAPI, for 
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2 hours at room temperature. Cells were visualised immediately, using the EVOS FLoid 
Cell Imaging Station (ThermoFisher Scientific).  
2.2.7.3. Image Analysis using ImageJ 
Image analysis to determine nuclear translocation of the signal in response to 
cytokine or LPS treatment was performed using Fiji (ImageJ) and particularly the Coloc2 
algorithm340. For every group of treatments, the Pearson’s r-values for every single cell, 
representing the degree of nuclear colocalisation between DAPI and A488 or A568, were 
obtained.  
 Statistical analyses 
Statistical analyses of all data were performed using GraphPad Prism 4.0 software. 
Data are expressed as median values. Multiple comparisons were made using Kruskal-
Wallis or Friedman non-parametric test with Dunn’s post-hoc test. Potential correlations 
between increasing cytokine concentrations and pro-inflammatory protein gene 
expression was explored using the non-parametric Spearman correlation test. For the 
existence of a positive correlation, the value for the correlation coefficient (r) had to be 
between 0.7 and 1. 
For the IF experiments, for nuclear co-localisation to be statistically significant, the 
r-values should range between 0.7 to 1. Therefore, in all the statistical analysis diagrams 
a horizontal dashed line starting from the 0.7 value on the y-axis separates the cells of 
each treatment in two groups; the low r-value group for cells displaying moderate to low 
degree of nuclear co-localisation and the high r-value group for cells displaying 




In this chapter, a detailed presentation of the principles and protocols of all the 
methods and techniques used to address the specific aims and objectives of this project 




3. Chapter 3: Identifying the key pro-inflammatory stimuli in glomerular 
endothelial cell-mediated inflammation 
Work from this chapter has been published in Scientific Reports341 (see Appendix D). 
3.1. Introduction 
LN is a complex disease, with one of its main features being the presence of various 
pro-inflammatory cytokines in the kidney microenvironment that significantly 
contribute to chronic inflammation induced GFB damage (see section 1.4). This can 
cause impaired blood plasma filtration resulting in proteinuria and haematuria, clinically 
detected via examination of patients’ urine samples342,343. Although there is limited 
knowledge about the involvement of the human GEnCs in LN inflammation and 
production of pro-inflammatory mediators, strong evidence exists that HUVECs344,345 
and human brain microvascular endothelial cells (HBMECs)346,347, when cultured in 
vitro under appropriate pro-inflammatory stimuli such as tumour necrosis factor-alpha 
(TNF-α), interleukin-1 beta (IL-1β) and lipopolysaccharide (LPS), elicit a robust 
inflammatory response. This response involves nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) activation and production of adhesion molecules 
and cytokines. Thus, uncovering the role of human GEnCs, could provide further insight 
into LN pathogenesis.  
3.2. Aim 
To assess the pro-inflammatory profile of the human GEnCs using an in vitro 




Objective 1: To determine the effects of pro-inflammatory cytokines involved in 
LN in ciGEnC expression of novel urinary biomarkers for LN and pro-inflammatory 
protein production, and to determine which of these cytokines have the most prominent 
effect. 
To address this objective, an in vitro model of LN was developed using human ciGEnCs 
(see section 2.2.2) that were exposed to a pro-inflammatory environment, including 
cytokines involved in LN (TNF-α, IL-1β, IL-6, IL-13, IFN-α, IFN-γ, VEGF) and LPS. 
Subsequently, the ciGEnC pro-inflammatory phenotype was investigated via testing the 
production, surface expression and secretion of pro-inflammatory proteins; adhesion 
molecules, co-stimulatory molecules, urinary biomarkers, blood cell growth factors, 
cytokines and chemokines, all involved in binding and recruitment of immune cells to 
inflamed tissues. 
Objective 2: To test whether the pro-inflammatory stimulated ciGEnCs activate 
important pro-inflammatory transcription factors. 
To address this objective, the ciGEnCs were treated with TNF-α, IL-1β and IFN-γ (being 
the mediators from objective 1 that elicited the most robust responses) and the induction 
of transcription factor nuclear translocation was tested. 
Objective 3: To assess the viability of ciGEnCs after pro-inflammatory stimulation. 
To address this objective, the ciGEnCs were treated with the cytokines found to have the 
most prominent effect on ciGEnC pro-inflammatory activation as well as LPS, and their 
apoptosis/necrosis levels were tested. 
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 Chapter hypothesis  
Under in vitro stimulation with pro-inflammatory cytokines and with LPS the 
ciGEnCs will exhibit a robust pro-inflammatory phenotype including activation of pro-
inflammatory transcription factors, and increased secretion of cytokines, chemokines 
and blood cell growth factors and surface expression of adhesion and co-stimulatory 
molecules. This phenotype will be an active response to pro-inflammatory stimuli and 
not an event occurring due to ciGEnC death. 
3.3. Materials and Methods 
 ciGEnC preparation and treatment 
The fully differentiated ciGEnCs were seeded on 6-well plates for apoptosis assays 
(Annexin V-FITC and PI staining), 12-well plates for adhesion molecule (VCAM-1, 
ICAM-1), and co-stimulatory molecule (PD-L1, ICOS-L) FC assays, 6-well plates for 
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha (Iκ-
Bα) WB experiments,  12-well plates for SYBR Green real-time PCR (MCP-1, VCAM-
1, TF and L-PGDS mRNA expression), ELISA assays (MCP-1, sVCAM-1, IL-6, IL-8, 
IL-10, M-CSF, GM-CSF, IP-10, MIP-1α, TNF-α, IFN-γ) and IF assays (NF-κΒ, STAT-
1, STAT-2) and on 24-well plates for mRNA concentration response real-time PCR 
assays.  
Subsequently, ciGEnCs were incubated at 37oC (with 5% CO2) for 15 minutes, 30 
minutes, 4 hours and 24 hours with 10 ng/ml of human recombinant IFN-α, IFN-γ, TNF-
α, IL-1β, IL-6, IL-13 and VEGF individually and in combination. The potential effect of 
bacterial endotoxin inflammation was also examined via 1 μg/ml of LPS treatment. 
Untreated ciGEnCs cultured in media without addition of pro-inflammatory cytokines 
or LPS, were included at all experiments for the identification of potential treatment-
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induced changes in mRNA, protein and transcription factor levels compared to basal 
ciGEnC levels. 
 qRT-PCR for the expression of urinary biomarkers 
The ciGEnCs were stimulated for 24 hours with IFN-α, IFN-γ, TNF-α, IL-1β, IL-6, 
IL-13 and VEGF alone and in combination and with LPS. Subsequently, the cells were 
washed and immediately lysed with Trizol to perform Trizol-chloroform RNA 
extraction. RNA was transcribed to cDNA and qRT-PCR was performed to investigate 
the expression levels of the urinary biomarkers for active LN biomarkers; AGP, CP, L-
PGDS, TF, NGAL, MCP-1, VCAM-1. 
 ELISA assays  
The secretion of MCP-1, sVCAM-1, IL-6, IL-8, IL-10, M-CSF, GM-CSF, MIP-1α, 
IP-10, TNF-α and IFN-γ was tested with single ELISAs or a Luminex multiplex ELISA 
assay, utilising conditioned media from ciGEnCs treated for 24 hours with cytokines (as 
above) and LPS. Conditioned media from IL-6 and VEGF treatments were excluded as 
they induced no change in the mRNA expression of the urinary biomarkers. However, 
IL-6 and VEGF were still included in the combined cytokine treatment (All). 
 Concentration response for TNF-α, IL-1β, IL-13 and IFN-γ 
A concentration response experiment was performed for TNF-α, IL-1β, IL-13 and 
IFN-γ to ensure that the 10 ng/ml used for ciGEnC stimulation was the lowest in vitro 
concentration able to induce a robust increase in the expression of pro-inflammatory 
genes. The ciGEnCs were treated for 24 hours with TNF-α, IL-1β, IL-13 and IFN-γ with 
10 ng/ml being the highest concentration used to perform ten-fold serial dilutions, with 
10 pg/ml being the lowest concentration used (10 ng/ml → 1 ng/ml → 100 pg/ml → 1 
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pg/ml). Following completion of the 24-hour treatments, the conditioned media were 
removed, cells were washed with PBS and were immediately lysed with Trizol to carry 
out a Trizol-chloroform RNA extraction and, subsequently, cDNA transcription that was 
used for qRT-PCR assays. 
The TNF-α-, IL-1β-, IL-13- and IFN-γ-stimulated ciGEnCs were found to 
incrementally upregulate the mRNA expression of pro-inflammatory genes following 
stimulation with increasing cytokine concentrations, with the 10 ng/ml treatments 
inducing the most robust effect.  
A positive correlation was observed between increasing concentrations of TNF-α 
and MIP-1α mRNA (r=0.9, p=0.08) and a statistically significant correlation for 
increasing concentrations of TNF-α and M-CSF (r=1, p=0.02) mRNA levels (Figure 
3.1). A positive correlation, although not statistically significant, was also observed 
between increasing doses of TNF-α and IL-8 (r=0.7, p=0.23) and GM-CSF (r=0.7, 
p=0.23) mRNA levels (Figure 3.1). No strong correlation was found between increasing 
TNF-α concentrations and MCP-1 (r=0.6, p=0.35) and VCAM-1 (r=0.5, p=0.45) mRNA 
levels, however the highest TNF-α concentration (10 ng/ml) induced the expression of 




Figure 3.1 24-hour TNF-α concentration response assays.  
Changes in the mRNA expression levels of MCP-1, MIP-1α, VCAM-1, IL-8, M-CSF and GM-
CSF following treatments with increasing concentrations of TNF-α. N=3-4/group. Data are 
presented as (Mean +/- SEM) and correlations are analysed using non-parametric Spearman’s 
test. HK: ACTB, TUBB, TBP. 
 
From the IL-1β concentration response experiments, a positive correlation occurred 
between increasing concentrations of IL-1β and mRNA levels of MCP-1 (r=0.9, 
p=0.08), and a statistically significant correlation was observed for increasing IL-1β 
concentrations and MIP-1α (r=1, p=0.02), IL-6 (r=1, p=0.02), IL-8 (r=1, p=0.02), M-
CSF (r=1, p=0.02) and GM-CSF (r=1, p=0.02) mRNA levels (Figure 3.2). 
 
r=0.6, p=0.35 r=0.5, p=0.45 r=0.9, p=0.08 




Figure 3.2 24-hour IL-1β concentration response assays.   
Changes in the mRNA expression levels of MCP-1, MIP-1α, IL-6, IL-8, M-CSF and GM-CSF 
following treatments with increasing concentrations of IL-1β. N=3-4/group. Data are presented 
as (Mean +/- SEM) and correlations are analysed using non-parametric Spearman’s test. HK: 
ACTB, TUBB, TBP. 
 A significant positive correlation (r=1, p=0.02) was also observed between 
increasing concentrations of IL-13 and VCAM-1 mRNA levels (Figure 3.3). 
 
Figure 3.3 24-hour IL-13 concentration response assays..  
Changes in the mRNA expression levels of VCAM-1 following treatments with increasing 
concentrations of IL-13. N=3-4/group. Data are presented as (Mean +/- SEM) and correlations 
are analysed using non-parametric Spearman’s test. HK: ACTB, TUBB, TBP 
r=0.9, p=0.08 
r=1, p=0.02 r=1, p=0.02 




 Finally, a positive correlation (r=0.9, p=0.08) was observed for increasing 
concentrations of IFN-γ and IP-10 mRNA levels but no correlation was observed 
between IFN-γ and IL-10 mRNA levels which were generally lowly expressed (Figure 
3.4). 
 
Figure 3.4 24-hour IFN-γ concentration response assays.  . 
Changes in the mRNA expression levels of IP-10 and IL-10 following treatments with increasing 
concentrations of IFN-γ. N=3-4/group. Data are presented as (Mean +/- SEM) and correlations 
are analysed using non-parametric Spearman’s test. HK: ACTB, TUBB, TBP 
 FC for leukocyte adhesion molecules, T cell co-stimulatory molecules and 
cytokine receptors 
The ciGEnCs were treated for 4 or 24 hours with TNF-α, IL-1β, IL-13, IFN-γ and 
LPS. Following completion of treatments, the conditioned media were removed, cells 
were washed with PBS, trypsinised and pelleted at 300 xg for 5 minutes and were then 
resuspended in PBS with 0.1% BSA and stained for 30 minutes on ice with antibodies 
specific for human E-/P-selectin, VCAM-1, ICAM-1, PD-L1 and ICOS-L, prior to flow 
cytometric analysis. 
 ciGEnC viability  
The ciGEnCs were treated for 24 hours with TNF-α, IL-1β, IL-13, IFN-γ and LPS. 




the cell pellets were resuspended in HBSS and initially stained with Annexin V – FITC 
(15 minutes on ice) and then with PI (5 minutes, room temperature, dark) to perform a 
flow cytometric apoptosis assay. 
 Western Blotting for Iκ-Bα 
ciGEnCs were stimulated for 15 and 30 minutes with TNF-α, IL-1β, IL-13, IFN-γ 
and LPS, washed with ice-cold PBS and immediately after the washes were lysed using 
ice-cold RIPA buffer with protease inhibitor cocktail (15 minutes on ice, with occasional 
swirling). Cell lysates were collected, sonicated and centrifuged for 10 minutes at 
approximately 11,000 xg, Supernatants were collected, and protein concentration of each 
sample was determined with BCA assay. From each sample equal protein concentrations 
were loaded onto gels for electrophoresis, using sample buffer together with DTT as 
previously described in the Materials & Methods (see section 2.2.6). Human Iκ-Bα levels 
were detected on the membranes, with human β-actin used as a loading control.  
 Immunofluorescence for NF-κB, STAT-1 and STAT-2 
The ciGEnCs were treated for 15 and 30 minutes with TNF-α, IL-1β and LPS to 
investigate NF-κB nuclear translocation and with IFN-γ to investigate STAT-1 and 
STAT-2 nuclear translocation. Following the end of treatments cells were washed with 
ice-cold PBS, were fixed with formaldehyde for 20 minutes, washed with PBS and were 
permeabilised with Triton-X for 10 minutes. Subsequently, the cells were washed with 
PBS, were incubated at room temperature for at least 1 hour with PBS and 0.1% BSA 
and were then blocked with anti-human NF-κΒ, STAT-1 and STAT-2 antibodies at 4oC 
overnight. Following overnight incubation, cells were washed with PBS, blocked for 2 
hours at room temperature with secondary fluorescence-conjugated antibodies and 
immediately afterwards PBS was added and ciGEnCs were visualised using the EVOS 
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FLoid Cell Imaging Station. Image analysis took place using Fiji (Image J) as previously 
described within the general “Materials and Methods” (see section 2.2.7.3). 
 Statistical analyses 
Changes between two different groups were studied using non-parametric Mann-
Whitney test whereas changes among three or more groups were studied using Kruskal-
Wallis or Friedman’s test with Dunn’s post-hoc test. Potential correlations (r >= 0.7) 
were tested using non-parametric Spearman’s test. 
3.4. Results 
 Inflammatory stimulation of ciGEnCs induces the production of urinary 
biomarkers and pro-inflammatory proteins 
3.4.1.1.Investigating the mRNA expression and secretion of urinary biomarkers 
ciGEnC expression of urinary biomarker mRNA was tested after 24 hours of 
cytokine and LPS incubation. No basal, cytokine- or LPS-induced mRNA expression 
levels of AGP, CP, or NGAL were detected. This indicated that the human GEnCs are 
not able to produce these biomarkers and therefore, other renal cell types or immune 
cells could be responsible for their production.  
MCP-1 and VCAM-1 mRNA expression levels were significantly increased 
following certain cytokine treatments or LPS treatment (Figure 3.5 A-B). More 
specifically, for MCP-1 and VCAM-1 mRNA expression, TNF-α (3.67 [3.1-3.2], 
p=0.004), IL-1β (2.3 [1.2-3.1], p=0.05) and the combined cytokine treatment (All: 3.6 
[3.6-5.4], p=0.001) significantly increased MCP-1 levels compared to untreated 
ciGEnCs (0.17 [0.07-0.7]) (Figure 3.5-A) whereas IL-13 (0.62 [0.29-0.74], p=0.002) 
significantly upregulated VCAM-1 expression compared to the untreated cells (0.03 
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[0.02-0.11]), as did the combined cytokine treatment (0.17 [0.12-0.25]), potentially due 
to the combined action of IL-13 with TNF-α  (Figure 3.5-Β).  The ciGEnCs were also 
able to express L-PGDS and TF mRNA. However, in low basal levels that were not 
altered by cytokine or LPS treatments (Figure 3.5 C-D).  
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Figure 3.5 qRT-PCR for MCP-1, VCAM-1, L-PGDS and TF mRNA after 24-hour treatments 
with cytokines and LPS.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in L-
PGDS mRNA levels. D. Changes in TF mRNA levels N=5-6/group. Data presented as median 
ΔΔCt, are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *p ≤0.05, **p ≤0.01 vs 
untreated. HK gene: YWHAZ. 
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At the protein level, the combination of all cytokines (All: 3,755pg/mL [3,159-3,989], 
p=0.008) led to significantly higher levels of secreted MCP-1 compared to the untreated 
cells (800 pg/mL [346-1,856]) (Figure 3.6-A), an effect also observed for LPS 
(2,876pg/mL [2,457-3,072], p=0.04). A significant increase in secreted levels of 
sVCAM-1 (Figure 3.6-B) was only induced by IL-13 (1,539pg/mL [731-1,718], p=0.02) 
compared to the untreated cells (192pg/mL [73-661]). Culture media after IL-6 and 
VEGF treatment were excluded from Luminex ELISA analysis due to space limitations 
and due to lack of mRNA induction for MCP-1 and VCAM-1.  
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Figure 3.6 Urinary biomarker secretion after 24-hour ciGEnC-stimulation with individual 
cytokines, combination of all cytokines (All) and LPS.  
A. MCP-1. B. sVCAM-1. N=5-6/group. Data presented as median concentrations are analysed 
using Kruskal-Wallis test with Dunn’s post-hoc test, *p≤0.05, **p≤0.01 vs untreated.  
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3.4.1.2.Investigating the secretion of pro-inflammatory proteins 
As the ciGEnCs substantially produce and secrete only two out of the seven 
identified novel urinary biomarkers for LN 15 (MCP-1 that is a chemokine and VCAM-
1 that is an adhesion molecule), it was hypothesised that the role of GEnCs in the 
initiation and sustainability of LN renal inflammation can be related to the production 
and local secretion of various pro-inflammatory proteins. To address this hypothesis, 
changes in secretion levels of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-6 
and IL-10 and chemokines such as MIP-1α, IP-10 and IL-8 as well as blood cell growth 
factors such as GM-CSF and M-CSF, were examined via Luminex ELISA assay.  
Culture media after IL-6 and VEGF treatment were excluded from Luminex ELISA 
analysis due to space limitations and due to lack of mRNA induction for MCP-1 and 
VCAM-1.  
Cytokine secretion following stimulation with cytokines and LPS 
IFN-γ (8pg/mL [7-9], p=0.029), IL-1β (11pg/ml [7-13], p=0.011) and LPS (14pg/ml 
[8-21], p=0.0005) treatments significantly upregulated TNF-α secretion compared to 
untreated cells (3.5pg/ml [3-4]) (Figure 3.7-A). The single TNF-α treatment and the 
combined cytokine treatment were excluded as they gave false positive results due to the 
presence of recombinant human TNF-α, however these treatment groups were still 
included in the statistical analysis. LPS treatment (28pg/ml [2-42], p=0.005) induced the 
secretion of significantly higher amounts of IFN-γ compared to untreated cells (1pg/ml 
[1-1]) (Figure 3.7-B). The single IFN-γ treatment and the combined cytokine treatment 
were excluded from the graphs as they gave false positive results due to the presence of 




IL-6 secretion was significantly upregulated after IL-1β (3,479pg/ml [1,599-5,273], 
p=0.0004) and LPS stimulation (3,323pg/ml [1,083-5,228], p=0.0007) (Figure 3.7-C) 
compared to untreated ciGEnCs (31pg/ml [11-163]). IFN-γ (18pg/ml [14-21], p=0.004), 
combined cytokine treatment (All: 24pg/ml [22-24], p<0.0001) and LPS (17pg/ml [8-
21], p=0.009) significantly increased IL-10 secretion compared to untreated cells 
(0.5pg/ml [0.3-0.7]) (Figure 3.12-D).  
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Figure 3.7. Cytokine secretion after 24-hour ciGEnC-stimulation with individual cytokines, 
combination of all cytokines (All) and LPS.  
A. TNF-α. B. IFN-γ. C. IL-6. D. IL-10. N=5-6/group. Data presented as median concentrations 
are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *P≤0.05, **P≤0.01, 
***p≤0.001, ****p≤0.0001 vs untreated.  
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Chemokine secretion following stimulation with cytokines and LPS 
Α trend was observed for increased IL-8 secretion after combined cytokine 
treatment (All; 6,127pg/mL [3,664-6,255], p=0.066) compared to untreated cells 
(623pg/ml [449-1,503]) (Figure 3.8-A). IFN-γ (3,015pg/ml [2,530-3,201], p=0.008) and 
combination of cytokines (All: 3,222pg/ml [3,153-3,262], p=0.0003) significantly 
upregulated IP-10 secretion compared to untreated cells (2pg/ml [2-4]), as did LPS 
(2,870pg/ml [847-3,218], p=0.013) (Figure 3.8-B). TNF-α (222pg/ml [221-223], 
p=0.048), IL-1β (222pg/ml [213-226], p=0.049) and the combined cytokine treatment 
(All:  239pg/ml [233-243], p=0.0002) significantly increased the secretion of MIP-1α 
compared to untreated cells (209pg/ml [207-209], as did LPS (226pg/ml [215-230], 
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Figure 3.8 Chemokine secretion after 24-hour ciGEnC-stimulation with individual cytokines, 
combination of all cytokines (All) and LPS.  
A. IL-8. B. IP-10. C. MIP-1α. C. IL-6. N=5-6/group. Data presented as median concentrations 
are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *P=0.05, **p=0.01, 
***p≤0.001 vs untreated.  
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Blood cell growth factor secretion following stimulation with cytokines and LPS 
The combined cytokine treatment led to secretion of significantly higher amounts 
of M-CSF (All: 3,755pg/ml [3,159-3,989], p=0.001) compared to untreated cells 
(800pg/ml [346-1,856]), as did LPS (2876pg/ml [2,457-3,072], p=0.04) (Figure 3.9-A). 
IL-1β (2,284pg/ml [710-2,748], p=0.0001) and TNF-α (522pg/ml [493-722], p=0.02) 
significantly increased the secretion of GM-CSF compared to untreated cells (20pg/ml 
[17-40]), as did the combined cytokine treatment (All: 1,010pg/ml [323-1,925], 
p=0.002) and LPS (790pg/ml [231-1,882], p=0.008) (Figure 3.9-B).  
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Figure 3.9 Blood cell growth factor secretion after 24-hour ciGEnC-stimulation with 
individual cytokines, combination of all cytokines (All) and LPS.  
A. M-CSF. B. GM-CSF. N=5-6/group. Data presented as median concentrations are analysed 





 Inflammatory stimulation leads to differential expression of cellular adhesion 
and co-stimulatory molecules 
The endothelium is responsible for the recruitment and activation of leukocytes to 
the glomerular space by upregulating expression of cellular adhesion and co-stimulatory 
molecules (see section 1.4). The role of TNF-α, IL-1β, IL-13, IFN-γ and LPS, as the five 
most robust in vitro ciGEnC stimuli among those tested for pro-inflammatory protein 
secretion, were assessed by determining their ability to modulate the surface expression 
of three leukocyte adhesion molecules and two T cell co-stimulatory molecules, known 
to play important roles in the inflammatory properties of the endothelia; E-/P-selectin, 
VCAM-1, ICAM-1, PD-L1 and ICOS-L.  
The fluorescence intensity signals were measured, and the geometric mean of the 
fluorescence intensity was calculated for each treatment condition and the geometric 
mean fluorescence intensity value for isotype control was subtracted from these values. 
Isotype control geometric mean values higher than those of untreated/treatment groups, 
indicated lack of surface expression (demonstrated as 0 values). 
3.4.2.1.E-/P-selectin surface expression following TNF-α and IL-13 stimulation 
The surface expression of E-/P-selectin by ciGEnCs was tested following 4- and 24-
hour treatments with TNF-α and IL-13 alone, or in combination. Basal expression of E-
/P-selectin was low at 4 hours (Figure 3.10-A) and almost negligible at 24 hours (Figure 
3.10-B). Furthermore, no statistically significant changes were observed at either 4 or 24 





Figure 3.10  E-/P-selectin surface expression following 4- and 24-hour stimulation with TNF-
α and IL-13 alone, or in combination.  
A. 4-hour E-/P-selectin surface expression following IL-13 and TNF-α treatments. B. 24-hour 
E-/P-selectin surface expression following IL-13 and TNF-α treatments. Data presented as 
(median [range]) are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS. 
 
3.4.2.2.VCAM-1 and ICAM-1 surface expression following stimulation with cytokines 
and LPS 
TNF-α and IL-13, alone or in combination, had no significant effect on VCAM-1 
(Figure 3.11-A) surface expression at 4 hours. At 24 hours, TNF-α (14 [7-86], p=0.008) 
and more markedly the combined action of IL-13 and TNF-α (IL-13+TNF-α: 54 [11-
157], p=0.0007) significantly upregulated surface expression of VCAM-1 compared to 
untreated ciGEnCs (3 [0-4]) (Figure 3.11-B). At 4 hours, LPS (10 [6-38], p=0.01) 
significantly increased the surface expression of VCAM-1 compared to untreated 
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ciGEnCs (0 [0-0)] (Figure 3.11-C).  At 24 hours, IL-1β, IFN-γ and LPS exhibited no 





Figure 3.11   VCAM-1 surface expression following 4- and 24-hour stimulation with cytokines and LPS.  
A. 4-hour VCAM-1 surface expression following IL-13 and TNF-α treatments. B. 24-hour VCAM-1 surface expression following IL-13 and TNF-α treatments. 
C. 4-hour VCAM-1 surface expression following IL-1β, IFN-γ and LPS treatments. D. 24-hour VCAM-1 surface expression following IL-1β, IFN-γ and LPS 
treatments. N=4-6/group. Data presented as (median [range]) were analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *p≤0.05, **p≤0.01, 




           TNF-α and IL-13, alone or in combination, had no significant effect on VCAM-
1 (Figure 3.12-A) surface expression at 4 hours. At 24 hours, TNF-α alone (19,789 
[13,348-25,897], p=0.009) significantly upregulated surface expression of the 
constitutively expressed ICAM-1 compared to untreated ciGEnCs (6,609 [3,984-9,632]) 
(Figure 3.12-B). IL-13 (5,836 [4,684-10,747], p=NS) had no effect on ICAM-1 surface 
levels. IL-1β, IFN-γ and LPS treatments had an effect predominantly on ICAM-1. IL-1β 
(5,770 [4,874-9,777], p=0.04) and LPS (7,323 [5,593-9,734], p=0.007) significantly 
increased surface ICAM-1 expression at 4 hours compared to untreated ciGEnCs (2,278 
[1,415-3,265]) (Figure 3.12-C). This effect was not only sustained for up to 24 hours of 
continuous incubation, but also both IL-1β (6,562 [5,953-9,673], p=0.004) and LPS 
(7,997 [5,497-12,334], p=0.002) further enhanced ICAM-1 surface expression 




Figure 3.12 ICAM-1 surface expression following 4- and 24-hour stimulation with cytokines and LPS.  
A. 4-hour ICAM-1 surface expression following IL-13 and TNF-α treatments. B. 24-hour ICAM-1 surface expression following IL-13 and TNF-α treatments. 
C. 4-hour ICAM-1 surface expression following IL-1β, IFN-γ and LPS treatments. D. 24-hour ICAM-1 surface expression following IL-1β, IFN-γ and LPS 




3.4.2.3.PD-L1 and ICOS-L surface expression following stimulation with cytokines and 
LPS 
IFN-γ had no effect on ICAM-1 or VCAM-1 but at 24 hours significantly increased 
the surface expression of PD-L1 (IFN-γ: 3549 [2199-3828], p=0.02), a negative T cell 
co-stimulatory molecule348, compared to untreated ciGEnCs (1763 [793-2067]) (Figure 
3.13-B). Finally, surface ICOS-L expression was significantly increased at 24 hours only 
by IL-1β (380.4 [365.4-401.4], p=0.035) compared to untreated ciGEnCs (55.1 [52.1-




Figure 3.13 PD-L1 and ICOS-L surface expression following 4- and 24-hour stimulation with TNF-α, IL-1β, IL-13, IFN-γ and LPS.  
Α. 4-hour surface PD-L1 expression. B. 24-hour surface PD-L1 expression. C. 4-hour surface ICOS-L expression. D. 24-hour surface ICOS-L expression. N=3-
5/group. Data presented as (median [range]) were analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *p≤0.05 vs untreated. 
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 Inflammatory protein production is not associated with increased cellular death 
The apoptotic/necrotic levels of ciGEnCs after 24-hour incubation with TNF-α, IL-
1β, IL-13, IFN-γ and LPS were tested, in order to elucidate whether the production of 
pro-inflammatory proteins was an active process, or, a passive process due to cell death. 
The majority of ciGEnCs remained viable (Anx V-/PI-) after 24-hour treatment with 
cytokines and LPS similarly to the untreated ciGEnCs (Figure 3.14-A). No significant 
changes were observed in the levels of apoptotic (Anx V+/PI-) (Figure 3.14-A) and late 





Figure 3.14  ciGEnC viability after 24 hours of TNF-α, IL-1β, IL-13, IFN-γ and LPS 
exposure.  
A. Viable (Anx V-/PI-), early apoptotic (Anx V+/PI-) and late apoptotic/necrotic (Anx V+/PI+) 
ciGEnCs after 24 hours of exposure to cytokines and LPS. N=5/group. B. Representative dot-
plots for each treatment. 
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 TNF-α, IL-1β and LPS can induce Iκ-Bα degradation 
In order to determine whether the effects observed in ciGEnCs following cytokine 
and LPS treatments are mediated through the NF-κB pathway, an immunoblot assay was 
used to determine Iκ-Bα expression. This was to evaluate its degradation levels as, under 
appropriate stimulation, Iκ-Bα that is bound on NF-κB in the cytoplasmic area gets 
degraded leading to release and subsequent NF-κB nuclear translocation349. 
At both 15 and 30 minutes of ciGEnC incubation, TNF-α and IL-1β were able to 
induce Iκ-Bα degradation compared to the untreated ciGEnCs whereas LPS only 
induced Iκ-Bα degradation at 30 minutes. At 15 minutes, TNF-α incubation led to a 2-
fold decrease in Iκ-Bα levels and IL-1β led to a 3.9-fold decrease in Iκ-Bα levels (Figure 
3.15-A). At 30 minutes, TNF-α and IL-1β induced a 1.6-fold and a 7.1-fold decrease in 
Iκ-Bα levels compared to the untreated ciGEnCs. In addition, LPS treatment led to a 2-
fold decrease in Iκ-Bα levels (Figure 3.15-B). IL-13 and IFN-γ did not promote Iκ-Bα 





Figure 3.15  WB for Iκ-Bα protein expression after 15 and 30 minutes of ciGEnC stimulation 
with TNF-α, IL-1β, IL-13, IFN-γ and LPS.  
A. Representative image and graph of Iκ-Bα and β-actin Western blots, following 15-minute 
stimulation. B. Representative image and graph of Iκ-Bα and β-actin Western blots, following 
30-minute stimulation N=5 group. Data presented as (median [range]) in ratio diagrams are 
analysed using Friedman test with Dunn’s post-hoc test, *p≤0.05 vs untreated. 
 
 Pro-inflammatory protein release is occurring through NF-κB and STAT-1 
induction in ciGEnCs 
Upon activation by pro-inflammatory cytokines or LPS, pro-inflammatory 
transcription factors such as NF-κB, STAT-1 and STAT-2, will translocate from the 
cytoplasm to the nucleus of a cell leading to production of pro-inflammatory gene 
expression. NF-κB is activated via phosphorylation after the phosphorylation and 
degradation of its cytoplasmic inhibitor Iκ-Bα, whereas STATs will be activated via 
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phosphorylation and can subsequently form STAT-1 – STAT-1 homodimers or STAT-
1 – STAT-2 heterodimers that will translocate within the nucleus.  
Nuclear translocation of NF-κB following TNF-α, IL-1β and LPS stimulation and 
of STAT-1 and STAT-2 after IFN-γ stimulation, was used to determine pro-
inflammatory pathway activation.  
Based on the r-values for DAPI and A488 co-localisation, TNF-α and IL-1β 
promoted NF-κB nuclear translocation at both 15 (Figure 3.16) and 30 minutes (Figure 
3.17) with IL-1β (15 minutes: r=0.7, p<0.0001, 30 minutes: r=0.9, p<0.0001) 
displaying a more pronounced effect than TNF-α (15 minutes: r=0.4, p=0.001, 30 
minutes: r=0.7, p<0.0001) whereas LPS demonstrated a low to moderate effect only 




Figure 3.16 20x IF images of ciGEnCs and diagrams of statistical analysis for NF-κB 
activation and nuclear translocation, after 15 minutes of stimulation with cytokines and LPS. 
 A. Treatments of ciGEnCs with TNF-α, IL-1β and LPS for 15 minutes for NF-κB nuclear 
translocation. B. Statistical analysis. Data (r-values for nuclear co-localisation of DAPI and A488 
for each treatment group) representative of three similar experimental repeats are presented as box 
and whisker plots and were analysed using Kruskal-Wallis test with Dunn’s post-hoc test. **p≤0.01, 




Figure 3.17 20x IF images of ciGEnCs and diagrams of statistical analysis for NF-κB 
activation and nuclear translocation, after 30 minutes of stimulation with cytokines and LPS.  
A. Treatments of ciGEnCs with TNF-α, IL-1β and LPS for 30 minutes for NF-κB nuclear 
translocation. B. Statistical analysis. Data (r-values for nuclear co-localisation of DAPI and A488 
for each treatment group) representative of three similar experimental repeats are presented as box 
and whisker plots and were analysed using Kruskal-Wallis test with Dunn’s post-hoc test. 
****p≤0.0001 vs untreated. Scale bars: 100μm. 
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According to the r-values for DAPI and A456 co-localisation, IFN-γ moderately to 
highly induced STAT-1 nuclear translocation at 15 minutes (r=0.6, p<0.0001) (Figure 
3.18) and at 30 minutes (r=0.6, p<0.0001) (Figure 3.19) while it could not induce STAT-
2 activation (Figures 3.20 and 3.21).  
As IL-13 altered solely VCAM-1 and not any other of the pro-inflammatory genes 






Figure 3.18 20x IF images of ciGEnCs and diagrams of statistical analysis for STAT-1 
activation and nuclear translocation, after 15 minutes of stimulation with IFN-γ.   
A. Treatments of ciGEnCs with IFN-γ for 15 minutes for STAT-1 nuclear translocation. B. Statistical 
analysis. Data (r-values for nuclear co-localisation of DAPI and A568 for each treatment group) 
representative of three similar experimental repeats are presented as box and whisker plots and were 




Figure 3.19  20x IF images of ciGEnCs and diagrams of statistical analysis for STAT-1 
activation and nuclear translocation, after 30 minutes of stimulation with IFN-γ.  
A. Treatments of ciGEnCs with IFN-γ for 30 minutes for STAT-1 nuclear translocation. B. Statistical 
analysis. Data (r-values for nuclear co-localisation of DAPI and A568 for each treatment group) 
representative of three similar experimental repeats are presented as box and whisker plots and were 




Figure 3.20 20x IF images of ciGEnCs and diagrams of statistical analysis for STAT-2 
activation and nuclear translocation, after 15 and 30 minutes of stimulation with IFN-γ.  
A. Treatments of ciGEnCs with IFN-γ for 15 and 30 minutes for STAT-1 nuclear translocation. 
B-C. Statistical analysis. Data (r-values for nuclear co-localisation of DAPI and A488 for each 
treatment group) representative of three similar experimental repeats are presented as box and 







The experimental plan in this chapter aimed to investigate the pro-inflammatory 
profile of the human ciGEnCs following stimulation with cytokines known to be 
upregulated in the serum of patients with LN (IL-1β, TNF-α, IFN-α, IFN-γ, IL-6 and 
VEGF) and with LPS. In murine models of LN, LPS is known to play a critical role in 
LN exacerbation after a bacterial infection350–352 but can also disrupt the normal function 
of human endothelial cells during human endotoxemia353. As physiologically the GEnCs 
are found at the interface between blood circulation and the glomerular renal tissue, it 
was hypothesised that, during LN renal disease, the GEnCs would acquire a pro-
inflammatory phenotype able to enhance and promote local inflammation and, therefore, 
kidney-specific damage. 
The ciGEnCs were treated for 15 minutes or 30 minutes and for 4 hours or 24 hours 
with 10 ng/ml of cytokines previously found by our laboratory and by other studies to 
be elevated in plasma and/or serum samples of JSLE patients with LN, or shown by 
other studies to be expressed in the glomerular renal tissue of JSLE or adult patients with 
LN, or bear certain polymorphisms associated with JSLE; IFN-α184, IFN-γ327,354, TNF-
α164,327, IL-1β327,355,356, IL-6327 and IL-13327 and VEGF327,357. The potential effect of 
bacterial endotoxin inflammation was also examined via 1μg/ml LPS treatment, which, 
in murine models of LN and in human endotoxemia, is known to play a critical role in 
LN exacerbation after a bacterial infection350–353. 
The findings using the in vitro model of human ciGEnCs indicate that like 
HUVECs345,358,359, HBMECs360–362 and HMECs363, upon activation with TNF-α, IL-1β, 
IL-13, IFN-γ and with LPS, ciGEnCs can increase the production of various pro-
inflammatory proteins. These include cytokines (IL-6, IL-10, TNF-α, IFN-γ), 
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chemokines (IL-8, MCP-1, MIP-1α, IP-10), blood cell growth factors (M-CSF, GM-
CSF) adhesion molecules (ICAM-1, VCAM-1, sVCAM-1) and positive co-stimulatory 
molecules (ICOS-L). All pro-inflammatory proteins found to be upregulated by human 
ciGEnCs have been previously shown to be involved in human LN or other types of 
human renal disease (Table 3.1), as described below. 
Pro-inflammatory stimulus Proteins produced by ciGEnCs 
TNF-α M-CSF, GM-CSF, MIP-1α, MCP-1, 
Surface VCAM-1, ICAM-1 
IL-1β IL-6, M-CSF, GM-CSF, MIP-1α, TNF-
α, MCP-1, ICAM-1, ICOS-L 
IL-13 Soluble and cell surface VCAM-1 
IFN-γ IL-10, IP-10, TNF-α, PD-L1 
LPS IL-6, IL-10, IP-10, MIP-1α, IFN-γ, 
MCP-1, ICAM-1 
Table 3.1  Synopsis of proteins produced by cytokine- and LPS-mediated stimulation of 
ciGEnCs. 
MCP-1 promotes kidney infiltration by inflammatory immune cells such as 
monocytes and dendritic cells in LN, and its expression within the glomerulus and can 
be predictive of poor renal outcomes in JSLE patients with LN229. MIP-1α, a chemokine 
which activates and attracts human granulocytes, macrophages and monocytes364 has 
been shown, together with MCP-1, to promote macrophage recruitment and activation 
in the kidneys of patients with crescentic GN215. Increased mRNA levels of human GM-
CSF, which promotes the maturation and differentiation of macrophages, neutrophils, 
eosinophils and basophils205, have been found to be expressed by in vitro cultured human 
renal tubular cells derived from interstitial fibrotic kidneys compared to tubular cells 
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derived from non-fibrotic kidneys313. In addition, GM-CSF and M-CSF protein levels 
have been shown to be increased in human GN213.  
High levels of the pleiotropic cytokine IL-6 which -among other functions- 
promotes B- and T cell differentiation171 have been shown to be produced by LN patients 
compared to healthy control patients365 and high amounts of urinary IL-6 have been 
correlated with diffuse proliferative (class IV) active LN173. Serum levels of circulating 
TNF-α have been linked to glomerular protein expression of ICAM-1 which has been 
correlated with renal glomerular capillary damage in biopsy samples161.  In addition, 
TNF-α gene polymorphisms leading to excessive TNF-α production can predispose 
patients to LN development and TNF-α protein levels have been found to be upregulated 
in the plasma of active LN patients162.   
IP-10 is a chemokine that mediates T cell accumulation to the inflamed tissues190,191 
and serum levels have been found to be significantly upregulated in LN patients192 and 
subsequent studies have highlighted urinary IP-10 mRNA as a reliable indicator of 
diffuse proliferative (class IV) LN as well as a potential biomarker for treatment 
effectiveness193.  
Serum IL-10, which is another pleiotropic cytokine, was found to be elevated in 
systemic lupus erythematosus (SLE) patients with LN compared to SLE patients without 
LN366 whereas plasma IL-10 has been found to be significantly elevated in JSLE patients 
with active disease312. In human LN, urinary M-CSF  levels were found to be predictors 
of renal flares in diffuse proliferative (Class IV) LN patients211 whereas serum and urine 
M-CSF could prove to be a reliable and sensitive biomarker for LN212.  
Significantly increased IFN-γ positive immune-histochemical staining has been 
observed in biopsies from juvenile-onset LN patients compared to healthy controls315. 
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IL-8, a potent neutrophil chemokine, has been found to be one of the cytokines most 
commonly involved -via increased urine or serum levels- in several paediatric renal 
diseases, including vesicoureteral reflux367, renal scarring368, acute pyelonephritis368 and 
idiopathic nephrotic syndrome369.  
VCAM-1 is a cell-surface protein induced upon inflammation and involved in the 
migration and adhesion of inflammatory cells such as lymphocytes, monocytes, 
eosinophils, and basophils to the vascular endothelium254. VCAM-1 expression as well 
as VCAM-1 serum and urinary levels have been shown to be significantly upregulated 
in LN370,371. Furthermore, in patients with active focal (Class III) and diffuse (Class IV) 
LN, the levels of sVCAM-1 were shown to be significantly elevated compared to LN 
patients in remission257. The urinary levels of ICAM-1, another adhesion molecule 
which is constitutively expressed by human endothelia but which is upregulated upon 
inflammation and promotes leukocyte binding to the endothelium372, has been found to 
together with the urinary levels of VCAM-1 to be upregulated in LN patients with focal 
(Class III), diffuse (Class IV) and membranous (Class V) LN compared to those with 
minimal mesangial (Class I) and proliferative mesangial (Class II) LN and to SLE 
patients without renal involvement373. 
In JSLE, decreased PD-L1 expression by antigen-presenting cells has been 
associated with active disease374,375. In patients with active SLE, ICOS-L plasma levels 
have been found to be increased compared to patients with inactive SLE376. PD-L1 
surface expression that was upregulated at 24 hours in ciGEnCs by IFN-γ treatment, can 
prevent the activation of CD-8+ T cells348 and inhibit the autoreactive T cell function377. 
However, after 24 hours, IL-1β significantly increased surface expression of the positive 
CD4+ T cell co-stimulatory molecule, ICOS-L378.  
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TNF-α and IL-1β, the prototypical inflammatory cytokines379, were found to 
particularly upregulate MCP-1 (combined cytokine treatment led to significantly higher 
levels of secreted MCP-1 which could be mainly attributed to TNF-α and IL-1β 
combination), MIP-1α and GM-CSF. Although no statistical significance occurred with 
the analyses used in this study, TNF-α and IL-1β appeared to increase IL-8 secretion, as 
did the combined cytokine treatment. IL-1β and LPS significantly upregulated IL-6 and 
TNF-α secretion and LPS had a prominent effect in MIP-1α and GM-CSF secretion. 
A study in which HBMECs were treated for 4, 24 and 72 hours with TNF-α and IL-
1β, showed that the two cytokines differentially regulate the pro-inflammatory profile of 
the cells, with TNF-α inducing the highest levels of secreted IL-8, IL-6 and MCP-1 at 
72 hours and IL-1β promoting higher levels of IL-8, IL-6, IP-10 and GM-CSF secretion 
at 24 hours, although the highest  MCP-1 levels after IL-1β treatment were also observed 
at 72 hours346. In addition, HBMECs have been shown to significantly increase MIP-α 
secretion after stimulation with TNF-α, IL-1β and LPS for 24, 48 and 72 hours, with the 
highest peak being observed at 72 hours360. As this study only investigated the secretion 
of these proteins at 24 hours, further increases may be expected to occur at later time-
points for IL-6, IL8, IP-10, GM-CSF and MIP-1α. 
The combined cytokine treatment, which could be mainly attributed to TNF-α, IL-
1β and IFN-γ led to increased amounts of secreted M-CSF. In HMECs, M-CSF mRNA 
expression has been shown to be upregulated after TNF-α treatment363 whereas in human 
saphenous vein endothelial cells, TNF-α, IL-1 and LPS were found to increase M-CSF 
mRNA expression after 4 (for LPS) or 6 hours (for TNF-α and IL-1) of activation380. M-
CSF mRNA in the HMECs studies was upregulated at earlier time-points than that of 
the 24-hour time that was used in this study; this is consistent with the hypothesis that 
pro-inflammatory gene transcription could occur at an earlier time-point (4 or 6 hours, 
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depending on the stimuli), leading to increased pro-inflammatory protein secretion at a 
later time-point, such as the 24 hours used in the experiments for ciGEnC M-CSF 
secretion. 
IFN-γ predominantly increased the secretion of high amounts of IP-10 and of IL-10 
as did combined cytokine treatment in which IFN-α seems to further enhance the IFN-γ 
effect on IP-10 and IL-10 secretion. In addition, LPS induced increased IP-10 and IL-10 
secretion levels. The effect of IFN-γ on IP-10 upregulated secretion has also been 
observed in human brain endothelium after 48 hours381 and therefore in ciGEnCs, further 
IFN-γ-mediated IP-10 increases may be expected at later time-points.  
At 24 hours, IL-13 in combination with TNF-α significantly increased the surface 
expression of VCAM-1. This finding comes in agreement with a previous study on 
fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) where elevated and 
sustained VCAM-1 levels were achieved by the capacity of IL-13 (or IL-4) to stabilise 
VCAM-1 mRNA at 24 hours of incubation, after initial stimulation with TNF-α382. It is 
important to note that FLS have been suggested to be similar to undifferentiated 
endothelial cells383  and have been previously shown to share similar immune-
phenotypes with HUVECs384. Furthermore, LPS exhibited an acute effect on increased 
VCAM-1 surface expression only at 4 hours but not at 24 hours. Moreover, in this study 
IL-13 led to a significant increase in secreted levels of sVCAM-1; IL-13 exerted an effect 
solely on surface and soluble VCAM-1 and not on expression or secretion of any other 
pro-inflammatory protein. In contrast to VCAM-1 surface expression that was cytokine-
induced, ICAM-1 was constitutively expressed by the ciGEnCs and its surface 
expression was significantly increased by IL-1β and LPS at both 4 and 24 hours and by 
TNF-α only at 24 hours. ICAM-1 upregulation by TNF-α, IL-1β and LPS has also been 
confirmed in HUVECs in a 72-hour time-course experiment experiment385 and therefore 
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further increases in ciGEnC ICAM-1 levels may be expected at a later time-point than 
that of 24 hours. It is important to note that the cytokines and LPS tested, had a 
differential effect on ciGEnC surface expression of VCAM-1 and ICAM-1, suggesting 
that different pro-inflammatory stimuli could lead to recruitment of different kidney-
infiltrating immune cell populations. 
This study mainly focused on the effect of cytokines (TNF-α, IL-1β, IFN-γ, IL-13) 
and LPS on inducing ciGEnC VCAM-1 and ICAM-1 surface expression. The effect of 
TNF-α and IL-13 on E-/P-selectin surface expression, however, was also tested. 
Nonetheless, basal E-/P-selectin expression by ciGEnCs was almost negligible and was 
not modified by TNF-α and IL-13 treatments, either alone or in combination. In contrast, 
IL-13 has been shown to upregulate P-selectin expression on HUVECs386 and TNF-α 
has been found to upregulate expression of E-selectin by human pulmonary artery 
endothelial cells387.  
Other cytokines, such as IL-1β and IFN-γ and/or LPS, might have a greater effect 
on E-/P-selectin expression by ciGEnCs. There a strong possibility, however, the 
ciGEnCs might not be able to express E- and P-selectin as murine GEnCs have been 
shown to lack P-selectin expression388,389. Furthermore, limited to almost negligible 
levels of E- and P-selectin expression have been observed in the glomeruli of lupus-
prone mice390. In addition, in a study using 108 human renal biopsies from patients with 
primary renal disease and allograft recipients and 10 healthy control renal biopsies, weak 
E-selectin expression in the renal vasculature was immunohistochemically detected only 
in two patients’ renal biopsies391. Thus, limited expression of E- and P-selectin by human 
GEnCs in contrast to the more prominent expression of VCAM-1 and ICAM-1 could 
lead to selective recruitment of more monocytes/macrophages and lymphocytes to the 
inflamed glomerulus and of smaller numbers of neutrophils. It should be noted, however, 
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that technical and experimental limitations could have led to lack of E-/P-selectin 
expression of ciGEnCs, such as trypsin-induced cleavage of E- and P-selectin from the 
surface of ciGEnCs. For this reason, future studies could investigate the intracellular 
protein levels as well as the secreted protein levels and mRNA expression of E- and P-
selectin by ciGEnCs. Furthermore, immunofluorescence could be used as an alternative 
techniqueto detect surface E- and P-selectin expression. 
At 24 hours, surface levels of the constitutively expressed PD-L1 were mainly 
upregulated in ciGEnCs by IFN-γ treatment as has been previously shown also with 
HUVECs348. PD-L1 is known to play an important role in preventing the activation of 
CD-8+ T cells348 and inhibiting the function of autoreactive T cells377. However, the 
increased presence of a variety of pro-inflammatory cytokines within the nephritic renal 
glomeruli could counteract the protective effect of PD-L1 by upregulating the GEnC 
surface expression of positive T cell co-stimulatory molecules, such as ICOS-L378 which 
is preferentially expressed by the endothelium instead of the CD80 and CD86 positive 
co-stimulatory molecules378. Therefore, the balance between PD-L1 and ICOS-L, could 
determine the increased presence of either CD4+ or CD8+ T cells within the renal 
endothelium. Indeed, at 24 hours ICOS-L surface expression was significantly induced 
by IL-1β. In HUVECs, surface PD-L1 expression has been shown to be upregulated by 
IFN-γ alone or in combination with TNF-α after 48 hours of incubation348  therefore 
suggesting further PD-L1 upregulation on ciGEnCs at later time-points after IFN-γ 
stimulation. Similarly to ciGEnCs, in both HUVECs and heart microvascular endothelial 
cells, IL-1β (but also TNF-α) was found to increase surface ICOS-L expression after a 
24-hour stimulation378. 
The ciGEnC incubation time-points (4 and 24 hours) reflect an acute phase 
inflammation stage284  rather than a chronic inflammation stage and future studies should 
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focus on longer time-response experiments, to unravel changes in expression of pro-
inflammatory proteins induced by chronic exposure of ciGEnCs to pro-inflammatory 
stimuli. The 24-hour cytokine and LPS stimulation led to only minor levels of 
apoptotic/necrotic ciGEnCs, supporting the hypothesis that at this stage the human 
ciGEnCs maintain their integrity and acquire a pro-inflammatory phenotype due to 
endothelial cell activation and not due to cell death.  
To further determine the effectiveness of the treatments with TNF-α, IL-1β, IL-13 
and IFN-γ, concentration-response experiments were performed using serial dilutions 
with a 1000-fold range; the highest concentration used for all in vitro experimental 
assays was10 ng/ml and the lowest concentration was 10 pg/ml. This tested the effect of 
the four cytokines using concentrations similar to those that have been detected within 
plasma samples of patients with active or inactive LN327. The ciGEnCs incrementally 
upregulated the mRNA expression of the pro-inflammatory molecules tested in response 
to increasing cytokine concentrations and a positive correlation was found between 
increasing concentrations and mRNA levels, although not always statistically 
significant. Therefore, it could be speculated that as a renal flare in active LN is in 
progress, the presence of cytokines such as TNF-α, IL-1β, IL-13 and IFN-γ within the 
glomeruli will gradually increase. This increase, will lead to a local cytokine gradient 
formation at the areas of inflammation, affecting the surrounding ECM components, and 
neighbouring renal or resident/infiltrating immune cells.  
Having identified the human ciGEnCs as potent pro-inflammatory contributors, the 
next step was to investigate which mechanistic pathways could be responsible for their 
activation and subsequent pro-inflammatory action. The activation of important 
transcription factors was explored in response to TNF-α (NF-κB), IL-1β (NF-κB), IFN-
γ (STATs) and LPS (NF-κB). The transcription factor NF-κB is known to be mainly 
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upregulated by TNF-α and IL-1β but also by LPS, STAT-1 is known to be upregulated 
by IFN-γ and STAT-2 is known to be upregulated mainly by IFN-α. NF-κB, which was 
activated by TNF-α, IL-1β and LPS, is a central pro-inflammatory transcription factor, 
heavily involved in the overall  pro-inflammatory response of the endothelial cells by 
inducing the expression of multiple downstream target genes, including; IL-6, IL-8, IL-
1β, MCP-1, MIP-1α, IP-10, GM-CSF, M-CSF, IFN-γ, TNF-α, VCAM-1 and ICAM-
1280,281, which were all upregulated at the 24-hour time-point following TNF-α, IL-1β or 
LPS stimulation.  
Apart from NF-κΒ nuclear translocation demonstrated via IF, TNF-α-, IL-1β- and 
LPS-mediated NF-κΒ activation was further confirmed via WB for Iκ-Bα. In resting 
cells where no cytokine- or LPS-activation occurs, Iκ-Bα is bound to NF-κΒ leading to 
NF-κB cytoplasm retention and inhibition of its nuclear translocation349. However, upon 
cytokine- or LPS-activation Iκ-Bα is phosphorylated and degraded via the proteasome 
pathway, allowing for NF-κΒ to be phosphorylated in turn, and subsequently to be 
transported to the nucleus349. Indeed, in contrast to IFN-γ and IL-13 which did not seem 
to play a role in Iκ-Bα degradation, TNF-α, IL-1β and LPS did induce Iκ-Bα degradation 
with the 30-minute time-point exhibiting the most prominent effect on Ικ-Bα 
degradation for both cytokines but also for LPS. This was also confirmed via the IF 
experiments, where 30-minute TNF-α-, IL-1β- and LPS- activation led to increased NF-
κB nuclear translocation compared to the 15-minute activation. At 15 minutes, TNF-α 
induced only low levels of NF-κB nuclear translocation while LPS almost failed to 
induce NF-κB translocation, similarly to 15-minute Iκ-Bα degradation levels. IL-1β 
exerted a robust effect on both Iκ-Bα degradation and NF-κB nuclear translocation at 
both time-points. LPS had in general the least robust effect when compared to IL-1β and 
TNF-α at both time-points. Indeed, a study using HUVECs to unravel their pro-
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inflammatory activation pattern following IL-1β, TNF-α -and LPS stimulations after 
3.75, 7, 15, 30, 60, 120 and 240 minutes found that, especially between 15 and 60 
minutes of activation, IL-1β had the most robust effect in NF-κB activation and nuclear 
translocation compared to TNF-α and LPS, with LPS having the weakest effect in NF-
κB translocation344. 
STAT-1, which was activated by IFN-γ, has been shown to induce transcriptional 
activation of target genes such as IP-10, ICAM-1, MCP-1 and PD-L2392. In this study, 
IFN-γ was able to promote ciGEnCs upregulation of IP-10 and PD-L1 at 24 hours. 
STAT-1 activation can lead to formation of STAT-1 homodimers which subsequently 
translocate within the nuclei and induce the transcription of their target genes393. In 
contrast to IFN-α which also activates STAT-2 via phosphorylation leading to formation 
of STAT-1 – STAT-2 heterodimers392,394, IFN-γ did not induce STAT-2 activation.  
Therefore, IFN-γ-mediated activation of ciGEnCs favours the formation of STAT-1 
homodimers instead of STAT-1- STAT-2 heterodimers. The 30-minute IFN-γ activation 
seemed to have the most prominent effect in STAT-1 nuclear translocation. Regarding 
the role of IL-13, future studies are necessary to identify more IL-13 target genes but 
also to test its potential pro-fibrotic effect on ciGEnCs which could be mediated via 
TGF-β1 induction395. Future in vitro NF-κB and STAT-1 studies using knockdown 
assays are necessary to further verify whether the upregulated ciGEnC production of 
pro-inflammatory proteins is a direct cause of activation of those transcription factors. 
Taken together, these data suggest that human GEnCs play a central role in LN 
inflammation. As demonstrated by the in vitro human ciGEnC model, the GEnCs are 
not just passive bystanders but do actively respond to the renal pro-inflammatory 
environment created in kidney disease, via producing a range of pro-inflammatory 
molecules that could exacerbate the renal inflammation. Within the nephritic kidneys, 
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the secretion of this variety of pro-inflammatory cytokines, chemokines, blood cell 
growth factors and the surface expression of adhesion molecules by the GEnCs (all 
summarised on Table 3.1) could attract and increase the numbers of glomeruli-
infiltrating immune cells (Figure 3.22). At the same time, cytokines such as TNF-α, IL-
6 or IFN-γ could activate the neighbouring podocytes and MCs (Figure 3.22). Therefore, 





Figure 3.21 Potential effect of stimulated GEnCs in LN based on the in vitro findings.  
Under the highly inflammatory environment created within the glomeruli by the presence of 
TNF-α, IL-1β, IL-13 and IFN-γ but also by the potential presence of LPS, the human GEnCs will 
be activated to produce, secrete and express a variety of pro-inflammatory cytokines, 
chemokines, blood cell growth factors and adhesion molecules that will further exacerbate the 
renal disease by either promoting the infiltration of immune cells within the glomeruli or by 





In conclusion, the human ciGEnCs were found to respond to certain pro-
inflammatory cytokines and to LPS via upregulating pro-inflammatory transcription 
factors and producing a variety of pro-inflammatory cytokines, chemokines, blood cell 
growth factors, novel urinary biomarkers for active LN, adhesion and co-stimulatory 
molecules. The acquisition of pro-inflammatory ciGEnC phenotype is not due to cell 




4. Chapter 4: Investigating the effect of the renal microenvironment on the pro-
inflammatory phenotype of the human GEnCs  
4.1. Introduction 
As demonstrated in Chapter 3, the human GEnCs are potent producers of pro-
inflammatory proteins, actively contributing to the renal pro-inflammatory environment 
in LN. More specifically, using an in vitro model of LN, the human ciGEnCs were found 
to produce a variety of proteins: adhesion molecules able to mediate leukocyte binding 
(VCAM-1, ICAM-1), positive T cell co-stimulatory molecules (ICOS-L) and cytokines 
(TNF-α, IFN-γ, IL-6, IL-10), chemokines (IL-8, IP-10, MIP-1α) and blood cell growth 
factors (M-CSF, GM-CSF) that could promote leukocyte infiltration, maturation and 
activation within the kidneys. Furthermore, the cytokines produced by the GEnCs could 
potentially activate their neighbouring glomerular cells; podocytes and MCs. 
However, by directly interacting with the blood circulating factors and with rest of 
the glomerular renal cells, the human GEnCs may not only affect their surrounding 
environment but, in turn, they may also be affected by this environment. The presence 
of pro-inflammatory cytokines within the glomerulus, some of them produced by the 
GEnCs themselves, could lead to podocyte and mesangial cell activation. Thus, the 
production of more pro-inflammatory cytokines could in turn further activate the 
GEnCs. Furthermore, infiltrating immune cells such as neutrophils and macrophages are 
among the first to reach the sites of inflammation early at the acute inflammatory phase, 
with neutrophil recruitment preceding that of macrophages396,397. Thus, these circulating 
immune cells could further enhance GEnC activation via release of a variety of 
mediators. Pro-inflammatory mediators released by all of the different types of immune 
cells (innate and adaptive immune system-derived), could also affect the GEnCs via their 
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presence in the blood plasma/serum, leading to expression of pro-inflammatory genes 
and of genes associated with ECM production and remodelling that are involved in renal 
tissue fibrosis and CKD398,399. 
Exploring the effect of the renal microenvironment on the GEnCs will help gain 
insight into the complex interactions between GEnCs and the rest of the cell types that 
communicate with the glomerular endothelium. Therefore, a more physiological in vitro 
model of LN could be developed, imitating the interactions taking place within the 
kidneys of the human organism. 
4.2. Aim 
To investigate the potential effect of the glomerular renal microenvironment on 
GEnC pro-inflammatory profile using multiple in vitro ciGEnC models. 
 Objectives 
Objective 1: To assess whether ciGEnC treatments with JSLE patient and paediatric 
healthy control sera can modify their fibrotic and pro-inflammatory phenotype. 
To address this objective, sera from JSLE patients with active and inactive LN and sera 
from healthy controls were used to stimulate ciGEnCs in vitro. Subsequently, changes 
in the expression of fibrosis-related genes and of pro-inflammatory genes (same as those 
tested in gene and protein level in Chapter 3), were investigated. 
Objective 2: To determine whether glomerulus-infiltrating immune cells such 
neutrophils and macrophages could potentially have a paracrine effect the pro-
inflammatory activation of GEnCs. 
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To address this objective, conditioned media from stimulated human neutrophils, 
macrophages and THP-1 cells were used to in vitro stimulate the ciGEnCs; subsequently 
potential changes in the expression of pro-inflammatory genes/proteins were tested. 
Objective 3: To determine whether GEnC-neighbouring renal cells, podocytes and 
MCs, could potentially have a paracrine effect the pro-inflammatory activation of 
GEnCs. 
To address this objective, conditioned media from stimulated conditionally immortalised 
human podocytes and MCs were used to in vitro stimulate the ciGEnCs; subsequently 
potential changes in the expression of pro-inflammatory genes were tested. 
 Chapter hypothesis  
The GEnCs do not only affect their microenvironment via producing pro-
inflammatory factors upon renal disease but they can also be affected by their 
microenvironment in return. Thus, in vitro ciGEnC treatment with serum samples from 
patients with active LN will upregulate the production of pro-inflammatory genes and 
genes related to ECM production/remodelling, compared to serum samples from patients 
with inactive LN and HCs. Furthermore, ciGEnC treatment with conditioned media from 
cytokine- and LPS-activated neutrophils, macrophages, podocytes and MCs, will 
promote the expression of pro-inflammatory genes and production of pro-inflammatory 
proteins. 
4.3. Materials and Methods 
 ciGEnC preparation and treatment 
Fully differentiated ciGEnCs were seeded on 12-well plates for all treatments. 
Subsequently, they were incubated at 37oC (with 5% CO2) for 24 hours (h) with serum 
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samples or with conditioned media of previously stimulated neutrophils, macrophages, 
and podocytes or MCs. A minimum of three consecutive passages of ciGEnCs was used 
for all experiments. 
4.3.1.1.Serum treatments 
The ciGEnCs were treated for 4 or 24 hours with 5% sera in media without FBS 
from JSLE patients with active LN (renal BILAG A/B) and inactive LN (renal BILAG 
D/E) and from healthy controls (HCs; n=10/group). For these experiments, the age and 
sex of healthy controls was matched to those of JSLE patients whenever that was 
possible. The median age of HCs was 13 years, the median age of active LN patients wa 
15 years and the median age of inactive LN patients was 14.5 years; 90% of active and 
inactive LN patients and 70% of HCs were females.  Patients’ and HCs’ demographic 
information is presented on Table 4.1. Following stimulation, the cells were washed in 




Table 4.1 Patient and healthy control demographics. 
 
4.3.1.2.Neutrophil conditioned media treatments 
Neutrophils isolated from healthy volunteers (see section 2.2.1) (n=5) were re-
suspended in RPMI (+10% FBS), seeded onto 12-well plates at a concentration of 
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1x106/mL and stimulated for 1h with 10ng/mL TNF-α, 10ng/mL IFN-γ or 1μg/mL LPS. 
Following this, neutrophils were collected and centrifuged at 200xg for 10 mins to pellet 
the cells and the conditioned media was collected and stored at -80°C until use.  
The neutrophil conditioned media was used to treat fully differentiated ciGEnCs for 
24h. Following stimulation, the cells were washed in PBS and lysed in Trizol for RNA 
extraction.  
4.3.1.3.Primary macrophage conditioned media treatments 
PBMCs were isolated from healthy volunteers (see section 2.2.1) (n=7) and were 
re-suspended in RPMI (+10% FBS). These were seeded into 12-well plates at 37°C for 
2h, following this the non-adherent lymphocytes were removed, and the adherent 
monocytes were treated with RPMI (+10% FBS, 1% penicillin-streptomycin and 
50ng/mL M-CSF) to aid their differentiation into macrophages. These were then 
incubated at 37°C for 7 days. Macrophage differentiation was confirmed using light 
microscopy (Figure 4.1). 
 
Figure 4.1  Macrophages following 7-day treatment with 50ng/mL M-CSF. 
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Macrophages were then treated for 48 hours with 10ng/mL IFN-γ or 1μg/mL LPS 
at 37°C, following this the conditioned media were collected and stored at -80°C until 
use. 
The macrophage conditioned media were used to treat fully differentiated ciGEnCs 
for 24h. Following stimulation, the cells were washed in PBS and lysed in Trizol for 
RNA extraction. 
4.3.1.4.THP-1 cell line conditioned media treatments 
Primary human macrophage cultures yielded low numbers of cells due to the small 
volumes of blood (<20mL) permitted by our ethics. Thus THP-1 macrophages were used 
to further explore the paracrine effects of human macrophages on GEnCs.  
Undifferentiated THP-1 cells in suspension were seeded into 6 well plates at a 
concentration of 750,000 cells per well. The THP-1 cells were then treated with 100 
ng/ml of PMA in RMPI (+ 10% FBS) at 37oC (5% CO2) for 4-5 days to aid their 
differentiation into fibroblast-like macrophages and their attachment to the bottom of the 




Figure 4.2 THP-1 macrophage culture.  
Before PMA stimulation, the undifferentiated THP-1 cells are non-adherent and have a 
spherical shape. At 48 hours after PMA stimulation the THP-1 cells attach to the bottom of the 
plates and start changing their morphology by developing some protrusions. By the end of the 




Following differentiation, the THP-1 macrophages were treated with fresh media 
for 24h and then incubated with 10ng/mL IFN-γ or 1μg/mL LPS in RPMI (+10% FBS) 
for 48h. Conditioned media was collected and frozen at -80°C until use.  
TNF-α and IL-1β secretion into the conditioned media was assessed using R&D 
DuoSet ELISA analysis as described in section 2.2.5. The conditioned media was then 
used to treat the ciGEnCs for 24h. Additionally conditioned media were treated for 2h 
with 1μg/mL anti-human TNF-α Ab and with 10μg/mL human recombinant interleukin-
1 receptor antagonist (IL-1Ra), following treatment this conditioned media was used to 
treat ciGEnCs for 24h to determine the effects of TNF-α and IL-1β blockade. Following 
stimulation, the ciGEnCs were washed in PBS and lysed in Trizol for RNA extraction.  
4.3.1.5.Podocyte and mesangial cell conditioned media treatments 
Conditionally immortalised human podocytes259 and MCs400 kindly provided by 
Professor Moin Saleem (Children’s Renal Unit and Academic Renal Unit, University of 
Bristol, UK) were initially cultured at 33oC (5% CO2) in RPMI-1640 (+L-glutamine) 
with 10% FBS and 1%  ITS. Upon reaching 50-70% confluence, podocytes and MCs 
were seeded into 12-well plates and transferred at 37 oC (5% CO2) for 10-14 days and 7-
10 days respectively, until they were fully differentiated. The fully differentiated 
podocytes and MCs were treated for 24 hours with 10 ng/ml of key cytokines involved 
in LN and JSLE pathogenesis - TNF-α, ΙL-1β, IFN-α, IFN-γ - and with 1 μg/ml of LPS. 
Subsequently, the podocyte and MC conditioned media were collected and were 
used to treat the ciGEnCs for 24 hours. The ciGEnCs were then washed with PBS and 
lysed in Trizol for RNA extraction. 
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 qRT-PCR analysis 
RNA was extracted and transcribed to cDNA as previously described in the 
Materials and Methods (Section 2.2.3). This cDNA was used for qRT-PCR analysis to 




Table 4.2 Primers used for qRT-PCR. 
 Statistical Analyses 
Changes between two different groups were studied using non-parametric Mann-
Whitney test whereas changes among three or more groups were studied using Kruskal-
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Wallis or Friedman’s test with Dunn’s post-hoc test, using the GraphPad Prism 4.0 
software. For changes after neutrophil, conditionally immortalised podocyte and 
mesangial cell conditioned media, multiple t-tests were performed with p-value 
corrections for multiple comparisons using the Holm-Sidak method. For changes after 
THP-1 conditioned media (with or without anti-TNF-α/IL-1Ra addition), Kruskal-
Wallis test was performed with corrected p-values. 
 TNF-α blocking assay using anti-TNF-α optimisation 
To verify that anti-TNF-α and IL-1Ra target and inhibit the pro-inflammatory 
effects of TNF-α and IL-1β respectively, ciGEnCs were seeded onto 12-well plates and 
following differentiation were treated for 24h with 10 ng/ml of TNF-α alone or in 
combination with 1 μg/ml of anti-TNF-αAb and with 10 ng/ml of IL-1β alone or in 
combination with 1 μg/ml or 10  μg/ml of IL-1Ra. After the 24h treatment, the ciGEnC 
conditioned media were collected and used for Luminex ELISA, while the ciGEnCs 
were lysed with Trizol for RNA extraction. In addition, treated ciGEnCs were assessed 
for the expression of NF-κB using IF staining. 
TNF-α can elicit its effects on GEnCs through activation and translocation of NF-
κB to the nucleus, therefore NF-κB nuclear localisation was assessed in untreated cells 
where the majority of the transcription factor was found in the cytosol as demonstrated 
by low co-localisation of DAPI and NF-κB staining (r-value: 0.02 [-0.4-0.92])). Upon 
treatment with 10ng/mL TNF-α for 30 mins NF-κB staining co-localised with DAPI 
staining suggesting nuclear translocation was occurring (r-value: 0.73[-0.15-0.95). 
Following pre-treatment with 1μg/mL anti-TNF-α nuclear levels of NF-κB (r-value: 0.24 
[-0.61-0.91]) returned similar to those seen in untreated cells (r-value: 0.02 [-0.4-0.92])) 




Figure 4.3 Effect of anti-TNF-αAb treatments on TNF-α-mediated NF-κB nuclear 
translocation.  
A. 20x IF images of ciGEnCs following 30-minute stimulation with TNF-α alone or with TNF-α 
together with 1 μg/ml of anti-TNF-αAb or 1 μg/ml of goat IgG B. Statistical analysis diagram. Data 
(r-values for nuclear co-localisation of DAPI and A488 for each treatment group) representative of 
three similar experimental repeats are presented as box and whisker plots and are analysed using 
Mann-Whitney test. ****p≤0.0001 vs TNF-α. Scale bars: 100μm.  
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After 24 hours of combined treatment with 10 ng/ml of TNF-α and with 1 μg/ml of 
anti-TNF-αAb, the ciGEnCs displayed similar levels of IL-8, GM-CSF, MCP-1, MIP-
1α and VCAM-1 mRNA expression, compared to those of the untreated ciGEnCs 
(Figure 4.4). Changes in the mRNA expression of these genes were tested as in Chapter 
3 their expression was shown to be affected in a TNF-α concentration-dependent manner 
(section 3.4.3, Figure 3.1).  
More specifically, GM-CSF mRNA levels of untreated ciGEnCs (0.001 [0.001-
0.002], P=0.02) were significantly lower than those of TNF-α-treated cells (0.03 [0.004-
0.05]) whereas a trend was observed for lower GM-CSF mRNA levels after anti-TNF-α 
treatment (0.002 [0.0008-0.003], P=0.06) compared to TNF-α-treated ciGEnCs (Figure 
4.4-A). Similarly, IL-8 mRNA levels dropped close to untreated ciGEnCs’ baseline 
levels (0.04 [0.025-0.07], P=0.04) and a trend was observed after anti-TNF-α treatment 
(0.05 [0.02-0.12], p=0.079) compared to TNF-α-treated ciGEnCs (0.5 [0.08-0.86]) 
(Figure 4.4-B).  
MCP-1 mRNA levels were significantly decreased after anti-TNF-α treatment (0.1 
[0.04-0,4], P=0.02) and reached similar levels to those of untreated ciGEnCs (0.07 [0.06-
0.11], P=0.006) compared to TNF-α-treated cells (1.15 [0.15-2.9]) (Figure 4.4-C). 
Although no statistically significant changes occurred in VCAM-1 mRNA expression of 
untreated and anti-TNF-α-treated ciGEnCs compared to TNF-α-treated ciGEnCs, the 
VCAM-1 mRNA levels were considerably lower than those of TNF-α-treated ciGEnCs 
(Figure 4.4-D).  
183 
 






























0 .0 5 *
P = 0 .0 6P = 0 .0 2
T N F -
a n ti-  T N F -































P = 0 .0 8P = 0 .0 3
T N F -
a n ti-  T N F -





























4 P = 0 .0 8
T N F -
a n ti-  T N F -





























4 P = 0 .0 8
T N F -
a n ti-  T N F -
A . B .
C . D .
 
Figure 4.4 Effect of anti-TNF-α Ab treatments on TNF-α-mediated pro-inflammatory gene 
expression.  
Changes in the mRNA expression levels of GM-CSF (A), IL-8 (B), MCP-1 (C), and VCAM-1 (D) 
following 24-hour treatments with TNF-α alone or with TNF-α together with 1 μg/ml of anti-
TNF-α Ab. N=4/group. Data presented as median [range] are analysed using Kruskal-Wallis 
test, with Dunn’s post-hoc test, *P≤0.05 vs untreated. HK: ACTB, TUBB, TBP. 
 
Similarly, GM-CSF, IL-8, MIP-1α and Μ-CSF secreted protein levels of ciGEnCs 
treated with (TNF-α + anti-TNF-α Ab), were more similar to those of untreated ciGEnCs 
compared to those of TNF-α-treated ciGEnCs (Figure 4.5). More specifically, TNF-α-
mediated secretion was statistically significantly increased (174pg/ml [41-354], p=0.03) 
compared to untreated ciGEnCs (14pg/ml [12-18]) and anti-TNF-α antibody (Ab) 
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addition (33pg/ml [12-56]) brought GM-CSF levels closer to those of untreated ciGEnCs 
(Figure 4.5-A).  
Although not statistically significantly higher, IL-8 levels of TNF-α-treated 
ciGEnCs (4,450pg/ml [2,791-5,740]) were more elevated compared to those of untreated 
[1,197pg/ml [988-2,004]) and (TNF-α + anti-TNF-α Ab)-treated ciGEnCs [2,636pg/ml 
[843-5,331]) (Figure 4.5-B). Similarly, the MIP-1α levels of TNF-α-treated ciGEnCs 
(4,450pg/ml [2,791-5,740]) were higher -but not statistically significantly- compared to 
those of untreated [1,197pg/ml [988-2,004]) and (TNF-α + anti-TNF-α Ab)-treated 





Figure 4.5 Effect of anti-TNF-αAb treatments on TNF-α-mediated pro-inflammatory protein 
secretion.  
Changes in the secretion levels of GM-CSF (A), IL-8 (B), MIP-1α (C) following 24-hour 
treatments with TNF-α alone or with TNF-α together with 1 μg/ml of anti-TNF-α Ab. N=4/group. 
Data presented as median [range] are analysed using Kruskal-Wallis test, with Dunn’s post-
hoc test, *P≤0.05 vs untreated. 
 
 IL-1β blocking assay using IL-1Ra optimisation 
Similar to TNF-α, IL-1β can also elicit its effects on GEnCs through activation and 
translocation of NF-κB to the nucleus, therefore NF-κB nuclear localisation was also 
assessed in untreated cells; in untreated cells the majority of the transcription factor was 
found in the cytosol as demonstrated by low co-localisation of DAPI and NF-κB staining  
(r-value: 0.31 [-0.32-0.93]).  
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After IL-1β inhibition with IL-1Ra, IF assay revealed that the nuclear translocation 
of NF-κΒ was moderately suppressed with 1 μg/ml of IL-1Ra (r-value: 0.74 [-0.26-
0.96]) and more strongly suppressed with 10 μg/ml IL-1Ra (r-value: 0.52 [-0.25-0.9]) 
compared to IL-1β-treated ciGEnCs (r-value: 0.85 [-0.06-0.97]) (Figure 4.6). The 
untreated ciGEnCs displayed the lowest levels of NF-κB activation (r-value: 0.31 [-0.32-





Figure 4.6 Effect of IL-1Ra treatments on IL-1β-mediated NF-κB nuclear translocation. 
 A. 20x IF images of ciGEnCs following 30-minute stimulation with IL-1β alone or with IL-1β 
together with 1 or 10 μg/ml IL-1Ra. B. Statistical analysis diagram. Data (r-values for nuclear co-
localisation of DAPI and A488 for each treatment group) representative of three similar 
experimental repeats are presented as box and whisker plots and are analysed using Mann-Whitney 




After 24 hours of combined treatment with 10 ng/ml of IL-1β and with 1 or 10 μg/ml 
of IL-1Ra, the ciGEnCs displayed similar levels of IL-6, IL-8, MCP-1, MIP-1α and GM-
CSF mRNA expression, compared to those of the untreated ciGEnCs (Figure 4.7). 
Changes in the mRNA expression of these genes were tested as in Chapter 3 their 
expression was shown to be affected in an IL-1β concentration-dependent manner 
(section 3.4.3, Figure 3.2).  
The levels of mRNA expression of IL-6, IL-8, and MCP-1 progressively decreased 
with increasing doses of IL-1Ra combined with 10 ng/ml of IL-1β (Figure 4.7). More 
specifically, a trend was observed for lower IL-6 mRNA levels after treatment with 10 
μg/ml of IL-1Ra (0.2 [0.1-0.3], P=0.09) compared to IL-1β treatments (0.7 [0.4-3.4]) 
from which the untreated ciGEnCs’ IL-6 levels (0.04 [0.004-0.24], P=0.002) were 
statistically significantly lower (Figure 4.7-A). IL-8 mRNA expression was statistically 
significantly decreased following 10 μg/ml IL-1Ra treatment (0.43 [0.23-1.3], P=0.03) 
and that was also observed in untreated ciGEnCs (0.24 [0.018-1], P=0.004) compared to 
IL-1β treatment (4.5 [1.8-8.7]) (Figure 4.7-B).  
For MIP-1α, a trend was observed for decreased mRNA expression levels after 10 
μg/ml IL1-Ra treatments (0.0004 [0.0001-0.0007], P=0.09) compared to IL-1β 
treatments (0.002 [0.0004-0.004]). MCP-1 mRNA levels after 10 μg/ml IL-1Ra 
treatments (0.05 [0.01-0.23], P=0.002) were decreased to reach expression levels similar 
to baseline expression levels of untreated ciGEnCs (0.05 [0.003-0.22], P=0.002) when 
compared to IL-1β-treated ciGEnCs (0.96 [0.34-2.14]) (Figure 4.7-C). For the MIP-1α 
and GM-CSF mRNA, only the 10 μg/ml of IL-1Ra led to expression levels similar to 
those of untreated ciGEnCs, although none of them were statistically significantly 
decreased (Figure 4.7-D & 4.7-E).  
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Figure 4.7 Effect of IL-1Ra treatments on IL-1β-mediated pro-inflammatory gene expression.  
Changes in the mRNA expression levels of IL-6 (A), IL-8 (B), MCP-1 (C), MIP-1α (D) and GM-
CSF (E) following 24-hour treatments with IL-1β alone or with IL-1β together with 1 or 10 μg/ml 
of IL-1Ra. N=4/group. Data presented as median [range] are analysed using Kruskal-Wallis 




The effect of IL-1Ra (10 μg/ml) on IL-1β was also tested at the protein level and 
IL-6, IL-8, IL-10, GM-CSF and MIP-1α secreted protein levels of ciGEnCs treated with 
(IL-1β + 10 μg/ml IL-1Ra), were more similar to those of untreated ciGEnCs compared 
to those of IL-1β-treated ciGEnCs.   
More specifically, the IL-1β-mediated secreted levels of IL-6 (5,445 pg/ml [1,639-
5,815], p=0.003), IL-8 (5,697 pg/ml [4,871-5,866[, p=0.008), GM-CSF (1,518 pg/ml 
[234-1,626], p=0.003) and MIP-1α (398 pg/ml [382-406], p=0.005) were statistically 
significantly increased compared to untreated ciGEnCs (IL-6: 147 pg/ml [0-158]; IL-8: 
1,714 pg/ml [325-1,887]); GM-CSF: 14 pg/ml [7-16] ; MIP-1α: 285 pg/ml [260-304]). 
The ciGEnCs treated with (IL-1β + 10 μg/ml IL-1Ra) exhibited IL-6 (620 pg/ml [276-
765]), IL-8 (3,347 pg/ml [1,675-3,613]), GM-CSF (50 pg/ml [20-62]) and MIP-1α (326 
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Figure 4.8 Effect of IL-1Ra treatments on IL-1β-mediated pro-inflammatory protein 
secretion.  
Changes in the secretion levels of IL-6 (A), IL-8 (B), IL-10 (C), IP-10 (D), MIP-1α (E) and M-
CSF (F), GM-CSF (G) and TNF-α (H) following 24-hour treatments with IL-1β alone or with 
IL-1β together with 10 μg/ml of IL-1Ra. N=4/group. Data presented as (Mean +/- SEM) are 
analysed using Kruskal-Wallis test, with Dunn’s post-hoc test. *p≤0.05, **p≤0.01 vs untreated. 
 
4.4. Results 
 Effect of LN patient sera on pro-inflammatory gene expression by ciGEnCs 
The effect of 5% JSLE patient sera on ciGEnCs was assessed and compared to 5% 
healthy control sera after 4 and 24h. For the 24h serum incubations, the JSLE patients 
were stratified into active LN (renal BILAG A/B) and inactive LN (renal BILAG D/E) 
and compared to healthy controls.  
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4.4.1.1.ECM- and fibrosis-related genes 
ECM deposition is an important pathological change seen in LN, the GFB is formed 
from contributions by both the GEnCs and the podocytes and remodeling of this will 
have a significant effect on the filtration properties of the glomerulus. To determine how 
JSLE patient sera leads to changes in the production of ECM components by GEnCs the 
expression of mRNA for genes involved in ECM remodeling were assessed.  
No significant differences were seen in the mRNA for COL1A1 after the comparison 
of HC serum treatments to JSLE serum treatments at 4h (Figure 4.9-A). At 24h, JSLE 
serum treatments significantly decreased COL1A1 mRNA expression by the ciGEnCs 
(0.001 [0.0002-0.01], p=0.05) compared to HC serum treatments (0.003 [0.0006-0.007]) 
(Figure 4.9-B) but no statistically significant changes were observed when the JSLE 
serum treatments were distinguished onto active and inactive LN sera (Figure 4.9-C). 
No statistically significant changes occurred for COL1A2 (Figure 4.9-D-F), COL3A1 
(Figure 4.9-G-I) or COL4A1 (Figure 4.9-J-L) at 4 or 24h. 
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Figure 4.9 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on collagen mRNA expression.  
4-hour and 24-hour changes in COL1A1 (A, F), COL2A1 (B, G), COL3A1 (C, H), COL4A1 (D, 
I) mRNA expression levels; comparisons between HC and JSLE serum treatments. 24-hour 
changes in COL1A1 (J), COL2A1 (K), COL3A1 (L), COL4A1 (M) mRNA expression levels; 
comparisons of HC serum treatments with active and inactive LN serum treatments. Data 
presented as median ΔΔCt [range] are analysed with Mann-Whitney test or Kruskal-Wallis with 
Dunn’s post-hoc test. *p≤0.05, JSLE serum vs HC/active or inactive LN serum vs HC. N=10-
20/group. HK: ACTB, TUBB. 
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Fibronectin (FN) mRNA was expressed at low levels following treatment with HC 
sera, no statistically significant differences occurred after 4h of JSLE serum incubation 
(Figure 4.10-A). At 24h, a trend was observed for increased FN mRNA expression after 
JSLE serum treatments (1.2 [0.7-1.6], p=0.06) compared to HC serum treatments (0.9 
[0.8-1.4]) (Figure 4.10-B). When JSLE serum treatment were stratified into active and 
inactive LN disease serum treatments, no trend or statistical significance was observed 
(Figure 4.10-C). 
Regarding the laminin genes, no statistically significant changes were observed for 
laminin subunit beta 1 (LAMB1) mRNA expression following 4 or 24h stimulation 
(Figure 4.10-D-F). Laminin subunit beta 2 (LAMB2) mRNA was expressed at low levels 
following treatment with HC sera, and no statistically significant differences occurred 
after 4h of JSLE serum incubation (Figure 4.10-G). LAMB2 mRNA expression was 
statistically significantly increased by JSLE serum treatments (0.004 [0.002-0.007], 
p=0.04) compared to HCs (0.003 [0.0003-0.005]) (Figure 4.10-H). When distinguished 
into active and inactive LN disease serum treatments, the inactive serum treatments 
(0.004 [0.003-0.007], p=0.04) statistically significantly increased LAMB2 expression 
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Figure 4.10 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on fibronectin and laminin mRNA expression. 
 4-hour and 24-hour changes in FN (A, D), LAMB1 (B, E), LAMB2 (C, F) mRNA expression 
levels; comparisons between HC and JSLE serum treatments. 24-hour changes in FN (G), 
LAMB1 (H), LAMB2 (I) mRNA expression levels; comparisons of HC serum treatments with 
active and inactive LN serum treatments. Data presented as median ΔΔCt [range] are analysed 
with Mann-Whitney test or Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05, JSLE serum vs 





No statistically significant changes were seen in the mRNA expression of tissue 
inhibitor of metalloproteinases 1 (TIMP1) (Figure 4.11-A-C) or matrix 
metalloproteinase (MMP) 2 (MMP2) (Figure 4.11-D-F) following ciGEnCs’ treatments 
with JSLE sera compared to HCs, at either 4h or 24h. A trend was observed (p=0.06) for 
decreased ciGEnC expression of MMP7 after the 4h JSLE serum treatments (0.4 [0.1-
1.7]) compared to HC treatments (0.9 [0.3-1.8]) (Figure 4.11-G) but no remarkable 
changes were observed at 24h (Figure 4.11-H & I). No statistically significant 
differences were observed for MMP7 by JSLE sera compared to HC sera at either 4h or 
24h (Figure 4.11-A) or MMP9 at any time point (Figure 4.11-J-L).  
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Figure 4.11. Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of 
JSLE or HC sera on TIMP1 and MMPs mRNA expression.  
4-hour and 24-hour changes in TIMP1 (A, F), MMP2 (B, G), MMP7 (C, H), MMP9 (D, I) mRNA 
expression levels; comparisons between HC and JSLE serum treatments. 24-hour changes in 
TIMP1 (J), MMP2 (K) MMP7 (L), MMP9 (M) mRNA expression levels; comparisons of HC 
serum treatments with active and inactive LN serum treatments. Data presented as median ΔΔCt 
[range] are analysed with Mann-Whitney test or Kruskal-Wallis with Dunn’s post-hoc test. 




4.4.1.2. Pro-inflammatory mediators 
The expression of pro-inflammatory genes and subsequent production of pro-
inflammatory proteins by the human GEnCs was tested following cytokine and LPS 
treatments, and data presented in Chapter 3. As statistically significant changes were 
observed following certain stimuli, the effect of serum treatments on the same genes was 
tested and is presented in this Chapter.  
At 4h, no statistically significant differences were observed for TNF-α mRNA levels 
(Figure 4.12-A). The 24h JSLE serum treatments did not modify TNF-α mRNA levels 
compared to HCs (Figure 4.12-B), however when distinguished into active and inactive 
LN serum treatments the latter significantly decreased TNF-α mRNA expression (0.0003 
[0.0001-0.0009], p=0.03) compared to HC serum treatments (0.0008 [0.0004-0.002]) 
(Figure 4.12-C).  
No statistically significant differences were observed at 4h for IL-1β mRNA 
expression when the HC effect was compared to the JSLE serum effect (Figure 4.12-
D). A trend was observed for increased IL-1β mRNA expression after JSLE serum 
treatments (0.003 [0.0008-0.006], p=0.07]) compared to HCs (0.002 [0.0008-0.004]) 
(Figure 4.12-E), however no statistically significant change occurred when the JSLE 
serum treatments were distinguished into active and inactive LN (Figure 4.12-F).  
No changes in IL-6 levels were observed at 4h of HC and JSLE serum treatments 
(Figure 4.12-G). JSLE serum treatments (0.002 [0.0007-0.003], p=0.03) significantly 
increased IL-6 mRNA expression compared to HCs (0.001 [0.0006-0.002]) (Figure 
4.12-H) and a trend was observed for increased IL-6 mRNA expression following active 
LN serum treatments (0.002 [0.0006-0.002], p=0.06) compared to HCs (0.001 [0.0006-
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0.002]) (Figure 4.12-KI). Finally, no statistically significant changes were observed for 
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Figure 4.12 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on cytokine mRNA expression.  
4-hour and 24-hour changes in TNF-α (A, F), IL-1β (B, G), IL-6 (C, H), IL-10 (D, I) mRNA 
expression levels; comparisons between HC and JSLE serum treatments. 24-hour changes in 
TNF-α (J), IL-1β (K) IL-6 (L), IL-8 (M) mRNA expression levels; comparisons of HC serum 
treatments with active and inactive LN serum treatments. Data presented as median ΔΔCt 
[range] are analysed with Mann-Whitney test or Kruskal-Wallis with Dunn’s post-hoc test. 




Among the chemokine genes tested, no statistically significant differences were 
observed for IL-8 (Figure 4.13-A-C) and MIP-1α (Figure 4.13-D-F) mRNA expression 
following HC and JSLE serum treatments at 4 and 24h and no differences were observed 
at 24h when the JSLE serum treatments were distinguished into active and inactive LN. 
At 4h, no statistically significant changes in IP-10 mRNA levels were observed 
between HC and JSLE serum treatments (Figure 4.13-G). A trend was observed for 
decreased IP-10 mRNA expression following JSLE serum (0.00005 [0.000004-0.0005], 
p=0.055) treatments compared to HCs (0.0001 [0.00003-0.0008]) (Figure 4.13-H). 
When JSLE serum was distinguished into active and inactive LN serum, the inactive LN 
serum treatments (0.00005 [0.00002-0.0001], p=0.04) significantly decreased IP-10 
mRNA levels compared to HCs (0.0001 [0.00003-0.0008]) but no significant difference 
was demonstrated between HCs and active LN serum treatments (0.0001 [0.000004-
0.0005]) (Figure 4.13-I).  IP-10 mRNA, however, was in general very lowly expressed 
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Figure 4.13 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on chemokine mRNA expression.  
4-hour and 24-hour changes in IL-8 (A, D), MIP-1α (B, E), IP-10 (C, F) mRNA expression 
levels; comparisons between HC and JSLE serum treatments. 24-hour changes in IL-8 (G), MIP-
1α (H) IP-10 (I) mRNA expression levels; comparisons of HC serum treatments with active and 
inactive LN serum treatments. Data presented as median ΔΔCt [range] are analysed with Mann-
Whitney test or Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05, JSLE serum vs HC/active or 
inactive LN serum vs HC. N=10-20/group. HK: ACTB, TUBB. 
No statistically significant differences were observed in the mRNA expression 
levels of urinary biomarkers for childhood LN activity (MCP-1, VCAM-1, L-PGDS, TF) 
at either 4h or 24h following HC and JSLE serum treatments or HC and active/inactive 
LN serum treatments, with TF and L-PGDS  demonstrating negligible expression levels 
Figure 4.14).   
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Figure 4.14 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on urinary biomarker mRNA expression.  
4-hour and 24-hour changes in MCP-1 (A, F), VCAM-1 (B, G), TF (C, H), L-PGDS (D, I) mRNA 
expression levels; comparisons between HC and JSLE serum treatments. 24-hour changes in 
MCP-1 (J), VCAM-1 (K) TF (L), L-PGDS (M) mRNA expression levels; comparisons of HC 
serum treatments with active and inactive LN serum treatments. Data presented as median ΔΔCt 
[range] are analysed with Mann-Whitney test or Kruskal-Wallis with Dunn’s post-hoc test. 




M-CSF (Figure 4.15-A-C) and GM-CSF (Figure 4.15-D-F) mRNA expression by 
ciGEnCs following 4h incubation with sera taken from HC was not affected by treatment 
with sera from JSLE patients. Levels of M-CSF and GM-CSF mRNA were similar at 
24h and again were unaffected by sera treatments. Further stratification of JSLE patients 
into active and inactive LN revealed no differences between groups (Figure 4.15).   
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Figure 4.15 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on blood cell growth factor mRNA expression.  
4-hour and 24-hour changes in M-CSF (A, C), GM-CSF (B, D) mRNA expression levels; 
comparisons between HC and JSLE serum treatments. 24-hour changes in M-CSF (E), GM-CSF 
(F) mRNA expression levels; comparisons of HC serum treatments with active and inactive LN 
serum treatments. Data presented as median ΔΔCt [range] are analysed with Mann-Whitney 
test or Kruskal-Wallis with Dunn’s post-hoc test. p=NS, JSLE serum vs HC/active or inactive 





Similarly, TNFR1 (Figure 4.16-A-C), TNFR2 (Figure 4.16-D-F), IL-1RI (Figure 
4.16-G-I) and IL-1RII (Figure 4.16-J-L) mRNA expression by ciGEnCs following 4h 
incubation with HC sera was not affected by JSLE serum treatments. Levels of TNFR1, 
TNFR2, IL-1RI and IL-1RII were similar at 24h and again were unaffected by different 
serum treatments. Further stratification of JSLE patients into active and inactive LN 
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Figure 4.16 Effect of 4-hour and 24-hour ciGEnC treatments with 5% concentrations of JSLE 
or HC sera on TNF-α and IL-1β receptor mRNA expression.  
4-hour and 24-hour changes in TNFR1 (A, F), TNFR2 (B, G), IL-1RI (C, H), IL-1RII (D, I) 
mRNA expression levels; comparisons between HC and JSLE serum treatments. 24-hour 
changes in TNFR1 (J), TNFR2 (K) IL-1RI (L), IL-1RII (M) mRNA expression levels; 
comparisons of HC serum treatments with active and inactive LN serum treatments. Data 
presented as median ΔΔCt [range] are analysed with Mann-Whitney test or Kruskal-Wallis with 
Dunn’s post-hoc test. p=NS, JSLE serum vs HC/active or inactive LN serum vs HC. N=10-
20/group. HK: ACTB, TUBB. 
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In general, the 4h serum treatments did not induce any significant changes in the 
mRNA expression levels between JSLE- and HC-treated groups whereas the 24h serum 
treatments led to more trends or significant changes in the mRNA expression of the 
genes tested. 
 Effect of human neutrophil conditioned media on pro-inflammatory gene 
production by GEnCs 
Neutrophils isolated from healthy adult blood donors were stimulated for 1h with 
TNF-α, IFN-γ and LPS and their conditioned media together with those of untreated 
neutrophils were collected and used to incubate ciGEnCs for 24h in order to test potential 
changes in pro-inflammatory gene expression. Untreated, TNF-α, IFN-γ- and LPS-
treated ciGEnCs were included at all times and were compared to their neutrophil 
conditioned media counterparts in order to evaluate the potential effect of the neutrophil 
conditioned media on ciGEnCs and to ensure that this effect was not just a consequence 
of cytokine and LPS treatments. 
4.4.2.1. Cytokine and Chemokine mRNA expression after treatment with neutrophil 
conditioned media 
ciGEnCs expressed low levels of mRNA for IL-6 (Figure 4.17-A), IL-8 (Figure 
4.17-B), MIP-1α (Figure 4.17-C), and IP-10 (Figure 4.17-D), under basal conditions 
(untreated ciGEnCs), and no significant change was noted following incubation with 
conditioned media from untreated neutrophils. When treated with conditioned media 
from TNF-α-, IFN-γ- and LPS-activated neutrophils the ciGEnC expression levels of IL-
6, IL-8, MIP-1α and IP-10 did not differ from those of the TNF-α-, IFN-γ- and LPS-
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Figure 4.17 Effect of 24-hour ciGEnC treatments with untreated, TNF-α-, IFN-γ- and LPS-
treated human neutrophil conditioned media on cytokine and chemokine mRNA expression.  
Changes in IL-6 (A), IL-8 (B), MIP-1α (C), IP-10 (D) mRNA expression levels. Data presented 
as interleaved scatter plots are analysed by multiple t-tests with p-value corrections using the 
Holm-Sidak test (ciGEnCs vs neutrophil conditioned media-treated ciGEnCs: Untreated, TNF-




4.4.2.2.Urinary biomarker mRNA expression after treatment with neutrophil 
conditioned media 
No statistically significant changes were observed for MCP-1 (Figure 4.18-A) and 
VCAM-1 (Figure 4.18-B) mRNA expression when untreated ciGEnCs were compared 
to ciGEnCs stimulated with untreated neutrophil conditioned media.  When treated with 
conditioned media from TNF-α-, IFN-γ- and LPS-activated neutrophils the ciGEnC 
expression levels of MCP-1 and VCAM-1 did not differ from those of the TNF-α-, IFN-
γ- and LPS-treated ciGEnCs (Figure 4.18). 
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Figure 4.18 Effect of 24-hour ciGEnC treatments with untreated, TNF-α-, IFN-γ- and LPS-
treated human neutrophil conditioned media on urinary biomarker mRNA expression.  
Changes in MCP-1 (A), VCAM-1 (B) mRNA expression levels. Data presented as interleaved 
scatter plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs neutrophil conditioned media-treated ciGEnCs: Untreated, TNF-α, IFN-γ, LPS). 




4.4.2.3.Blood cell growth factors mRNA expression after treatment with neutrophil 
conditioned media 
ciGEnCs expressed low levels of mRNA for M-CSF (Figure 4.19-A) and GM-CSF 
(Figure 4.19-B), under basal conditions (untreated ciGEnCs), and no significant change 
was noted following incubation with conditioned media from untreated neutrophils. 
When treated with conditioned media from TNF-α-, IFN-γ- and LPS-activated 
neutrophils the ciGEnC expression levels of M-CSF and GM-CSF did not differ from 
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Figure 4.19 Effect of 24-hour ciGEnC treatments with untreated, TNF-α-, IFN-γ- and LPS-
treated human neutrophil conditioned media on blood cell growth factor mRNA expression. 
 Changes in M-CSF (A), GM-CSF (B) mRNA expression levels. Data presented as interleaved 
scatter plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs neutrophil conditioned media-treated ciGEnCs: Untreated, TNF-α, IFN-γ, LPS). 




4.4.2.4.Cytokine receptors mRNA expression after treatment with neutrophil 
conditioned media 
No statistically significant changes were observed for TNFR1 (Figure 4.20-A), 
TNFR2 (Figure 4.20-B), IL-1RI (Figure 4.20-C) and IL-1RII (Figure 4.20-D) mRNA 
expression when untreated ciGEnCs were compared to ciGEnCs stimulated with 
untreated neutrophil conditioned media.  When treated with conditioned media from 
TNF-α-, IFN-γ- and LPS-activated neutrophils the ciGEnC expression levels of TNFR1, 
TNFR2, IL-1RI and IL-1RII did not differ from those of the TNF-α-, IFN-γ- and LPS-
treated ciGEnCs (Figure 4.20). 
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Figure 4.20 Effect of 24-hour ciGEnC treatments with untreated, TNF-α-, IFN-γ- and LPS-
treated human neutrophil conditioned media on TNF-α and IL-1β receptor mRNA 
expression.  
Changes in TNFR1 (A), TNFR2 (B), IL-1RI (C), IL-1RII (D) mRNA expression levels. Data 
presented as interleaved scatter plots are analysed by multiple t-tests with p-value corrections 
using the Holm-Sidak test (Untreated, TNF-α, IFN-γ, LPS). *p≤0.013, ***p≤0.00075. N=3-
8/group. HK: ACTB, TUBB, TBP. 
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 Effect of human macrophage conditioned media on the pro-inflammatory gene 
production by GEnCs 
The effect of human macrophage conditioned media on ciGEnCs was explored. 
However, due to low cell number generated by primary human macrophages, an in vitro 
THP-1 macrophage/ciGEnC model was also developed. 
Human monocytes were isolated from healthy adult blood donors and differentiated 
into macrophages (MΦ) using M-CSF. Initially, the MΦ were treated for 48h with IFN-
γ and LPS. Subsequently the untreated, IFN-γ and LPS ΜΦ conditioned media were 
collected and used to treat ciGEnCs for 24h in order to explore potential changes in 
MCP-1, VCAM-1, IL-6 and IL-8 mRNA expression (these pro-inflammatory genes were 
used to initially perform a pilot assay in order to determine whether a substantial effect 
would be exerted on the ciGEnCs by the MΦ conditioned media) (Figure 4.21). Among 
all MΦ media treatments, the LPS MΦ media had the most prominent effect on ciGEnCs. 
The LPS MΦ media significantly increased MCP-1 mRNA expression (3 [2-4], p=0.01) 
compared to untreated ciGEnCs (0.1 [0.07-0.2]) (Figure 4.21-A) and similarly the LPS 
MΦ media significantly increased VCAM-1 mRNA levels (0.1 [0.02-0.2], p=0.01) 
compared to untreated ciGEnCs (0.01 [0.01-0.02]) (Figure 4.21-B) and IL-6 mRNA 
levels (0.9 [0.6-1], p=0.0006) compared to untreated ciGEnCs (0.02 [0.008-0.03]) 
(Figure 4.21-C). Although not statistically significantly, the LPS ΜΦ media 
considerably elevated IL-8 mRNA levels (1 [0.4-2]) compared to untreated ciGEnCs 
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Figure 4.21 Exploring the effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and 
LPS-treated human macrophage conditioned media on MCP-1, VCAM-1, IL-6 and IL-8 gene 
expression.  
Changes in MCP-1 (A), VCAM-1 (B), IL-6 (C) and IL-8 mRNA expression. Data presented as 
median ΔΔCt [range] are analysed with Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05, 
**p≤0.01, ***p≤0.001, vs Untreated. N=4-6/group. HK: TBP, TUBB. 
 
Treatment of ciGEnCs with conditioned media from MΦ treated with LPS induced 
an increase in the production of pro-inflammatory genes including MCP-1, VCAM-1, IL-
6 and IL-8. It was therefore hypothesised that as well as a direct LPS effect on ciGEnCs, 
LPS could induce the secretion of an inflammatory mediator that activates GEnCs, such 
as the prototypical pro-inflammatory cytokine TNF-α.  
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To test this hypothesis healthy adult donor blood samples were collected, and 
isolated monocytes were differentiated into human macrophages. These were treated 
with LPS for 24h with or without a 2h addition of anti-TNF-αAb (Ab) at 22h at 37oC 
and 5% CO2, before the conditioned media were collected and used to stimulate ciGEnCs 
for 24 h. Following stimulation, the ciGEnCs were lysed in Trizol for RNA extraction.  
4.4.3.1.Cytokine and chemokine mRNA expression after treatment with MΦ conditioned 
media 
The LPS MΦ media significantly increased IL-6 mRNA expression (1.3 [0.4-2], 
p=0.04) compared to untreated ciGEnCs (0.02 [0.01-0.05]) (Figure 4.22-A). However, 
anti-TNF-α Ab addition did not abolish the LPS MΦ effect (1.2 [0.4-1]) (Figure 4.22-
A), possibly because LPS itself has a strong effect on IL-6 mRNA expression. For IL-
8 mRNA expression, no statistically significant values occurred (Figure 4.22-B). MIP-
1α mRNA levels were not substantially affected by LPS ΜΦ media stimulation and 
therefore, no remarkable changes occurred (Figure 4.22 -C). A trend was observed for 
increased IP-10 mRNA expression after LPS ΜΦ media treatment (0.005 [0.0005-
0.006], p=0.06) compared to untreated ciGEnCs (0.0002 [0.0002-0.0004 (Figure 4.22-
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Figure 4.22 Exploring the effect of 24-hour ciGEnC treatment with LPS-treated human 
macrophage conditioned media -with or without anti-TNF-α Ab addition- on cytokine and 
chemokine gene expression.  
Changes in IL-6 (A), IL-8 (B), MIP-1α (C) and IP-10 (D) mRNA expression. Data presented as 
median ΔΔCt [range] are analysed with Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05 vs 
LPS ΜΦ-ciGEnCs. N=5/group. HK: TBP, TUBB. 
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4.4.3.2.Urinary biomarker mRNA expression after treatment with MΦ conditioned 
media 
The LPS MΦ media statistically significantly increased MCP-1 mRNA expression 
(11 [4-23], p=0.04) compared to untreated ciGEnCs (0.3 [0.2-1.2]) and anti-ΤΝF-αAb 
(Ab) addition to LPS ΜΦ media, prior to ciGEnC incubation, partially reduced MCP-
1 mRNA levels (7 [4-10], p=NS) (Figure 4.23-A). For VCAM-1 mRNA expression, no 
trends or statistically significant changes were observed, when the untreated (0.006 
[0.002-0.01]), LPS MΦ-treated (0.08 [0.009-0.2]) and LPS MΦ/anti-TNF-α-treated 
ciGEnCs (0.5 [0.006-0.07]) were compared (Figure 4.23-B).  
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Figure 4.23 Exploring the effect of 24-hour ciGEnC treatment with LPS-treated human 
macrophage conditioned media -with or without anti-TNF-αAb addition- on urinary 
biomarker gene expression.  
Changes in MCP-1 (A), VCAM-1 (B) mRNA expression. Data presented as median ΔΔCt [range] 
are analysed with Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05 vs LPS ΜΦ-ciGEnCs. 
N=5/group. HK: TBP, TUBB. 
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4.4.3.3.Blood cell growth factor mRNA expression after treatment with MΦ conditioned 
media 
No trends or statistically significant changes were observed for M-CSF mRNA 
expression, however the LPS MΦ media treatments (0.01 [0.006-0.03]) led to generally 
higher M-CSF mRNA levels compared to untreated ciGEnCs (0.003 [0.001-0.004]) 
(Figure 4.24-A). No remarkable changes were observed for GM-CSF mRNA levels 
(Figure 4.24-B). 
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Figure 4.24 Exploring the effect of 24-hour ciGEnC treatment with LPS-treated human 
macrophage conditioned media -with or without anti-TNF-αAb addition- on blood cell growth 
factor gene expression.  
Changes in M-CSF (A), GM-CSF (B) mRNA expression. Data presented as median ΔΔCt 
[range] are analysed with Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05 vs LPS ΜΦ-




4.4.3.4.Cytokine receptors mRNA expression after treatment with MΦ conditioned 
media 
A trend was observed for increased TNFR1 mRNA expression after LPS ΜΦ 
treatments (0.1 [0.03-0.1], p=0.07) compared to untreated ciGEnCs (0.05 [0.03-0.06]) 
(Figure 4.25-A). Anti-TNF-α Αb addition to the LPS MΦ media did not reverse the LPS 
MΦ media effect (0.09 [0.07-0.1]), suggesting that other pro-inflammatory factors 
secreted by the LPS-treated human macrophages or LPS itself might induce increased 
TNFR1 levels (Figure 4.25-A). No statistically significant changes were observed for 
TNFR2 (Figure 4.25-B). 
The LPS ΜΦ media significantly increased IL-1RI (0.01 [0.003-0.01], p=0.05) 
(Figure 4.25-C) and IL-1RII (0.01 [0.01-0.02], p=0.03) (Figure 4.25-D) mRNA 
expression compared to untreated ciGEnCs (IL-1RI: 0.002 [0.001-0.006], IL-1RII: 0.004 
[0.002-0.007]). Anti-TNF-α Αb addition to the LPS MΦ media did not reverse the LPS 
MΦ media effect for either IL-1RI (0.01 [0.008-0.02]) (Figure 4.25-C) or IL-1RII (0.01 
[0.009-0.02]) (Figure 4.25-D), suggesting that other pro-inflammatory factors secreted 
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Figure 4.25 Exploring the effect of 24-hour ciGEnC treatment with LPS-treated human 
macrophage conditioned media -with or without anti-TNF-αAb addition- on TNF-α and IL-
1β receptor gene expression.  
Changes in TNFR1 (A), TNFR2 (B), IL-1RI (C), IL-1RII (D) mRNA expression. Data presented 
as median ΔΔCt [range] are analysed with Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.05 
vs LPS ΜΦ-ciGEnCs. N=5/group. HK: TBP, TUBB. 
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 Effect of THP-1 conditioned media on pro-inflammatory gene expression by 
ciGEnCs 
To develop a more reproducible in vitro model for the study of the potential 
paracrine effect of human THP-1 macrophages on ciGEnCs, the THP-1 macrophages 
were initially stimulated for 48h with IFN-γ and LPS, with untreated THP-1 cells always 
being included in all assays.  
The untreated, IFN-γ- and LPS-stimulated THP-1 cοnditioned media were collected 
and initially, the presence of TNF-α and IL-1β within the THP-1 conditioned media was 
tested via ELISA.  
4.4.4.1.TNF-α and IL-1β secretion by the THP-1 macrophages 
In order to determine which mediators are being secreted from activated THP-1 cells 
that may be inducing pro-inflammatory changes within GEnCs the secretion of TNF-α 
and IL-1β by the THP-1 macrophages was tested after 48h of individual IFN-γ and LPS 
incubations.  
TNF-α secretion was significantly increased by LPS treatments (217 pg/ml [143-
503], p=) compared to untreated THP-1 cells (11 pg/ml [8-22]) (Figure 4.26-A) whereas 
IFN-γ did not modify basal THP-1 TNF-α secretion levels (11 pg/ml [3-33]) (Figure 
4.26-A). IFN-γ (67 pg/ml [37-135]) and LPS (72 pg/ml [50-228]) treatments did not 
significantly increase basal THP-1 IL-1β levels when compared to untreated ciGEnCs 
(32 pg/ml [29-101]) (Figure 4.26-B). 
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Figure 4.26 Changes in TNF-α and IL-1β secretion levels and fold changes following 48-hour 
stimulation of THP-1 cells with IFN-γ and LPS.  
Changes in TNF-α (A), IL-1β (B) secretion levels. Data presented as median concentration 
[range] are analysed with Kruskal-Wallis with Dunn’s post-hoc test. *p≤0.005, N=5/group.  
 
4.4.4.2.Investigating the effect of THP-1 conditioned media on ciGEnC expression 
and/or secretion of pro-inflammatory proteins 
Once it had been determined that TNF-α and IL-1β are expressed by THP-1 cells it 
was hypothesised that these cytokines could be responsible for inducing pro-
inflammatory gene expression by ciGEnCs in response to THP-1 conditioned media 
treatments. 
The untreated, IFN-γ- and LPS-stimulated THP-1 cοnditioned media were collected 
and were used with or without incubation with anti-TNF-α Αb and IL-1Ra for 2 hours 
at 37oC and 5% CO2 to stimulate the ciGEnCs for 24h. Subsequently, the expression 




4.4.4.3. Cytokine and chemokine mRNA expression after treatment with THP-1 
conditioned media 
ciGEnCs expressed low levels of mRNA for IL-6 (Figure 4.27-A) under basal 
conditions (untreated ciGEnCs), and no significant change was noted following 
incubation with conditioned media from untreated THP-1 cells. When treated with 
conditioned media from IFN-γ- and LPS-activated THP-1 cells the ciGEnC expression 
levels of IL-6 did not differ from those of the IFN-γ- and LPS-treated ciGEnCs. (Figure 
4.27-A). 
ciGEnC IL-8 mRNA levels were statistically significantly lower when anti-TNF-α 
Ab/IL-1Ra were added to the untreated THP-1 media (0.07 [0.05-0.2]) compared to the 
untreated THP-1 media (0.4 [0.3-0.6], p=0.01) alone (Figure 4.27-B). Nevertheless, the 
untreated THP-1 media-induced IL-8 levels did not significantly differ from the 
untreated ciGEnCs’ basal levels (0.2 [0.1-0.7]), although they were slightly higher 
(Figure 4.27-B). The IFN-γ THP-1 media significantly increased IL-8 mRNA 
expression (0.7 [0.1-7], p=0.018); this could not be attributed to the effects of residual 
IFN-γ as direct stimulation of ciGEnCs with IFN-γ did not replicate this effect (Figure 
4.27-B). Anti-TNF-α Ab/IL-1Ra addition brought IL-8 levels (0.07 [0.02-2]) closer to 
those of the IFN-γ-treated ciGEnCs (Figure 4.27-B).  
ciGEnCs expressed low levels of mRNA for MIP-1α (Figure 4.27-C) and IP-10 
(Figure 4.27-D) under basal conditions (untreated ciGEnCs), and no significant change 
was observed after stimulation with conditioned media from untreated THP-1 cells. 
When treated with conditioned media from IFN-γ- and LPS-activated THP-1 cells the 
ciGEnC expression levels of MIP-1α and IP-10 did not differ from those of the IFN-γ- 




Figure 4.27 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media, with or without anti-TNF-α Ab/IL-1Ra addition, on cytokine and 
chemokine mRNA expression. 
Changes in IL-6 (A), IL-8 (B), MIP-1α (C), IP-10 (D) mRNA expression. Data presented as 
interleaved scatter plots are analysed with Kruskal-Wallis with Dunn’s post-hoc test with 
corrected p-values for each treatment group (ciGEnCs vs THP-1 conditioned media-treated 




4.4.4.4.Urinary biomarker mRNA expression after treatment with THP-1 conditioned 
media 
No statistically significant changes were observed in MCP-1 mRNA expression 
which was lowly expressed by untreated ciGEnCs and these expression levels were not 
statistically significantly modified either by untreated THP-1 conditioned media or by 
the rest of the IFN-γ-/LPS-stimulated THP-1 conditioned media and IFN-γ/LPS 
ciGEnCs treatments (Figure 4.28-A).  
The IFN-γ THP-1 media led to statistically significantly higher VCAM-1 mRNA 
expression levels (0.02 [0.01-0.8], p=0.059) compared to the IFN-γ THP-1 media with 
anti-TNF-α/IL-1Ra addition (0.002 [0.0008-0.007]) (Figure 4.28-B). The IFN-γ THP-1 
media did not lead to statistically significantly higher VCAM-1 mRNA expression when 
compared to IFN-γ-treated ciGEnCs (0.01 [0.006-0.02]), although the VCAM-1 mRNA 
levels of the latter were lower than those of the IFN-γ THP-1 media-treated ciGEnCs 
(Figure 4.28-B).  
Similar to the IFN-γ THP-1 media, the LPS THP-1 media led to statistically 
significantly higher VCAM-1 mRNA expression levels (0.05 [0.04-0.2], p=0.01) 
compared to the LPS THP-1 media with anti-TNF-α/IL-1Ra addition (0.007 [0.005-
0.02]) (Figure 4.28-B). The LPS THP-1 media did not lead to statistically significantly 
higher VCAM-1 mRNA expression when compared to LPS-treated ciGEnCs (0.01 [0.01-
0.1]), although the VCAM-1 mRNA levels of the latter were lower than those of the (LPS 




Figure 4.28 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media, with or without anti-TNF-α Ab/IL-1Ra addition, on urinary 
biomarker gene expression.  
Changes in MCP-1 (A), VCAM-1 (B) mRNA expression. Data presented as interleaved scatter 
plots are analysed with Kruskal-Wallis with Dunn’s post-hoc test with corrected p-values for 
each treatment group (ciGEnCs vs THP-1 conditioned media-treated ciGEnCs: Untreated, IFN-
γ, LPS). *p≤0.017, N=3-5/group. HK: YWHAZ. 
 
4.4.4.5.Blood cell growth factor mRNA expression after treatment with THP-1 
conditioned media 
No statistically significant changes were observed in M-CSF (Figure 4.29-A) 
and GM-CSF (Figure 4.29-B) levels of mRNA expression which were lowly expressed 
by untreated ciGEnCs. These basal expression levels were not statistically significantly 
modified either by untreated THP-1 conditioned media or by the rest of the IFN-γ-/LPS-




Figure 4.29 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media, with or without anti-TNF-αAb/IL-1Ra addition, on blood cell 
growth factor gene expression.  
Changes in M-CSF (A), GM-CSF (B) mRNA expression. Data presented as interleaved scatter 
plots are analysed with Kruskal-Wallis with Dunn’s post-hoc test with corrected p-values for 
each treatment group (ciGEnCs vs THP-1 conditioned media-treated ciGEnCs: Untreated, IFN-
γ, LPS). p=NS, N=3-5/group. HK: YWHAZ. 
.  
4.4.4.6.Cytokine receptor mRNA expression after treatment with THP-1 conditioned 
media 
No statistically significant differences were observed for TNFR1 mRNA expression 
(Figure 4.30-A). Anti-TNF-α Ab/IL-1Ra addition to the untreated THP-1 (3x10-10 
[2x10-10  -6x10-10]), IFN-γ THP-1 (0.005 [0.003-0.04]) and LPS THP-1 media (2x10-10  
[4x10-11 -3x10-10]) prior to ciGEnC incubation led to a statistically significant decrease 
in TNFR2 expression when compared to ciGEnCs treated with untreated THP-1 media 
(0.003 [0.0004-0.004], p=0.017), IFN-γ THP-1 media (0.005 [0.003-0.04], p=0.014) and 
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LPS THP-1 media (0.007 [0.005-0.01], p=0.014) respectively (Figure 4.30-B). No 
significant changes were observed when untreated ciGEnCs (0.002 [0.001-0.003]), IFN-
γ-treated (0.001 [0.0007-0.002]) and LPS-treated ciGEnCs (0.002 [0.001-0.004]) were 
compared to their THP-1 media counterparts, although their TNFR2 expression was 
generally lower.  
No statistically significant differences were observed for IL-1RI mRNA expression 
(Figure 4.30-C). Anti-TNF-α Ab/IL-1Ra addition to the untreated THP-1 (0.0007 
[0.0004-0.001]), IFN-γ THP-1 (0.0009 [0.0006-0.001]) and LPS THP-1 media (0.0004  
[0.0002-0.008]) prior to ciGEnC incubation, led to a statistically significant decrease in 
IL-1RII expression when compared to ciGEnCs treated with untreated THP-1media 
(0.007 [0.004-0.03], p=0.017), IFN-γ THP-1 media (0.008 [0.003-0.03], p=0.014) and 
LPS THP-1 media (0.007 [0.005-0.01], p=0.014) respectively (Figure 4.30-D). No 
significant changes were observed when untreated ciGEnCs (0.005 [0.003-0.01]), IFN-
γ-treated (0.006 [0.003-0.008]) and LPS-treated ciGEnCs (0.009 [0.003-0.02]) were 
compared to their THP-1 media counterparts, although their IL-1RII expression was 




Figure 4.30 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media -with or without anti-TNF-α Ab/IL-1Ra addition- on TNF-α and 
IL-1β receptor gene expression.  
Changes in TNFR1 (A), TNFR2 (B), IL-1RI (C), IL-1RII (D) mRNA expression. Data presented 
as interleaved scatter plots are analysed with Kruskal-Wallis with Dunn’s post-hoc test with 
corrected p-values for each treatment group (ciGEnCs vs THP-1 conditioned media-treated 




4.4.4.7. Cytokine and chemokine secretion after treatment with THP-1 conditioned 
media 
The untreated THP-1 media induced a statistically significant increase in IL-6 
secretion (3,910 pg/ml [2,688-6,431], p=0.004) compared to untreated ciGEnCs (1,805 
pg/ml [1,246-1,949]) (Figure 4.31-A). Addition of anti-TNF-α Ab/IL-1Ra to the THP-
1 media prior to ciGEnC incubation led to generally lower IL-6 levels (1,954 pg/ml 
[1,768-2,275]) compared to the untreated THP-1 media effect, although not statistically 
significantly different (Figure 4.31-A).  
The IFN-γ THP-1 media induced a statistically significant increase in IL-8 secretion 
(6,336 pg/ml [6,169-6,507], p=0.002) compared to IFN-γ-treated ciGEnCs (1,328 pg/ml 
[981-3,004]) (Figure 4.31-Β). Addition of anti-TNF-α Ab/IL-1Ra to the THP-1 media 
prior to ciGEnC incubation did not sufficiently reduce the IL-8 levels (5,550 pg/ml 
[4,916-6,148]) suggesting that factors present within the IFN-γ THP-1 media other than 
TNF-α and IL-1β could have a more robust effect on the upregulation of IL-8 levels 
(Figure 4.31-Β).  
Finally, the untreated THP-1 media induced a statistically significant increase in IP-
10 secretion (389 pg/ml [156-2,223], p=0.008) compared to untreated ciGEnCs (5pg/ml 
[5-6]) (Figure 4.31-C). Addition of anti-TNF-α Ab/IL-1Ra to the THP-1 media prior to 
ciGEnC incubation did not lead to statistically significantly lower levels of IP-10 (187 




Figure 4.31 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media -with or without anti-TNF-αAb/IL-1Ra addition- on cytokine and 
chemokine secretion.  
Changes in IL-6 (A), IL-8 (B), IP-10 (C) secretion. Data presented as interleaved scatter plots 
are analysed with Kruskal-Wallis with Dunn’s post-hoc test with corrected p-values for each 
treatment group (ciGEnCs vs THP-1 conditioned media-treated ciGEnCs: Untreated, IFN-γ, 
LPS). *p≤0.017, **p≤0.0057, N=4-5/group. 
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4.4.4.8.Urinary biomarker protein secretion after treatment with THP-1 conditioned 
media 
The IFN-γ THP-1 media significantly increased MCP-1 secretion (1,252 pg/ml 
[1,128-1,501], p=0.008) compared to IFN-γ-treated ciGEnCs (255 pg/ml [235-292]) 
(Figure 4.32-A). Addition of anti-TNF-α Ab/IL-1Ra to the THP-1 media prior to 
ciGEnC incubation, led to generally lower MCP-1 levels (491 pg/ml [218-557]) 
compared to the IFN-γ THP-1 media effect, although no statistically significant 
differences were observed (Figure 4.32-A).  
sVCAM-1 secretion following IFN-γ THP-1 media treatments (131 pg/ml [29-187], 
p=0.071) was statistically significantly increased compared to IFN-γ THP-1 media with 
anti-TNF-α Ab/IL-1Ra addition (8 pg/ml [0-20]) (Figure 4.32-B). The IFN-γ THP-1 
media induced generally higher-but not statistically significantly higher- sVCAM-1 






Figure 4.32 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media -with or without anti-TNF-αAb/IL-1Ra addition- on urinary 
biomarker secretion.  
Changes in MCP-1 (A), sVCAM-1 (B) secretion. Data presented as interleaved scatter plots are 
analysed with Kruskal-Wallis with Dunn’s post-hoc test with corrected p-values for each 
treatment group (ciGEnCs vs THP-1 conditioned media-treated ciGEnCs: Untreated, IFN-γ, 
LPS). *p≤0.017, N=4-5/group.  
 
4.4.4.9. Blood cell growth factor secretion after treatment with THP-1 conditioned 
media 
The untreated THP-1 media significantly increased M-CSF secretion (1,527 pg/ml 
[1,161-1,907], p=0.013) compared to the untreated ciGEnCs (570 pg/ml [321-672]) 
(Figure 4.33-A). Nevertheless, addition of anti-TNF-α Ab/IL-1Ra did not manage to 
sufficiently suppress M-CSF secretion (1,224 pg/ml [1,171-1,832]) suggesting that other 
factors than TNF-α and IL-1β, present within the untreated THP-1 media, could also 
play a major role in M-CSF secretion (Figure 4.33-A). 
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The untreated THP-1 media (1,036 pg/ml [777-1,335], p=0.002) and the IFN-γ 
THP-1 media (1,020 pg/ml [457-3,847], p=0.002) significantly increased GM-CSF 
secretion compared to the untreated (176 pg/ml [102-187]) and IFN-γ-treated ciGEnCs 
(69 pg/ml [33-188]) respectively (Figure 4.33-B). Addition of anti-TNF-α/IL-1Ra did 
not statistically significantly suppress the effect of the untreated THP-1 media (406 
pg/ml [264-534]) and of the IFN-γ THP-1 media (228 pg/ml [195-264]) on GM-CSF 




Figure 4.33 Effect of 24-hour ciGEnC treatment with untreated, IFN-γ- and LPS-treated 
THP-1 conditioned media -with or without anti-TNF-α Ab/IL-1Ra addition- on blood cell 
growth factor secretion.  
Changes in M-CSF (A), GM-CSF (B) secretion. Data presented as interleaved scatter plots are 
analysed with Kruskal-Wallis with Dunn’s post-hoc test with corrected p-values for each 
treatment group (ciGEnCs vs THP-1 conditioned media-treated ciGEnCs: Untreated, IFN-γ, 
LPS). *p≤0.017, **p≤0.0057 N=4-5/group.  
 
4.4.4.10. NF-κB activation by LPS THP-1 media 
As the LPS-stimulated THP-1 conditioned media demonstrated the highest levels 
and fold-increases of TNF-α and IL-1β secretion (Figure 4.26), their effect on ciGEnC 
NF-κΒ activation was tested via IF (Figure 4.34). The ciGEnCs were treated for 30 
minutes with LPS alone, LPS THP-1 media and LPS THP-1 media with anti-TNF-α/IL-
1Ra addition and NF-κΒ nuclear translocation was determined via fluorescent 
microscopy (Figure 4.34-A).  
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LPS alone, induced a moderate NF-κB nuclear translocation as demonstrated by the 
r-values for nuclear co-localisation of DAPI and A488 (r-value: 0.67 [0.2-0.9]) whereas 
incubation of ciGEnCs with LPS THP-1 media significantly increased NF-κB nuclear 
translocation (r-value: 0.8 [0.1-1], p<0.0001) compared to the LPS-treated ciGEnCs 
(Figure 4.34-B). Addition of anti-TNF-α Αb/IL-1Ra to the LPS THP-1 media 
statistically significantly decreased NF-κΒ nuclear translocation levels (r-value: 0.7 
[0.09-0.9], p=0.0007) compared to the LPS THP-1 media-treated ciGEnCs, although 




Figure 4.34 Effect of 30-minute ciGEnC treatments with LPS, LPS THP-1 conditioned media 
and LPS THP-1 conditioned with anti-TNF-α Ab/IL-1Ra addition on NF-κB nuclear 
translocation.  
A. 20x IF images of ciGEnCs following 30-minute. B. Statistical analysis diagram. Data (r-values 
for nuclear co-localisation of DAPI and A488 for each treatment group) representative of three 
similar experimental repeats are presented as box and whisker plots and are analysed using Kruskal-
Wallis test with Dunn’s post-hoc test. ***p<0.001, ****p≤0.0001 vs LPS THP-1 conditioned media-
treated ciGEnCs. Scale bars: 100μm. 
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 Effect of podocyte conditioned media on pro-inflammatory gene expression by 
GEnCs 
Conditionally immortalised human podocytes were treated for 24h with pro-
inflammatory cytokines -TNF-α, IL-1β, IFN-α, IFN-γ- and LPS. Subsequently, the 24h 
podocyte conditioned media (together with untreated podocyte conditioned media) were 
collected and were used to treat the ciGEnCs for 24h. Changes in ciGEnC pro-
inflammatory gene expression were then tested. 
4.4.5.1.Cytokine mRNA expression after treatment with podocyte conditioned media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS podocyte conditioned media 
were not found to statistically significantly promote or upregulate cytokine mRNA 
expression (Figure 4.35). 
The untreated ciGEnCs’ basal expression levels of IL-6 (Figure 4.35-A) and IL-10 
(Figure 4.35-B) were low and were not modified by the untreated podocyte media 
treatments. Similarly, no remarkable changes were observed when cytokine/LPS 
ciGEnC treatments were compared to their cytokine/LPS-stimulated THP-1 conditioned 




Figure 4.35 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated podocyte conditioned media on cytokine gene expression.  
Changes in IL-6 (A), IL-10 (B) mRNA expression. Data presented as interleaved scatter plots 
are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test (ciGEnCs vs 
podocyte conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, IFN-γ, LPS). 
p=NS, N=4/group. HK: YWHAZ. 
 
4.4.5.2.Chemokine mRNA expression after treatment with podocyte conditioned media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS podocyte conditioned media 
were not found to statistically significantly promote or upregulate chemokine mRNA 
expression (Figure 4.36). 
The untreated ciGEnCs’ basal expression levels of IL-8 (Figure 4.36-A), MIP-1α 
(Figure 4.36-B) and IP-10 (Figure 4.36-C) were low and were not modified by the 
untreated podocyte media treatments. Similarly, no remarkable changes were observed 
when cytokine/LPS ciGEnC treatments were compared to their cytokine/LPS-stimulated 




Figure 4.36 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated podocyte conditioned media on chemokine gene expression.  
Changes in IL-8 (A), MIP-1α (B), IP-10 (C) mRNA expression. Data presented as interleaved 
scatter plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs podocyte conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, 
IFN-γ, LPS). p=NS, N=4/group. HK: YWHAZ. 
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4.4.5.3.Urinary biomarker mRNA expression after treatment with podocyte conditioned 
media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS podocyte conditioned media 
were not found to statistically significantly promote or upregulate urinary biomarker 
mRNA expression (Figure 4.37). 
The untreated ciGEnCs’ basal expression levels of MCP-1 (Figure 4.37-A) and 
VCAM-1 (Figure 4.37-B) were low and were not modified by the untreated podocyte 
media treatments. Similarly, no remarkable changes were observed when cytokine/LPS 
ciGEnC treatments were compared to their cytokine/LPS-stimulated THP-1 conditioned 
media ciGEnC treatment counterparts. 
 
Figure 4.37 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated podocyte conditioned media on urinary biomarker gene expression.  
Changes in MCP-1 (A), VCAM-1 (B) mRNA expression. Data presented as interleaved scatter 
plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs podocyte conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, 
IFN-γ, LPS). p=NS, N=4/group. HK: YWHAZ. 
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4.4.5.4.Blood cell growth factor mRNA expression after treatment with podocyte 
conditioned media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS podocyte conditioned media 
were not found to statistically significantly promote or upregulate blood cell growth 
factor mRNA expression (Figure 4.38). 
The untreated ciGEnCs’ basal expression levels of M-CSF (Figure 4.38-A) and 
GM-CSF (Figure 4.38-B) were low and were not modified by the untreated podocyte 
media treatments. Similarly, no remarkable changes were observed when cytokine/LPS 
ciGEnC treatments were compared to their cytokine/LPS-stimulated THP-1 conditioned 
media ciGEnC treatment counterparts. 
 
Figure 4.38 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated podocyte conditioned media on blood cell growth factor gene expression.  
Changes in M-CSF (A), GM-CSF (B) mRNA expression. Data presented as interleaved scatter 
plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs podocyte conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, 
IFN-γ, LPS). p=NS, N=4/group. HK: YWHAZ. 
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These findings could suggest that, at this (24h) time-point, the podocytes are unable 
to contribute to the pro-inflammatory phenotype of the GEnCs potentially due to 
inadequate pro-inflammatory protein production. 
 Effect of MC conditioned media on pro-inflammatory gene expression by 
GEnCs 
Conditionally immortalised human MCs were treated for 24h with pro-
inflammatory cytokines -TNF-α, IL-1β, IFN-α, IFN-γ- and LPS. Subsequently, the 24h 
MC conditioned media (together with untreated MC conditioned media) were collected 
and were used to treat the ciGEnCs for 24h. Changes in ciGEnC pro-inflammatory gene 
expression were then tested. 
4.4.6.1.Cytokine mRNA expression after treatment with MCs conditioned media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS MCs conditioned media were 
not found to statistically significantly increase cytokine mRNA expression (Figure 
4.39). 
The untreated ciGEnCs’ basal expression levels of IL-6 (Figure 4.39-A) and IL-10 
(Figure 4.39-B) were low and were not altered by the untreated MC media treatments. 
Similarly, no robust changes were observed when cytokine/LPS ciGEnC treatments 






Figure 4.39 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated MC conditioned media on cytokine gene expression.  
Changes in IL-6 (A), IL-10 (B) mRNA expression. Data presented as interleaved scatter plots 
are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test (ciGEnCs vs 
MCs conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, IFN-γ, LPS). p=NS, 
N=4/group. HK: YWHAZ. 
 
4.4.6.2.Chemokine mRNA expression after treatment with MCs conditioned media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS MCs conditioned media were 
not found to statistically significantly increase chemokine mRNA expression (Figure 
4.40). 
The untreated ciGEnCs’ basal expression levels of IL-8 (Figure 4.40-A), MIP-1α 
(Figure 4.40-Β) and IP-10 (Figure 4.39-C) were low and were not altered by the 
untreated MC media treatments. Similarly, no robust changes were observed when 
cytokine/LPS ciGEnC treatments were compared to their cytokine/LPS-stimulated THP-
1 conditioned media ciGEnC treatment counterparts. 
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Figure 4.40 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated MC conditioned media on chemokine gene expression.  
Changes in IL-8 (A), MIP-1α (B), IP-10 (C) mRNA expression. Data presented as interleaved 
scatter plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs MCs conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, IFN-
γ, LPS). p=NS, N=4/group. HK: YWHAZ. 
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4.4.6.3.Urinary biomarker mRNA expression after treatment with MCs conditioned 
media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS MCs conditioned media were 
not found to statistically significantly increase urinary biomarker mRNA expression 
(Figure 4.41). 
The untreated ciGEnCs’ basal expression levels of MCP-1 (Figure 4.41-A) and 
VCAM-1 (Figure 4.41-Β) were low and were not altered by the untreated MC media 
treatments. Similarly, no robust changes were observed when cytokine/LPS ciGEnC 
treatments were compared to their cytokine/LPS-stimulated THP-1 conditioned media 
ciGEnC treatment counterparts. 
 
Figure 4.41 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated MC conditioned media on urinary biomarker gene expression.  
Changes in MCP-1 (A), VCAM-1 (B) mRNA expression. Data presented as interleaved scatter 
plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs MCs conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, IFN-
γ, LPS). p=NS, N=4/group. Fold changes in MCP-1 (C), VCAM-1 (D) mRNA expression. HK: 
YWHAZ. 
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4.4.6.4.Blood cell growth factor mRNA expression after treatment with MCs conditioned 
media 
The untreated, TNF-α, IL-1β, IFN-α, IFN-γ and LPS MCs conditioned media were 
not found to statistically significantly increase blood cell growth factor mRNA 
expression (Figure 4.42). 
The untreated ciGEnCs’ basal expression levels of M-CSF (Figure 4.42-A) and 
GM-CSF (Figure 4.42-Β) were low and were not altered by the untreated MC media 
treatments. Similarly, no robust changes were observed when cytokine/LPS ciGEnC 
treatments were compared to their cytokine/LPS-stimulated THP-1 conditioned media 
ciGEnC treatment counterparts. 
 
Figure 4.42 Effect of 24-hour ciGEnC treatment with untreated, TNF-α-, IL-1β-, IFN-α, IFN-
γ- and LPS-treated MC conditioned media on blood cell growth factor gene expression.  
Changes in M-CSF (A), GM-CSF (B) mRNA expression. Data presented as interleaved scatter 
plots are analysed by multiple t-tests with p-value corrections using the Holm-Sidak test 
(ciGEnCs vs MCs conditioned media-treated ciGEnCs: Untreated, TNF-α, IL-1β, IFN-α, IFN-
γ, LPS). p=NS, N=4/group. HK: YWHAZ. 
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These findings could suggest that, at this (24h) time-point, the MCs are unable to 
contribute to the pro-inflammatory phenotype of the GEnCs potentially due to inability 
of adequate pro-inflammatory protein production. 
4.5. Discussion 
The experiments presented in this chapter, aimed to investigate how the renal 
microenvironment, including neighbouring glomerular cells, blood-circulating factors 
and infiltrating neutrophils and macrophages could affect the human GEnCs. Due to 
their pivotal role in pro-inflammatory protein production, as shown in Chapter 3, it was 
hypothesised that, through interacting with their surrounding environment, the human 
GEnCs would be able to sustain and reinforce their pro-inflammatory phenotype. 
To verify this hypothesis in a physiologically relevant model, the ciGEnCs were 
treated for 4 and 24 hours with serum samples from JSLE patients with active and 
inactive LN and from healthy controls. This way, the potential effect on GEnCs exerted 
by the secreted factors released within the circulation (hormones, acute-phase proteins 
from the liver, dietary factors, secreted factors from other tissues and immune cell-
derived pro-inflammatory factors) was tested. Furthermore, conditioned media from 
previously cytokine- or LPS-activated or untreated primary human neutrophils and 
macrophages, THP-1 macrophages, podocytes and MCs were used to stimulate the 
ciGEnCs for 24 hours. This way, the effect of secreted factors produced by cell types 
that can potentially interact with the GEnCs, was also investigated. 
The 4-hour serum treatments did not reveal any significant changes in the expression 
levels of the genes tested. The 24-hour serum treatments did not induce significant 
increases in the mRNA expression levels of most pro-inflammatory genes tested. 
However, IL-6 and to a lesser extent IL-1β mRNA levels were increased by the JSLE 
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sera compared to the HCs, whereas IP-10 mRNA levels tended to be decreased by the 
JSLE sera. IL-6 and IL-1β are two important pro-inflammatory cytokines that could 
contribute to the sustainability of the renal pro-inflammatory microenvironment, as 
previously described in Chapter 1 (literature review findings) and Chapter 3 (data from 
the in vitro ciGEnC model developed for this thesis’ experiments). It must be noted that 
the inactive and not the active LN serum treatments led to a decrease of pro-
inflammatory gene expression (especially TNF-α and IP-10) compared to HCs. This may 
indicate a differential distribution of cytokines and chemokines between active and 
inactive LN sera. In addition, the 24-hour JSLE serum treatments were not able to 
modulate L-PGDS and TF mRNA expression, an outcome similar to that of cytokine or 
LPS treatments on these lowly expressed urinary biomarkers (Chapter 3). This finding 
corroborates the hypothesis that the human GEnCs are not the main source of all urinary 
biomarkers for LN but instead, they are specialising in producing the two biomarkers 
that are more closely related to pro-inflammatory responses; MCP-1 and VCAM-1. 
The lack of more marked expression of cytokine responses induced by the JSLE 
sera could be because within the patient samples derived from patients taking part in the 
UK JSLE Cohort Study and Repository, most of the JSLE patients have well-managed 
disease, and/or are on various medications (Table 4.1) used for suppression of their 
disease, and therefore suppression of pro-inflammatory responses. Sample numbers 
precluded evaluation of any specific effect of medication on outcomes of experiments 
presented here. 
Hydroxychloroquine (HCQ) is an anti-malarial drug that can inhibit T cell 
proliferation, production of pro-inflammatory cytokines such as IL-1, IL-6, IFN-α, IFN-
γ and TNF-α and in SLE, its main mechanism of action is thought to be the inhibition of 
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Toll-like receptors, leading to inhibition of antigen-recognition401. Furthermore when 
combined with mycophenolate mofetil (MMF), HCQ has been shown to promote renal 
disease remission in SLE patients with LN401,402. MMF inhibits purine biosynthesis and 
the proliferation of activated lymphocytes and is involved in both the induction and 
maintenance of LN therapy403.  
In this study, 70% of the active LN patients and 70% of the inactive LN patients 
whose sera were used were administered with HCQ. Furthermore, 50% of active LN 
patients and 60% of inactive LN patients were administered with MMF. Both HCQ and 
MMF were administered at similar amounts in both active and inactive LN patients. It 
is therefore possible that lack of more robust results regarding IL-6 and IL-1β induction 
after JSLE serum treatments and stratification of JSLE sera into active and inactive sera, 
could be attributed to the presence of HCQ and MMF within the sera. 
Azathioprine is a purine analog that impedes immune cell proliferation and along 
with steroids, it is administered to LN patients404. Prednisolone is a corticosteroid 
medication that suppresses inflammatory responses via blocking leukocyte access and 
binding to the sites of inflammation and reducing the expression of adhesion molecules 
and the production of pro-inflammatory cytokines such as TNF-α and IL-6405. 30% of 
active LN patients and 20% of inactive LN patients whose sera were used to treat 
ciGEnCs in this study were administered with azathioprine at similar doses whereas 60% 
of active LN patients and 60% of inactive LN patients were also treated with 
prednisolone (again, at similar doses). 
Rituximab is a chimeric anti-CD20 monoclonal Ab used to target mature B cells 
and pre-B cells, as B cell aberrant function leading to autoantibody production is one of 
the “hallmarks” of SLE406. Cyclophosphamide is a chemotherapy immunosuppressive 
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agent used for the treatment of patients with renal and central nervous system disease407. 
10% of active LN patients but no inactive LN patients were administered with rituximab. 
Similarly, 10% of active LN patients but no inactive LN patients were administered with 
cyclophosphamide. 
Finally, methotrexate is a folic acid antagonist that can impede immune cell 
proliferation408 whereas intravenous immunoglobulin (IVIG) has an immunomodulatory 
effect and is known to block macrophage FcRs and inhibit immune cell functions such 
as T cell proliferation and dendritic cell differentiation409. In this study, 20% of inactive 
LN patients but no active LN patients received methotrexate whereas 10% of inactive 
LN patients but no active LN patients were administered with IVIG. As the majority of 
JSLE patients received a combination of medications at the time that the serum samples 
were taken, it is possible that a variety of pro-inflammatory responses had already been 
efficiently suppressed.  
Similar to the pro-inflammatory genes tested, only a small number of the ECM-
related genes tested were modified by the JSLE serum treatments when compared to the 
HC treatments. LAMB2 expression by the ciGEnCs was significantly upregulated by the 
JSLE serum treatments and especially by the inactive LN serum treatments indicating 
that even during disease remission, pro-fibrotic changes might still be occurring. 
LAMB2 is one of the main components of the renal GBM, along with collagen type IV, 
heparan sulphate and nidogen410,411. Increased LAMB2 expression could suggest 
potential alterations in the physiological proportions of the GBM components.  
Furthermore, a trend was also observed for elevated ciGEnC FN mRNA levels after 
JSLE serum treatments compared to HC serum treatments. FN is the first ECM protein 
to be aberrantly accumulated and deposited in renal fibrosis412 and physiologically it is 
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one of the main components of the MCs’ ECM410,413 but not of the main GBM 
components. Therefore, the elevated expression of FN mRNA by the ciGEnCs combined 
with the increased LAMB2 expression implies a potential for the serum of JSLE patients 
to promote the initiation of pro-fibrotic events locally in the kidney via inducing 
excessive ECM protein deposition by the human GEnCs; failure of resolution of these 
events, could eventually lead to glomerulosclerosis. It had to be noted that a study using 
human GEnCs and HUVECs, indicated the capacity of FN to act as a “bridge” that 
facilitated the internalisation of IgG3 monoclonal antibodies (obtained by lupus-prone 
MRL/gld mice) by the human endothelial cells414. Therefore, the increased presence of 
FN within the renal microenvironment could promote LN-mediated glomerular injury 
via more than one possible way.  
Finally, the levels of ciGEnC COL1A1 mRNA expression were found to be 
significantly decreased by JSLE serum treatments compared to those of HCs. Decreased 
type I collagen production within the kidney during renal disease, could potentially lead 
to an increase in other type I collagen chains or other collagen types, such as collagen 
type III and IV. Therefore, although at 24 hours COL3A1 and COL4A1 mRNA levels 
were not significantly modified, more chronic exposure of ciGEnC to JSLE sera could 
increase their expression compared to HCs. Similarly, although MMP mRNA levels 
were not significantly modulated at the 24-hour time-point, more chronic exposure could 
spur increased MMP levels leading to remodeling of the basement membrane and 
glomerulosclerotic changes. 
A limitation of this model was the low serum concentration used to induce 
responses. The 5% treatments were used to mimic the concentration of sera used in 
standard endothelial media. However, due to the limited sample volumes collected from 
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paediatric patients increased serum concentrations were unable to be assessed. Blood 
plasma, which consists of serum together with the fibrinogens, accounts for 55% of total 
human blood1. Therefore physiologically, inside the human body, the human serum is 
present in much higher amounts than the 5% human sera used for the in vitro treatment 
of ciGEnCs. This suggests that the concentration of pro-inflammatory factors in the 
serum samples used in vitro might have been too low to induce potent ciGEnC 
activation. Future work could test increased sera concentrations to determine if a greater 
effect could be demonstrated. 
In a study using HUVECs as well as a terminally differentiated endothelial cell line 
(EA.hy926), uraemic serum samples from patients with CKD and normal (human 
autologous) serum samples were used to treat the endothelial cells for 24 hours415. The 
normal serum treatment was performed at a concentration of 2.5% whereas a 
concentration response was performed for the uraemic serum treatments, including 1%, 
2.5%, 5% and 10%415. Apart from the 1% concentration that had no effect on the target 
protein tested in this study (Phospho-GSK-3β), the rest of the uraemic serum treatments 
(2.5%, 5% and 10%) had a positive concentration response effect on the target protein, 
whose production levels increased along with increasing serum concentrations415. In a 
similar in vitro study from the same group, 10% uraemic serum from CKD or 10% 
normal serum was used to treat HUVECs for 0, 6 and 12 hours, with the 6-hour time-
point leading to statistically significant decrease of the target protein expression 
(stromal-cell derived factor-1, SDF-1) by the HUVECs416.  
Thus, 10% and 15% dose response as well as time response (especially including 
more chronic time-points) ciGEnC treatments, could be necessary to thoroughly 
investigate the in vitro effect of active and inactive LN serum on ciGEnCs. It would 
however be imprudent to come to definite conclusions, as in the above studies HUVECs 
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and not human GEnCs have been utilised and furthermore serum from human patients 
with other diseases than LN have been used for treatments. 
With the JSLE serum treatments, the potential effect of pro-inflammatory and pro-
fibrotic mediators including mediators secreted by immune cells was tested. However, 
investigation took place more specifically of the effect of human neutrophils and 
macrophages as these two innate immune cell types are among the first to reach the sites 
of inflammation from a very early stage, that of acute phase inflammation. Experimental 
GN murine models have clearly demonstrated that upon acute renal inflammation, 
neutrophil and monocyte/macrophage glomerular accumulation occurs417–420. 
Furthermore, with the use of mouse models, the importance of neutrophil-
monocyte/macrophage interactions in the development of GN has been 
highlighted418,421. 
In humans, the use of healthy control renal biopsies has revealed the presence 
predominantly of monocytes/macrophages and secondarily of T cells within the healthy 
glomeruli422,423. Renal biopsies from patients with GN, have revealed that in crescentic 
and post-infectious GN the presence of monocytes and granulocytes was significantly 
increased within the glomeruli422. Furthermore, in a study where renal biopsies of SLE 
patients with GN (diffuse proliferative -active or sclerosing-, focal proliferative, 
mesangial, membranous and membranoproliferative GN) were studied, the presence of 
intra-capillary monocytes was significantly increased in diffuse proliferative GN423. In 
the same study, a strong correlation was found between infiltrating monocytes and the 
presence of subendothelial immune deposits, a finding that highlights the importance of 
the interactions between GEnCs and monocytes/macrophages423. 
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In renal biopsies of patients with anti-neutrophil cytokine Ab (ANCA)-associated 
GN and myeloperoxidase (MPO)-ANCA-associated vasculitis (MPO-AAV), the levels 
of MPO deposition were examined424. Again, increased presence of leukocytes within 
the glomeruli were observed, with monocytes/macrophages being the predominant 
leukocyte population followed by neutrophils and T cells424. As MPO is a lysosomal 
enzyme predominantly expressed by neutrophils and also an important component of 
NETs, the majority of MPO was found to be located within the glomerular-infiltrating 
neutrophils and monocytes/macrophages424. However, considerable amounts of 
extracellular MPO was also detected in the glomeruli in areas of NETs existence and the 
glomerular endothelium was found to be MPO-positive, suggesting that potential MPO 
transfer from neutrophils and monocytes/macrophages or MPO internalisation by the 
GEnCs could contribute to glomerular renal injury424. It has therefore been made clear, 
by both experimental GN models and studies focused on human renal biopsies, that both 
neutrophils and macrophages are playing a crucial role in glomerular renal injury.  
The role of neutrophils in LN, is further corroborated by data derived from a study 
using healthy control, rheumatoid arthritis (RA) and SLE sera to treat human neutrophils 
activated to produce NETs425. In this study, a subset of the SLE sera, derived from 
patients who had either developed LN or were prone to developing LN, strongly 
inhibited NET degradation due to either increased presence of DNAse inhibitor or 
increased presence of NET-binding antigens425. Apart from the prolonged exposure of 
NETs to the immune system due to defective clearance, human neutrophil-released 
enzymes, namely active human elastase and cathepsin G, have been shown to induce 
glomerular injury when in vivo infused in rats426. Finally it has to be noted that the 
importance of neutrophils in human LN is also pinpointed  by the fact that plasma and 
urine NGAL levels, are used as a biomarker for global renal disease activity in JSLE 
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patients427. Of course, NGAL can also be produced by other immune cells and therefore 
this marker does not purely indicate neutrophil infiltration. 
As the neutrophils act faster than the macrophages and they are the first immune 
cell type to accumulate to the inflamed tissues within a few minutes or a few hours428, 
the whole blood isolated human neutrophils were stimulated for just one hour with TNF-
α, IFN-γ and LPS. TNF-α, IFN-γ but also bacterial products are known to be important 
neutrophil priming agents (along with other cytokines or chemokines), leading to 
neutrophil activation429,430. Upon activation, human neutrophils are able to produce a 
variety of pro-inflammatory proteins, such as TNF-α, IL-1β, IL-6, IL-8, MCP-1, GM-
CSF, IFN-α and IFN-γ431. These pro-inflammatory proteins could then recruit more 
immune cells -for example neutrophils or macrophages- to the sites of inflammation, or 
potentially influence cells found locally in the inflamed tissues, such as the human 
endothelium. In this study, the neutrophil conditioned media did not significantly 
increase any of the genes tested. 
Classically activated M1-like macrophages432 are accumulated within the kidneys 
early at the initiation of acute renal inflammation (up to 48 hours) in animal models of 
GN420,433–435 and contribute to renal injury by producing pro-inflammatory cytokines 
such as TNF-α, IL-1β and IL-6436. On the contrary, in more chronic stages of renal 
inflammation (later than the first 48 hours) the M1-like macrophages are replaced by 
M2-like macrophages that promote healing and contribute to renal fibrosis in cases 
where resolution of inflammation is not achieved435. IFN-γ and LPS are known to 
promote differentiation towards the M1 macrophage phenotype437 and for this reason, 
both primary human macrophages and THP-1 macrophages were stimulated for 48 hours 
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with IFN-γ or LPS, as the 48-hour M1 polarisation time-point has been broadly used by 
other researchers. 
In a study using human blood isolated macrophages, the macrophages were 
polarised into M1-like after a 48-hour of combined treatment of 20 ng/ml of IFN-γ and 
100 ng/ml of LPS438 whereas in another study using human macrophages, the latter were 
polarised into M1-like via a 48-hour incubation with 10 ng/ml of IFN-γ and 1 μg/ml of 
LPS439. Similarly, in a study using THP-1 cells, the cells were polarised after a 48-hour 
incubation with 20 ng/ml of IFN-γ and 100 ng/ml of LPS440. Although different 
concentrations of IFN-γ and LPS have been mentioned throughout the literature to be 
used for the primary and THP-1 macrophage M1 polarisation treatments, in the current 
study I carried out the polarisation treatments using 10 ng/ml IFN-γ and 1 μg/ml LPS 
concentrations that were previously used in Chapter 3 to activate the ciGEnCs. 
Furthermore, I did not use IFN-γ and LPS in combination but each one alone as both 
IFN-γ alone and LPS alone have been shown to be able to induce M1 macrophage 
polarisation441–443. Therefore, future studies could potentially focus on the combined 
effect or IFN-γ and LPS in human primary macrophage and THP-1 macrophage pro-
inflammatory activation prior to usage of conditioned media to stimulate ciGEnCs. 
With the aid of the primary human macrophage media model that facilitated the 
initial exploration of potential effects of macrophage conditioned media on ciGEnCs, 
the human THP-1 macrophage/ciGEnC in vitro model was developed. Conditioned 
media from untreated, IFN-γ- and LPS-treated THP-1 macrophages with or without the 
presence of anti-TNF-α Ab/IL-1Ra, were collected and were used to stimulate the 
ciGEnCs for 24 hours. The rationale behind this approach was to validate the effect of 
human macrophage-secreted TNF-α and IL-1β on the human GEnCs, as such an event 
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could possibly occur upon renal inflammation. The infiltrating macrophages could be 
activated via the local pro-inflammatory microenvironment to produce pro-
inflammatory cytokines that could subsequently lead to GEnC activation. 
With TNF-α and IL-1β being responsible for the upregulated production by the 
ciGEnCs of most pro-inflammatory proteins tested in Chapter 3, the in vitro THP-1 
media/ciGEnCs model focused on investigating how the secretion of these two 
prototypical pro-inflammatory cytokines by the THP-1 cells would affect the ciGEnCs. 
After verifying that the THP-1 cells could secrete low, basal levels of TNF-α and IL-1β 
that were slightly elevated after IFN-γ stimulation and more robustly increased after LPS 
THP-1 stimulation, anti-TNF-α Ab and IL-1Ra were added onto the conditioned media 
to examine whether they would effectively block TNF-α and IL-1β action. 
To ensure that the use of anti-human TNF-α Ab and human recombinant IL-1Ra 
would specifically target TNF-α and IL-1β respectively, ciGEnCs were initially 
stimulated for 30 minutes or 24 hours with either TNF-α, with or without anti-TNF-α 
Ab, or IL-1β, with or without IL-1Ra (see Materials and Methods of this Chapter, 
4.4.8). The real-time PCR and ELISA assays performed, indicate that anti-TNF-α 
neutralising Ab and human recombinant IL-1Ra treatment abrogated the effect of TNF-
α and IL-1β respectively, and markedly decreased the mRNA expression and protein 
secretion of pro-inflammatory genes and proteins previously shown to be upregulated 
by the two cytokines. In addition, TNF-α- and IL-1β-mediated NF-κΒ nuclear 
translocation was also inhibited after anti-TNF-α and IL-1Ra addition respectively, 
providing evidence that anti-TNF-α and anti-IL-1β treatments could efficiently inhibit 
the formation of a pro-inflammatory environment within the kidneys in LN. 
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The THP-1 conditioned media, were able to induce changes in the mRNA 
expression of pro-inflammatory genes that were generally more robust than those 
induced by the human neutrophil conditioned media and often represented not only 
remarkable fold-changes but statistically significant changes, too. This could be 
explained by the fact that neutrophil infiltration and action within the inflammatory sites 
precedes that of macrophages and usually is not as long lasting as that of the 
macrophages. Therefore, the neutrophils could pave the way via initiating GEnC 
activation and secreting factors that could attract infiltrating macrophages within the 
kidneys. As in this study the potential secretion of different pro-inflammatory or 
chemotactic factors by cytokine- and LPS-stimulated neutrophils has not been tested, 
future studies could further delve into neutrophil-produced pro-inflammatory mediators. 
The expression of pro-inflammatory genes (VCAM-1, TNFR2) and the secretion of 
important pro-inflammatory proteins was found to be statistically significantly 
upregulated following THP-1 media activation; IL-6, IL-8, IP-10, MCP-1, sVCAM-1, 
M-CSF, GM-CSF. For some of the proteins (IP-10, M-CSF, and GM-CSF) upregulated 
by the THP-1 media, the addition of anti-TNF-α/IL-1Ra onto the media did not 
sufficiently reduce their expression or secretion.  
This was also observed in a smaller extent with some of the pro-inflammatory genes 
tested and could be explained by the fact that other pro-inflammatory mediators present 
within the THP-1 media could predominantly affect the expression/production of certain 
target genes/proteins. Furthermore, IFN-γ or LPS used to stimulate the THP-1 cells, 
could have a direct and robust effect on the genes or proteins tested. Indeed, as shown in 
Chapter 3, LPS can increase M-CSF, GM-CSF and IP-10 secretion and IFN-γ can induce 
high IP-10 secretion levels. It has to be noted that, although IFN-γ did not alter the basal 
THP-1 TNF-α secretion levels and only induced moderate to low IL-1β secretion, the 
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addition of anti-TNF-α Ab/IL-1Ra onto the IFN-γ THP-1 media led in most cases to 
remarkable suppression of pro-inflammatory gene or protein suppression. 
This could potentially be attributed to the fact that IFN-γ still present within the 
THP-1 media could induce TNF-α and IL-1β secretion by the ciGEnCs. ciGEnC - 
secreted TNF-α and IL-1β could act in an autocrine manner, further stimulating the 
ciGEnCs. As anti-TNF-α and IL-1Ra were added onto the THP-1 media in 
concentrations much higher (μg/ml) than those of THP-1 secreted TNF-α and IL-1β 
(pg/ml) to ensure efficient cytokine suppression, sufficient anti-TNF-α Ab/IL-1Ra 
quantities could be available to also block the ciGEnC-produced TNF-α and IL-1β. 
Furthermore, the effect of the basal TNF-α and IL-1-β THP-1 secreted levels on 
ciGEnCs should not be underestimated as the untreated THP-1 media were also found 
to increase the expression of a number of pro-inflammatory molecules by the human 
ciGEnCs. 
Using the THP-1 media/ciGEnC in vitro model, helped identify TNF-α and IL-1β 
macrophage secretion as an important event towards GEnC activation and demonstrate 
the effectiveness of anti-TNF-α Ab/IL-1Ra treatments in vitro, in terms of ciGEnC and 
macrophage targeting as a potential future therapeutic approach.  As this model was the 
one leading to the most robust ciGEnC activation, a simplified schematic representation 
is illustrated on Figure 4.43. Future studies should focus on elucidating how individual 
addition of anti-ΤΝF-α Ab and individual addition of IL-1Ra onto the THP-1 media 
could affect the production of pro-inflammatory genes and proteins. This way, the exact 





Figure 4.43 Potential effect of TNF-α and IL-1β secreting macrophages to GEnCs based on 
in vitro findings. 
Furthermore, in this experimental setup the concentration of THP-1-secreted TNF-
α and IL-1β was much lower (pg/ml) than that used for ciGEnC in vitro stimulation in 
Chapter 3 (10 ng/ml). Therefore, the full extent of the THP-1 activating effect on 
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ciGEnCs might have not been elucidated, due to experimental limitations. It is, however, 
very important to take into consideration that as also shown with the TNF-α and IL-1β 
concentration response qRT-PCR assays in Chapter 3, the ciGEnCs are satisfactorily 
responsive and can get activated even by low cytokine concentrations. Of course, more 
pro-inflammatory factors than just TNF-α and IL-1β present within the THP-1 media 
could affect the ciGEnCs and future work should also focus on identifying more 
macrophage-derived ciGEnC pro-inflammatory activators.  
It is also important to mention that as the media containing the highest TNF-α and 
IL-1β THP-1-secreted levels were the LPS THP-1 media, their ability to activate NF-κB 
was tested via IF. As a result, the ciGEnCs treated with LPS THP-1 media were found 
to promote NF-κB nuclear translocation more robustly compared to ciGEnCs treated 
with LPS alone or ciGEnCs treated with LPS THP-1 media with anti-TNF-α/IL-1Ra 
addition. Therefore, the in vitro data provide evidence for macrophage-secreted TNF-α- 
and IL-1β-induced GEnC pro-inflammatory activation, via NF-κΒ activation and 
nuclear translocation. 
The chimeric TNF-α blocking Ab infliximab, has been broadly used to treat human 
SLE and LN, although adverse effects have been reported444 and have been presented at 
this thesis’ Introduction. Therefore, in vitro findings in favour of anti-TNF-α treatments 
should always be treated with caution as an in vitro model cannot realistically imitate 
the complexity of the cellular and molecular structures within the human body. Anakinra 
(Kineret),  a recombinant IL1-Ra, is widely used as a first-line treatment in juvenile-
onset systemic idiopathic arthritis (JIA) with reportedly high efficacy and safety rates 
445,446.  However, Anakinra is not currently used in JSLE patient treatment and further 
validation using more complex in vitro and in vivo models and clinical evidence is 
necessary to decide whether IL-1Ra could be used for JSLE treatment.  
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The podocyte and MCs conditioned media had the least robust effect on in vitro 
ciGEnC activation and did not induce any statistically significant changes in pro-
inflammatory gene expression. It is possible that the main role of podocytes or MCs in 
renal inflammation is not that of the main pro-inflammatory contributors, or, that the 
production of pro-inflammatory factors by the podocytes and MCs is more limited 
compared to human GEnCs. In fact, research from our laboratory has shown that under 
pro-inflammatory stimuli human conditionally immortalised podocytes can secrete 
certain pro-inflammatory proteins447. 
As it has already been shown in this thesis, the human GEnCs are important intra-
renal pro-inflammatory players. Thus, among the renal glomerular cells in LN, the 
GEnCs could play a major role in pro-inflammatory protein production whereas the 
podocytes and MCs could dominate other routes of renal pathogenesis and destruction, 
such as; GFB destruction and proteinuria for the podocytes448 and fibrosis and renal 
scarring for the MCs449. Thus, future studies using pro-inflammatory cytokine-producing 
ciGEnC conditioned media for podocyte and MC activation, could generate very 
interesting results. Furthermore, it is important to note that although no paracrine 
podocyte and MC effect was observed on ciGEnCs, the cell-cell interactions among the 
three renal cell types should be investigated in the future as interesting findings could 
potentially arise. 
Taken together, the data generated in this chapter, indicate that the human GEnCs 
can be affected by their surrounding microenvironment. Under inflammatory conditions 
such as in LN, infiltrating immune cells and neighbouring renal cells could actively 
promote GEnC activation. The activated GEnCs, in turn, will produce higher levels of 
pro-inflammatory proteins that will recruit more immune cells within the glomeruli but 
in the same time will enhance podocyte and MC activation. A positive pro-inflammatory 
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feedback loop could therefore be created within the kidneys, with the human GEnCs 
acting as the “bridge” between the circulation and the renal tissue.  
4.6. Conclusions 
In conclusion, the human ciGEnCs did not exhibit a strong pro-inflammatory or pro-
fibrotic phenotype following treatments with JSLE patient sera, although IL-6, IL-1β, 
FN and LAMB2 mRNA expressions were increased. Similarly, ciGEnC treatments with 
human neutrophil, podocyte and MCs conditioned media did not induce a pro-
inflammatory response by the ciGEnCs. The THP-1 media, however, were able to 
promote a ciGEnC pro-inflammatory response, highlighting the importance of 




5. Chapter 5: Investigating the effect of urinary biomarkers on human ciGEnCs 
5.1. Introduction 
The human ciGEnCs are potent in vitro producers of only two (MCP-1 and sVCAM-
1) of the seven potential urinary biomarkers for active juvenile-onset LN investigated 
here, as identified previously in our laboratory326,327. The ciGEnCs also express in very 
low levels both TF and L-PGDS which, as shown in Chapters 3 and 4, were not affected 
or modified by either cytokine and LPS or serum treatments. Thus, the human GEnCs 
are not the main source of these urinary biomarkers within the kidney. It is most likely 
that their origin is either from other types of resident renal cells (although human 
podocytes have also been shown by our laboratory to not be the main source of the 
biomarkers) or from infiltrating and/or circulating immune cells447. Alternatively, the 
increase in the level of the biomarkers could be systemically induced and due to previous 
renal damage, the biomarkers could then be passively filtered through the glomerulus. 
A plausible scenario could be that kidney infiltrating immune cell populations such 
as macrophages, could be activated within the nephritic kidney and subsequently release 
these biomarkers. With the human GEnCs being on the front line of the glomerulus’ 
defence against blood circulating pro-inflammatory factors, the human GEnCs could 
eventually be affected by the presence of increasing numbers of urinary biomarkers in 
the glomerular lumen. Subsequently, biomarker-mediated alterations in the activation 
status of human GEnCs could contribute to GFB destruction, allowing for the passage 
of the biomarkers to the urinary space and, eventually, to their increased presence within 
the urine of LN patients. 
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Exploring the effect of the LN urinary biomarkers on human GEnCs could lead to 
findings explaining how intra-glomerular changes during LN renal flares contribute to 
the increased presence of these biomarker in the urine of JSLE patients. 
5.2. Aim 
To investigate the potential effect of the novel urinary biomarkers for LN on GEnC 
pro-inflammatory profile using an in vitro ciGEnC model. 
 Objectives 
Objective 1: To assess whether treatments with human recombinant urinary 
biomarkers could induce a pro-inflammatory phenotype on ciGEnCs. 
To address this objective, the ciGEnCs were in vitro stimulated with human recombinant 
biomarkers, individually or in combination, and the expression and/or production of pro-
inflammatory genes/proteins was tested. 
Objective 2: To determine whether the human recombinant urinary biomarker 
treatments can affect the ciGEnC viability. 
To address this objective, the ciGEnCs were in vitro stimulated with the human 
recombinant biomarkers in combination, and their apoptosis/necrosis levels were tested. 
 Chapter Hypothesis 
The urinary biomarkers for LN lead to pro-inflammatory activation of human 
GEnCs, promoting a sustained inflammatory renal microenvironment. 
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5.3. Materials and Methods 
 ciGEnC preparation and treatment with urinary biomarkers 
Fully differentiated ciGEnCs were seeded in 12-well plates for all treatments. 
Subsequently, they were incubated at 37oC (with 5% CO2) for 24 hours with human 
recombinant urinary biomarkers (AGP, CP, TF, L-PGDS, NGAL and MCP-1), alone or 
in combination. A minimum of three consecutive passages of ciGEnCs was used for all 
experiments. 
5.3.1.1.Human recombinant biomarker treatments 
The ciGEnCs were treated for 24 hours with six of the seven human recombinant 
urinary biomarkers for active LN; AGP, CP, TF, L-PGDS, MCP-1 and NGAL. VCAM-
1 was not used to treat the ciGEnCs, as the human ciGEnCs were found to be potent in 
vitro producers of both sVCAM-1 and surface VCAM-1 and a literature search did not 
reveal research findings for a potential effect of VCAM-1 on human endothelial cells. 
Therefore, the human GEnCs could rather affect their surrounding environment via 
producing VCAM-1 and not the opposite. Although MCP-1 is also potently secreted by 
stimulated human ciGEnCs in vitro, it was still used to treat the ciGEnCs, as MCP-1 has 
been shown to induce HUVEC apoptosis in vitro 450. The concentrations used for 
biomarker treatments reflected those found present in the urine of patients with active 
LN (high) and those found present in the urine of patients with inactive LN (low)327,451 




Table 5.1 Concentrations of urinary biomarkers used in in vitro experiments. 
 qRT-PCR analysis to test changes in pro-inflammatory gene expression in 
biomarker-treated ciGEnCs 
RNA from the biomarker-treated ciGEnCs was extracted and transcribed to cDNA 
as previously described in the Materials and Methods (section 2.3). This cDNA was 
used for qRT-PCR analysis to investigate changes in mRNA expression levels for genes 
listed in Table 5.2. 
 
Table 5.2 Primers used for detection of urinary biomarker expression by human 
macrophages; ACTB, TBP and TUBB were used as HK genes. 
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 ELISA assays to test changes in pro-inflammatory protein secretion in 
biomarker-treated ciGEnCs 
The secretion of MCP-1, sVCAM-1, IL-6, IL-8, IL-10, M-CSF, GM-CSF, MIP-1α, 
IP-10, TNF-α and IFN-γ was tested with single ELISAs or a Luminex multiplex ELISA 
assay, utilising conditioned media from ciGEnCs treated for 24 hours with the six human 
recombinant biomarkers at high and low concentrations. 
 Primary human macrophage culture and potential biomarker mRNA expression 
PBMCs were isolated from whole-blood samples of healthy volunteers as 
previously described in the Materials & Methods and were re-suspended in RPMI 
(+10% FBS). They were then seeded into 12-well plates at 37°C for 2 hours. Following 
this, the non-adherent lymphocytes were removed, and the adherent monocytes were 
treated with RPMI (+10% FBS, 1% penicillin-streptomycin and 50ng/mL M-CSF) to 
aid their differentiation into macrophages. These were then incubated at 37°C for 7 days. 
Macrophage differentiation was confirmed using light microscopy, as presented in 
Figure 4.1 of Chapter 4. 
Macrophages (MΦ) were then treated for 48h with 10ng/mL IFN-γ or 1μg/mL LPS 
at 37°C. Following this, the conditioned media were removed, and RNA was extracted 
and transcribed to cDNA as previously described in section 2.3. This cDNA was used 
for qRT-PCR analysis to investigate MΦ-derived urinary biomarker mRNA expression. 




Table 5.3 Primers used for detection of urinary biomarker expression by human 
macrophages; TUBB was used as a house keeping gene. 
 
 ciGEnC viability following biomarker treatments 
The ciGEnCs were treated for 24 hours with all human recombinant biomarkers, 
combined at either high or low concentrations. Subsequently, the ciGEnCs were 
trypsinised, centrifuged at 300 xg for 5 minutes and the cell pellets were resuspended in 
HBSS and initially stained with Annexin V – FITC (15 minutes on ice) and then with PI 
(5 minutes, room temperature, dark) to perform a flow cytometric apoptosis assay. 
 Statistical analyses 
Changes among three (or more) groups were studied using Kruskal-Wallis test with 
Dunn’s post-hoc test. In all cases a P value ≤ 0.05 was considered significant to reject 




 Human macrophages can express increased levels of mRNA of urinary 
biomarkers after IFN-γ or LPS stimulation 
To identify a potent cellular source of the LN urinary biomarkers, PBMC-isolated 
primary human macrophages (MΦ) were treated for 48 hours with either IFN-γ or LPS 
(untreated macrophages were always included). Subsequently, changes in the mRNA 
expression of AGP, CP, TF, VCAM-1, MCP-1 and NGAL were tested. 
The primary human macrophages were found not to express mRNA for NGAL. 
However, they did express mRNA for the other human urinary biomarkers tested. More 
specifically, the LPS treatments significantly increased AGP MΦ mRNA (0.001 [0-
0.01], p=0.01) compared to untreated MΦ (0 [0 - 4x10-6]) (Figure 5.1-A). CP mRNA 
expression was also statistically increased by LPS treatments (0.007 [0.0008-0.02], 
p=0.005) compared to untreated MΦ (0.0001 [0-0.0003]) (Figure 5.1-B). The human 
macrophages were also able to express TF and L-PGDS but the IFN-γ and LPS 
treatments did not statistically significantly alter the basal expression levels of TF and 
L-PGDS. (Figure 5.1-C & D). Finally, the IFN-γ-treated MΦ expressed statistically 
significantly higher levels of VCAM-1 (0.3 [0.007-0.1], p=0.008) (Figure 5.1-E) and 
MCP-1 mRNA (1.3 [0.7-2.3], p=0.03]) (Figure 5.1-F) compared to the untreated MΦ 
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Figure 5.1 qRT-PCR for MCP-1, VCAM-1, L-PGDS and TF mRNA after 48-hour treatments 
with cytokines and LPS.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in L-
PGDS mRNA levels. D. Changes in TF mRNA levels N=5-6/group. Data presented as median 
ΔΔCt, are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *p≤0.05, **p≤0.01 vs 
untreated. HK: TBP, TUBB.  
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 Individual biomarker treatments did not induce any changes in the mRNA 
expression of pro-inflammatory genes 
Before assessing the effect of combined biomarker treatment on the expression of 
pro-inflammatory genes by the ciGEnCs, the effect of each biomarker alone (AGP, CP, 
L-PGDS, TF, MCP-1, NGAL) after 24-hour incubations was also tested. No substantial 
changes, however, were found in the mRNA expression of the pro-inflammatory genes 
tested (N.B. the same genes tested on Chapter 3 following TNF-α, IL-1β, IL-13 and IFN-
γ ciGEnC stimulation and concentration response treatments) after either high or low 
biomarker concentrations were used. 
5.4.2.1.The effect of AGP on the pro-inflammatory gene expression  
The baseline mRNA levels of pro-inflammatory cytokines and chemokines 
expressed by the untreated ciGEnCs were not altered either by AGP high (20,600ng/mL) 
or AGP low (300ng/mL) 24-hour treatments. More specifically, no statistically 
significant changes were observed when the effects of AGP high and low concentration 
treatments on IL-6 (Figure 5.2-A), IL-8 (Figure 5.2-B), MIP-1α (Figure 5.2-C) and IP-
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Figure 5.2 qRT-PCR for pro-inflammatory cytokine and chemokine expression after 24-hour 
treatments with AGP high and low concentrations.  
A. Changes in IL-6 mRNA levels. B. Changes in IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes in IP-10 mRNA levels N=4/group. Data presented as median ΔΔCt, are 
analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS vs untreated. HK: ACTB, 
TBP, TUBB. 
 
The baseline mRNA levels of urinary biomarkers and blood cell growth factors 
expressed by the untreated ciGEnCs were not altered either by AGP high or AGP low 
24-hour treatments. More specifically, no statistically significant changes were observed 
when the effects of AGP high and low concentration treatments on MCP-1 (Figure 5.3-
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A), VCAM-1 (Figure 5.3-B), M-CSF (Figure 5.3-C) and GM-CSF (Figure 5.3-D) were 
compared to the basal expression levels in untreated ciGEnCs. 
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Figure 5.3 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with AGP high and low concentrations.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=4/group. Data presented as median 






5.4.2.2.The effect of CP on the pro-inflammatory gene expression.  
The basal levels of pro-inflammatory cytokine and chemokine mRNA expression were 
not altered either by CP high (4,700 ng/ml) or CP low (700 ng/ml) 24-hour treatments. 
More specifically, no statistically significant changes were observed for IL-6 (Figure 
5.4-A), IL-8 (Figure 5.4-B), MIP-1α (Figure 5.4-C) and IP-10 mRNA levels (Figure 
5.4-D) after CP treatments when compared to the expression levels in untreated 
ciGEnCs. 
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Figure 5.4 qRT-PCR for cytokine and chemokine expression after 24-hour treatments with 
CP high and low concentrations.  
A. Changes in IL-6 mRNA levels. B. Changes IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes IP-10 mRNA levels. N=5/group. Data presented as median ΔΔCt are 





The basal levels of pro-inflammatory urinary biomarker and blood cell growth 
factor mRNA expression were not altered either by CP high or CP low 24-hour 
treatments. More specifically, no statistically significant changes were observed for 
MCP-1 (Figure 5.5-A) or VCAM-1 (Figure 5.5-B) after CP treatments when those were 
compared to the untreated ciGEnCs. Similarly, the CP high and low concentrations were 
not able to modulate the basal mRNA expression levels of M-CSF (Figure 5.5-C) and 
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Figure 5.5 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with CP high and low concentrations.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=4/group. Data presented as median 
ΔΔCt, are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS. HK: ACTB, TBP, 
TUBB. 
5.4.2.3.The effect of TF on the pro-inflammatory gene expression  
The basal mRNA expression levels of cytokines and chemokines (expressed by the 
untreated ciGEnCs) were not modified either by TF high (4,900 ng/ml) or TF low (1,200 
ng/ml) 24-hour treatments. More specifically, no statistically significant changes in 
mRNA expression were observed when the effects of TF high and low concentration 
treatments on IL-6 (Figure 5.6-A), IL-8 (Figure 5.6-B), MIP-1α (Figure 5.6-C) and IP-
10 (Figure 5.6-D) were compared to the untreated ciGEnCs. 
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Figure 5.6 qRT-PCR for cytokine and chemokine expression after 24-hour treatments with 
TF high and low concentrations.  
A. Changes in IL-6 mRNA levels. B. Changes IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes IP-10 mRNA levels. N=5/group. Data presented as median ΔΔC, are 
analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS vs untreated. HK: ACTB, 
TBP, TUBB. 
 
The mRNA levels of urinary biomarkers expressed by the untreated ciGEnCs were 
not affected either by TF high or TF low 24-hour treatments. More specifically, no 
statistically significant changes were observed when the effects of TF high and TF low 
concentration treatments on MCP-1 (Figure 5.7-A) and VCAM-1 (Figure 5.7-B) were 
compared to the untreated ciGEnCs. Similarly, the TF high and low concentrations did 
not significantly change the expression of the blood cell growth factors, M-CSF (Figure 
5.7-C) and GM-CSF (Figure 5.7-D).   
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Figure 5.7 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with TF high and low concentrations.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=4/group. Data presented as median 






5.4.2.4.The effect of L-PGDS on the pro-inflammatory gene expression  
The basal levels of pro-inflammatory cytokine and chemokine mRNA expression 
were not altered either by L-PGDS high (1,200 ng/ml) or L-PGDS low (300 ng/ml) 24-
hour treatments. More specifically, no statistically significant changes were observed for 
IL-6 (Figure 5.8-A), IL-8 (Figure 5.8-B), MIP-1α (Figure 5.8-C) and IP-10 mRNA 
levels (Figure 5.8-D) after CP treatments when compared to the expression levels in 
untreated ciGEnCs. 
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Figure 5.8 qRT-PCR for cytokine and chemokine expression after 24-hour treatments with L-
PGDS high and low concentrations.  
A. Changes in IL-6 mRNA levels. B. Changes IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes IP-10 mRNA levels. N=5/group. Data presented as median ΔΔCt, are 




The basal levels of pro-inflammatory urinary biomarker and blood cell growth 
factor mRNA expression were not altered either by L-PGDS high or L-PGDS low 24-
hour treatments. More specifically, no statistically significant changes were observed for 
MCP-1 (Figure 5.9-A) or VCAM-1 (Figure 5.9-B) after L-PGDS treatments when those 
were compared to the untreated ciGEnCs. Similarly, the L-PGDS high and low 
concentrations were not able to modulate the basal mRNA expression levels of M-CSF 
(Figure 5.9-A) and GM-CSF (Figure 5.9-B) in ciGEnCs. 
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Figure 5.9 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with L-PGDS high and low concentrations.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=4/group. Data presented as median 




5.4.2.5.The effect of MCP-1 on the pro-inflammatory gene expression  
The basal mRNA expression levels of cytokines and chemokines (expressed by the 
untreated ciGEnCs) were not modified either by MCP-1 high (0.26 ng/ml) or MCP-1 
low (0.172 ng/ml) 24-hour treatments. More specifically, no statistically significant 
changes were observed when the effects of TF high and low concentration treatments on 
IL-6 (Figure 5.10-A), IL-8 (Figure 5.10-B), MIP-1α (Figure 5.10-C) and IP-10 (Figure 
5.10-D) were compared to the untreated ciGEnCs. 





































































































































0 .0 0 0
0 .0 0 2
0 .0 0 4
0 .0 0 6









































0 .0 0 0 0
0 .0 0 0 5
0 .0 0 1 0
0 .0 0 1 5
0 .0 0 2 0
A . B .
C . D .
 
Figure 5.10 qRT-PCR for cytokine and chemokine expression after 24-hour treatments with 
MCP-1 high and low concentrations.  
A. Changes in IL-6 mRNA levels. B. Changes IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes IP-10 mRNA levels. N=5/group. Data presented as median ΔΔCt, are 





The mRNA levels of urinary biomarkers expressed by the untreated ciGEnCs were 
not affected either by MCP-1 high or MCP-1 low 24-hour treatments. More specifically, 
no statistically significant changes were observed when the effects of MCP-1 high and 
low concentration treatments on MCP-1 (Figure 5.11-A) and VCAM-1 (Figure 5.11-B) 
were compared to the untreated ciGEnCs.  
The mRNA expression levels of M-CSF were statistically significantly increased 
after MCP-1 high treatments (0.001 [0.001-0.002], p=0.02) compared to MCP-1 low 
treatments (0.0009 [0.0009-0.001]). Although they were not statistically significantly 
higher of those of untreated ciGEnCs (0.001 [0.0007-0.001]), the M-CSF levels of the 
latter were, in general, lower than those induced by the MCP-1 high concentrations 
(Figure 5.11-C). The MCP-1 high and low concentrations did not significantly change 
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Figure 5.11 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with L-PGDS high and low concentrations.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=4/group. Data presented as median 






5.4.2.6.The effect of NGAL on the pro-inflammatory gene expression  
The baseline mRNA levels of pro-inflammatory cytokines and chemokines 
expressed by the untreated ciGEnCs were not altered either by NGAL high (34 ng/ml) 
or NGAL low (22.2 ng/ml) 24-hour treatments. More specifically, no statistically 
significant changes were observed when the effects of AGP high and low concentration 
treatments on IL-6 (Figure 5.12-A), IL-8 (Figure 5.12-B), MIP-1α (Figure 5.12-C) and 
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Figure 5.12 qRT-PCR for cytokine and chemokine expression after 24-hour treatments with 
NGAL high and low concentrations.  
A. Changes in IL-6 mRNA levels. B. Changes IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes IP-10 mRNA levels. N=5/group. Data presented as median ΔΔCt, are 






The baseline mRNA levels of urinary biomarkers and blood cell growth factors 
expressed by the untreated ciGEnCs were not altered either by AGP high or AGP low 
24-hour treatments. More specifically, no statistically significant changes were observed 
when the effects of AGP high and low concentration treatments on MCP-1 (Figure 5.13-
A), VCAM-1 (Figure 5.13-B), M-CSF (Figure 5.13-C) and GM-CSF (Figure 5.13-D) 
were compared to the basal expression levels in untreated ciGEnCs. 
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Figure 5.13 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with NGAL high and low concentrations.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=4/group. Data presented as median 




 The combined biomarker treatment did not have a prominent effect on pro-
inflammatory gene mRNA expression 
Following assessing the effect of individual biomarker treatments, the effect of 
combined 24-hour biomarker treatments (AGP, CP, L-PGDS, TF, MCP-1, NGAL) at 
high and low concentrations was assessed, as in vivo the biomarkers could be 
simultaneously present within the glomerulus upon renal inflammation.  After the 24-
hour ciGEnC incubations, potential changes in the mRNA expression of cytokines, 
chemokines, urinary biomarkers, blood cell growth factors (same cytokines, 
chemokines, urinary biomarkers and blood cell growth factors that were tested on 
Chapters 3 and 4). In addition, with TNF-α and IL-1β having the most robust effect on 
in vitro ciGEnC activation among all the cytokines tested in Chapter 3, potential changes 
in their receptors, were investigated.  
5.4.3.1.The effect of combined biomarker treatments on ciGEnC cytokine and chemokine 
mRNA expression 
IL-6 mRNA expression was significantly increased after the biomarker low 
concentration treatments (0.4 [0.3-0.9], p=0.05) but not after the biomarker high 
concentration treatments (0.3 [0.3-0.7]) when compared to the untreated ciGEnCs (0.2 
[0.03-0.4]) (Figure 5.14-A). No statistically significant differences were observed for 
IL-8 (Figure 5.14-B), MIP-1α (Figure 5.14-C) and IP-10 (Figure 5.14-D) mRNA 
expression after combined biomarker treatments (high and low) when those were 
compared to the baseline expression levels of the untreated ciGEnCs. 
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Figure 5.14 qRT-PCR for cytokine and chemokine expression after 24-hour treatments with 
combination of biomarkers.  
A. Changes in IL-6 mRNA levels. B. Changes IL-8 mRNA levels. C. Changes in MIP-1α mRNA 
levels. D. Changes IP-10 mRNA levels. N=6/group. Data presented as median ΔΔCt, are 





5.4.3.2.The effect of combined biomarker treatments on ciGEnC blood cell growth factor 
mRNA expression 
The combined biomarker treatments did not have a prominent effect on urinary 
biomarker mRNA expression. More specifically, no statistically significant changes 
were observed when the combined biomarker high and low concentration treatments on 
MCP-1 (Figure 5.15-A) and VCAM-1 (Figure 5.15-B) mRNA were compared to the 
untreated ciGEnCs. Similarly, the combined biomarker high and low concentrations did 
not significantly change the expression of M-CSF (Figure 5.15-C) and GM-CSF 
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Figure 5.15 qRT-PCR for pro-inflammatory urinary biomarker and blood cell growth factor 
expression after 24-hour treatments with combination of biomarkers.  
A. Changes in MCP-1 mRNA levels. B. Changes in VCAM-1 mRNA levels. C. Changes in M-
CSF mRNA levels. D. Changes in GM-CSF mRNA levels. N=6/group. Data presented as median 
ΔΔCt, are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS. HK: ACTB, TBP, 
TUBB. 
 
5.4.3.3.The effect of combined biomarker treatments on ciGEnC cytokine receptor 
mRNA expression 
TNFR1 (Figure 5.16-A) and TNFR2 (Figure 5.16-B) mRNA expression was not 
modulated by high or low concentration combined biomarker treatments compared to 
untreated ciGEnCs. Similarly, IL-1RI mRNA expression was also unaffected (Figure 
5.16-C). IL-1RII mRNA expression, however, was statistically significantly increased 
293 
 
after high-concentration combined biomarker treatments (0.004 [0.003-0.01], p=0.05) 
compared to the untreated ciGEnCs (0.002 [0.0005-0.009]) (Figure 5.16-D). 
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Figure 5.16 qRT-PCR for TNF-α and IL-1 recpetor expression after 24-hour treatments with 
combination of biomarkers.  
A. Changes in TNFR1 mRNA levels. B. Changes in TNFR2 mRNA levels. C. Changes in IL-1RI 
mRNA levels. D. Changes in IL-1RII mRNA levels. N=6/group. Data presented as median ΔΔCt, 






 The combined biomarker treatment did not have a prominent effect in pro-
inflammatory protein secretion 
No remarkable changes on pro-inflammatory gene expression were observed after 
the 24-hour combined high or low concentration biomarker treatments. However, as 
gene expression alone could not necessarily reflect changes in the protein level, the 
potential effect of 24-hour combined biomarker treatments on pro-inflammatory protein 
secretion (cytokines, chemokines, urinary biomarkers, blood cell growth factors) was 
also tested via ELISA, using ciGEnC conditioned media.  
5.4.4.1.The effect of combined biomarker treatments on ciGEnC cytokine secretion 
Potential changes in TNF-α, IFN-γ, IL-6 and IL-10 secretion were tested. However, 
neither the high nor the low biomarker concentrations induced any changes in the 
secretion of TNF-α (Figure 5.17-A), IFN-γ (Figure 5.17-B), IL-6 (Figure 5.17-C) or 
IL-10 protein (Figure 5.17-D). 
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Figure 5.17 Cytokine secretion after 24-hour ciGEnC-stimulation combined biomarker 
treatments.  
A. TNF-α. B. IFN-γ. C. IL-6. D. IL-10. N=4-5/group. Data presented as median concentrations 
are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS.  
 
5.4.4.2.The effect of combined biomarker treatments on ciGEnC chemokine secretion 
Potential changes in IL-8, MIP-1α and IP-10 secretion were tested. However, 
neither the high nor the low biomarker concentrations induced any changes in the 
secretion of IL-8 (Figure 5.18-A), MIP-1α (Figure 5.18-B) or IP-10 (Figure 5.18-C). 
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Figure 5.18 Chemokine secretion after 24-hour ciGEnC-stimulation combined biomarker 
treatments.  
A. IL-8. B. MIP-1α. C. IP-10. N=4-5/group. Data presented as median concentrations are 
analysed using Kruskal-Wallis test with Dunn’s post-hoc test, p=NS.  
 
5.4.4.3.The effect of combined biomarker treatments on ciGEnC blood cell growth factor 
secretion 
Potential changes in sVCAM-1, M-CSF and GM-CSF secretion were also 
investigated. However, neither the high nor the low biomarker concentrations induced 
any changes in the secretion of sVCAM-1 (Figure 5.19-A), M-CSF (Figure 5.19-B) or 
GM-CSF (Figure 5.19-C). 
The low biomarker treatments led to a significantly lower secretion of sVCAM-1 
(72 pg/ml [27-154], p=0.03) compared to secretion in the untreated ciGEnCs (189 pg/ml 
[170-212]) (Figure 5.19-A). M-CSF (Figure 5.19-B) and GM-CSF (Figure 5.19-C) 
secretion, however, remained unaffected. 
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Figure 5.19 Urinary biomarker and blood cell growth factor secretion after 24-hour ciGEnC-
stimulation combined biomarker treatments.  
A. sVCAM-1. B. M-CSF. C. GM-CSF. N=4-5/group. Data presented as median concentrations 
are analysed using Kruskal-Wallis test with Dunn’s post-hoc test, *P≤0.05.  
 
 The combined biomarker treatment did not have a prominent effect in surface 
adhesion molecule expression 
Potential changes in the surface expression of the adhesion molecules VCAM-1 and 
ICAM-1 were investigated after incubations of ciGEnCs for 24-hour with a combination 
of biomarkers at high or low concentrations.  
However, neither the high nor the low biomarker concentration treatments induced 
VCAM-1 surface expression by the ciGEnCs nor modified the basal surface ICAM-1 




Figure 5.20 VCAM-1 and ICAM-1 surface expression following 24-hour stimulation with 
combined biomarker treatments.  
A. 24-hour VCAM-1 surface expression. B. 24-hour ICAM-1 surface expression. N=4-5/group. 
Data presented as (median [range]) are analysed using Kruskal-Wallis test with Dunn’s post-
hoc test, p=NS. 
 
 The combined biomarker treatment did not induce increased cellular death 
The apoptotic/necrotic levels of ciGEnCs after 24-hour of incubation with all 
biomarkers at either high or low concentrations were tested. 
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The majority of ciGEnCs remained viable (Anx V-/PI-) after 24-hour treatment with 
high-concentration or low-concentration biomarkers, similarly to the untreated ciGEnCs 
(Figure 5.21-A & B). No significant changes were observed in the levels of apoptotic 
(Anx V+/PI-) and late apoptotic/necrotic (Anx V+/PI+) ciGEnCs among the different 
treatments (Figure 5.21-A & B). 
 
Figure 5.21 ciGEnC viability after 24 hours of combined biomarker treatments.  
A. Flow cytometric plots of Annexin V-FITC/PI-stained untreated ciGEnCs and ciGEnCs treated 
for 24 hours with biomarker high and low concentrations. B. Diagrams of viable (Anx V-/PI-), 
early apoptotic (Anx V+/PI-) and late apoptotic/necrotic (Anx V+/PI+) ciGEnCs after 24 hours 














This chapter aimed at investigating the potential role of the human urinary 
biomarkers on the human GEnCs. Although experimentally validated in a UK and two 
international cohorts of children with JSLE in our laboratory using patient urine 
samples452, these biomarkers are not currently used in clinic as routine diagnostic tools. 
In the future, however, they could prove to be an essential tool for routine monitoring of 
young JSLE patients’ renal disease activity. The ciGEnCs were previously shown to 
substantially express and produce only two of the human urinary biomarkers for LN, 
MCP-1 and VCAM-1, especially under pro-inflammatory stimulation (Chapter 3). 
Thus, the human GEnCs are not the main source of urinary biomarker production. 
For this reason, primary human monocytes were isolated, cultured in vitro and 
differentiated into macrophages and then were stimulated for 48 hours with IFN-γ or 
LPS to promote an M1-like phenotype. The human macrophages were found to express 
mRNA for all urinary biomarkers, except for NGAL. mRNA expression for AGP, CP, 
MCP-1 and VCAM-1 was considerably increased either after IFN-γ or after LPS 
stimulation, whereas the macrophage-expressed TF and L-PGDS basal levels were not 
altered by IFN-γ and LPS. The intra-renal presence of macrophages could therefore be 
an important source of urinary biomarkers within the nephritic kidneys. Thus, upon a 
renal flare, the kidney-recruited macrophages could stimulate and/or secrete the 
biomarkers within the renal microenvironment affecting, potentially, the human GEnCs 
and other glomerular components. 
The next step of this study was to treat in vitro the human ciGEnCs with human 
recombinant biomarkers individually or in combination, at either high or low 
concentrations. The high and low levels of biomarkers used for the ciGEnCs treatments 
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represent the “concentrated” levels of the biomarkers, after GFB filtration, as found in 
the urine of patients with active and inactive LN. They did not necessarily represent the 
intra-renal biomarker levels. Thus, it could be argued that as the human GEnCs are the 
first component of the GFB to encounter blood circulating factors, the LN biomarkers 
would be present in much less concentrated levels within the blood circulation by the 
time of their GEnC interaction. Consequently, potential changes observed in ciGEnCs 
after biomarker high/low treatments, could be attributed to abnormally high 
concentrations used and not to in vitro imitation of a physiological effect. It needs to be 
noted, however, that both the high and low biomarker treatments ranged among low 
microgram and predominantly between nanogram and picogram concentrations and as 
these concentrations are low, no further biomarker dilutions (lower concentrations) were 
used to treat the ciGEnCs in vitro. The lack of an in vitro effect of combined low-
concentration biomarker treatments on ciGEnCs, however, does not imply the lack of an 
in vivo effect on the human GEnCs. 
Furthermore, neither the high nor the low urinary biomarker concentrations, either 
when used to treat the cells individually or when used all together in combination, had 
any remarkable effect on the ciGEnCs. In general, apart from inducing IL-6 mRNA 
expression, the combined low biomarker treatments were not found to have any effect 
on the gene expression, protein secretion or surface expression of pro-inflammatory 
proteins tested. In a similar manner, apart from inducing IL-1RII mRNA expression, the 
combined high biomarker treatments neither reinforced the expression and production 
of pro-inflammatory proteins by the ciGEnCs nor induced a proportionate increase in 
the protein levels in comparison to the low biomarker treatments. In addition, the low 




The lack of urinary biomarker effect on human ciGEnCs might be attributed to 
several reasons. First, the human GEnCs might lack expression of some of the biomarker 
receptors and thus they could be unresponsive to the potential effect of the biomarkers. 
This possibility was not tested in this thesis project. For, example human brain 
endothelial cells of patients that underwent brain scans with positron emission 
tomography453 but also in vitro cultured human brain endothelial cells 454 have been 
found to express TF receptors. In rats, the liver endothelium has been shown to be 
responsible for CP uptake and internalisation via surface receptors for CP; subsequently 
the liver endothelium modifies CP and mediates its release and uptake by the 
hepatocytes455.  
Megalin or low-density lipoprotein-related protein 2 (LPR2), the receptor of 
NGAL456, is expressed by the human proximal tubular epithelial cells in the kidney457 
and also by the human renal podocytes458, however the human endothelium does not 
seem to express megalin. HUVECs and human dermal microvascular endothelial cells 
(HMECs) have been shown to express CCR2, the receptor of MCP-1459 whereas AGP, 
also known as ORM1, has the ability to bind glycoproteins of the endothelial cell 
glycocalyx, regulating the permeability of the endothelium12. Finally, a comprehensive 
literature search did not reveal any studies reporting the potential effect of L-PGDS 
binding onto human endothelial cells, however it has to be noted that L-PGDS 
expression itself on the vascular endothelium has been shown to be induced by fluid 
shear stress460. It is therefore possible that lack of increased expression levels of L-PGDS 
mRNA by the ciGEnCs after either cytokine/LPS or serum incubations as shown 
Chapters 3 and 4 respectively, could be attributed to the fact that no appropriate stimuli 
were used to induce L-PGDS expression. 
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Future studies on ciGEnCs could therefore test the surface expression of urinary 
biomarker receptors, especially megalin, CCR2 and TF receptors, including both basal 
expression levels as displayed by untreated ciGEnCs but also potential alterations of 
receptor expression levels following pro-inflammatory stimulation. Furthermore, the 
dynamics of AGP-ciGEnC glycocalyx binding could also provide interesting findings in 
terms of AGP-mediated regulation of human GEnC function. 
It should also be highlighted that ciGEnCs were exposed to biomarkers for only one 
time period (24 hours) and thus a more acute (2-12 hours) or chronic (48-96 hours) effect 
on the ciGEnCs could have been missed. For this reason, future studies could introduce 
time-response assays for individual and combined biomarker high and low 
concentrations, this time also including VCAM-1 (although in contrast to MCP-1, no 
literature evidence was found for VCAM-1 effect in pro-inflammatory protein 
expression, viability or other functions of the human endothelium). In addition, higher 
in vitro concentrations of the biomarkers could have a more robust effect on ciGEnCs. 
For example, 12- and 24-hour incubations of HUVECs with 1μg/ml of  human 
recombinant NGAL have been shown to induce a statistically significantly higher 
increase in the secreted levels of IL-6, IL-8 and MCP-1 compared to untreated 
HUVECs461. 
Moreover, the human urinary biomarkers could affect the human renal glomerular 
endothelium in different ways than modifying pro-inflammatory protein expression and 
reducing their viability, such as inducing changes in the permeability of GEnCs and 
GFB-related filtering capacity or modifying the glycocalyx structure of GEnCs. Indeed, 
HMECs from dermal tissue have been shown to express AGP, in contrast to ciGEnCs, 
and AGP is necessary for the capillary charge-selectivity barrier462. AGP has also been 
shown to have an anti-inflammatory effect on HUVECs via reducing their response to 
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histamine-mediated upregulation of metabolic pathways leading to increased 
acidification rates463.  In addition, AGP has been shown to inhibit in vitro angiogenesis 
as it was able to block the formation of capillary-like tubes by human lung microvascular 
endothelial cells  as well as endothelial cell adhesion to ECM and migration in wound 
healing assays464. Similarly, MCP-1 has been shown to promote angiogenesis on human 
aortic endothelial cells via inducing VEGFA465. Furthermore, MCP-1 has been found to 
have a chemotactic effect on  HUVECs and human dermal microvascular endothelial 
cells (HMECs)459. 
In addition to the reasons of lack of biomarker effect listed above, it is important to 
also consider another possibility. The biomarkers could be acting on the human 
glomerular endothelium of the kidney only in conjunction with pro-inflammatory 
cytokines such as TNF-α and IL-1β leading to “priming” of the endothelium. 
Alternatively, they could be using the cytokines as an “anchor” to bind to the cytokine 
receptors and potentially get internalised within the GEnCs. Henceforth, it is important 
that future studies use cytokines known to have an effect on human ciGEnCs, such as 
TNF-α, IL-1β, IL-13 and IFN-γ as shown on Chapter 3, to treat the cells along with the 
human recombinant biomarkers, at high or low concentrations, to investigate potential 
joint effects of cytokines and biomarkers. 
Finally, another possible explanation could be that the human urinary biomarkers 
for LN have no direct or indirect effect on human GEnCs. Instead, upon LN renal 
inflammation, immune cells such as human macrophages could be activated to produce 
and release the biomarkers locally in the kidney as acute-phase proteins or “alarm 
signals”. Continuing inflammation and lack of resolution of inflammation, could 
eventually lead to chronic renal disease and GFB damage and thus, as a bystander effect 
of GEnC (as well as podocyte and GBM) destruction, passive release of the human 
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urinary biomarkers could occur. The levels of the biomarkers present within the patients’ 
urine, could then be reflective of the extent of kidney damage, but without having 
themselves a role on the destruction of the glomerular renal structures. 
5.6. Conclusion 
In conclusion, the human ciGEnCs are not induced to produce pro-inflammatory 
proteins in vitro following treatments with high and low concentrations of the novel 
urinary biomarkers for active LN. No apoptosis or necrosis are observed under the 




6. Chapter 6: General Discussion 
6.1. Aims of the thesis 
The overarching aim of this thesis was to study in-depth the role of human GEnCs 
in LN inflammation to test the hypothesis that human GEnCs are not just passive 
bystanders but are actively involved in the development and perpetuation of renal 
inflammation in LN. 
An initial in-depth literature review did not identify a robust volume of experimental 
work on the pro-inflammatory activity of human GEnCs, indeed it identified a striking 
paucity of relevant data. In contrast to other types of human endothelial cells, such as 
HUVECs and human brain endothelial cells345,466, the ability of the human GEnCs to 
express and produce pro-inflammatory proteins under different pro-inflammatory 
stimuli had not been extensively studied. Moreover, in both adult-onset disease, but 
particularly in JSLE, the pro-inflammatory action of human GEnCs in the context of the 
inflammatory environment of the LN disease model had not been previously studied 
thoroughly. 
For all the above reasons and considering the important position of human GEnCs 
at the blood-renal tissue interface as well as their role as part of the GFB1, the focus of 
this thesis was to develop a number of different in vitro models of LN using human 
ciGEnCs so as to study different aspects of GEnC involvement in renal disease. Taking 
into consideration the possible interactions between the human GEnCs and other renal 
cells, blood circulating factors and immune cells, the in vitro ciGEnC models were used 
to create, as far as was possible within the limitations of an in vitro environment, a 
holistic picture of the human GEnC involvement in renal inflammation. To achieve these 
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goals, the human ciGEnCs were cultured and were exposed to various potential pro-
inflammatory stimuli, as presented and described in each of the Chapters 3, 4 and 5. 
6.2. Summarising the findings from ciGEnC experiments and their importance in 
the context of lupus nephritis 
Initially, the ciGEnCs were incubated for 15 minutes, 30 minutes, 4 hours and 
24 hours with cytokines known to be involved in LN (IFN-α, IFN-γ, TNF-α, IL-1β, IL-
6, IL-13, VEGF) and with LPS; the production of pro-inflammatory proteins, the 
activation of pro-inflammatory transcription factors as well as their survival after 24-
hour exposure to cytokines/LPS were then tested. 
The human ciGEnCs remained viable after cytokine/LPS exposure. They 
underwent NF-κB and STAT-1 activation and produced a variety of pro-inflammatory 
proteins due to stimulation induced by four out of the seven cytokines tested (TNF-α, 
IL-1β, IL-13 and IFN-γ) and LPS. These included; cytokines, chemokines, blood cell 
growth factors, urinary biomarkers, adhesion and co-stimulatory molecules. 
Importantly, all proteins produced by the ciGEnCs after cytokine/LPS stimulation have 
been previously associated with lupus pathogenesis and/or renal disease. These are all 





It has been demonstrated that in a cohort of JSLE patients, 21% of whom had 
LN, IL-6 and IL-10 levels in the plasma of patients with active disease were significantly 
elevated compared to patients with inactive and compared to the plasma samples of 
HCs312. In ASLE, urinary IL-6 has been suggested to be an important marker of renal 
disease activity467 whereas IL-10 serum levels have been found to be increased in SLE 
patients compared to HCs468. Furthermore in patients with type 2 diabetic nephropathy 
(DN), serum IL-6 levels have been found to be significantly elevated compared to serum 
samples from diabetic patients without nephropathy469 whereas IL-10 polymorphisms 
have been strongly linked to type 2 DN susceptibility470,471. 
In ASLE patients with LN, significantly higher levels of urinary IL-8 have been 
observed compared to ASLE patients without LN and compared to HCs472. IL-8 serum 
levels have been shown to be significantly increased in patients with chronic renal failure 
compared to healthy individuals473. Urinary MCP-1 is one of the most widely-studied 
biomarkers for ASLE474 and JSLE234,326 renal disease activity. With regards to renal 
transplantation, patients who suffered acute rejection were found to have significantly 
elevated urinary levels of MCP-1 compared to those who were good responders to anti-
rejection therapies475. 
MIP-1α has been found to be involved in the development of cellular crescents 
in human crescentic GN215. Furthermore, MIP-1α was found to be significantly enriched 
in the urine of LN patients compared to ASLE patients without LN476. Serum MIP-1α 
has also been found to be elevated in septic patients compared to healthy individuals in 
the serum of which MIP-1α was mostly undetectable
477. In a study that included JSLE 
patients, 65.2% of which had LN- and HCs, the serum IP-10 levels were found to be 
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significantly elevated in JSLE patients with overall active disease but also in JSLE 
patients with active LN compared to those with inactive LN478. Furthermore, in a cohort 
of type I diabetic patients, urinary IP-10 levels were found to be significantly elevated 
in patients with microalbuminuria and early progressive deterioration of renal function 
compared to those with microalbuminuria and stable renal function as well as compared 
normoalbuminuric patients with stable renal function479.  
In a study with AAV patients, significantly higher levels of M-CSF have been 
detected in their plasma compared to HCs480; the more striking differences in M-CSF 
plasma levels were observed between AAV patients with LN and HCs480. Furthermore, 
conditionally immortalised human podocytes have been found to in vitro secrete 
increased M-CSF levels following pro-inflammatory stimulation447. GM-CSF local 
kidney production by MCs has been observed in GN patients and its levels have been 
associated to LN213. Neutrophils from hemodialysis and CKD patients incubated with 
GM-CSF in vitro, demonstrated improved survival and viability481. 
In JSLE, serum levels of a key pro-inflammatory cytokine, TNF-α, have been 
found to be significantly elevated in patients with active disease, in patients with LN and 
in patients with depression, compared to HCs164. In patients with DN, TNF-α serum and 
urinary levels have also been found to be significantly elevated compared to HCs482,483. 
In renal tissues of JSLE patients with LN significantly higher levels of positive IFN-γ 
staining have been observed compared to HCs354. In type II diabetic patients, 
significantly higher IFN-γ and TNF-α plasma levels have been observed in those with 
kidney disease compared to those without kidney disease484. 
Urinary VCAM-1 is an important biomarker for childhood LN and renal disease 
activity234,236,326. In patients of Asian origin with type II diabetes, plasma VCAM-1 has 
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been found to be associated with diabetic kidney disease485. In ASLE patients with LN 
significantly higher levels of serum ICAM-1 were detected compared to HCs486. 
Furthermore, ICAM-1 serum levels have been found to be significantly elevated in type 
II diabetic patients with microalbuminuria and are considered to be associated with 
diabetic kidney disease severity487.  
In ASLE patients, plasma ICOS-L was found to be significantly elevated in those 
with active disease compared to those with inactive disease or compared to patients with 
RA and furthermore, increased soluble ICOS-L levels inversely correlated with B cell 
ICOS-L surface expression levels317. In kidney biopsies from patients with DN and focal 
segmental GN significantly increased ICOS-L levels have been observed during early 
stages of the renal disease488; ICOS-L levels are then robustly decreased during later 
stages of the renal disease488.  
Monocyte PD-L1 surface expression in JSLE patients with active SLE have been 
found to be significantly reduced compared to HCs whereas patients in remission 
exhibited normal PD-L1 expression levels374. In a study using PBMCs from patients 
with proliferative and non-proliferative GN, the frequencies of PD-1/PD-L1-expressing 
CD4+ and CD8+ T cells have been found to be significantly increased compared to HCs, 
with the proliferative GN patients exhibiting even higher frequencies compared to the 
non-proliferative GN patients489. 
In this study, TNF-α and IL-1β have been identified as the most robust ciGEnC 
stimuli among the four cytokines found to have a profound effect on ciGEnC activation, 
leading to increased production of the majority of the pro-inflammatory proteins tested 
(MCP-1, VCAM-1, ICAM-1, IL-6, IL-8, Μ-CSF, GM-CSF, MIP-1α, ICOS-
L).Following the findings presented in Chapter 3 and focusing on the significantly 
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increased production of pro-inflammatory proteins after cytokine/LPS stimulation, the 
target of all experimental assays performed and presented in Chapter 4 was to explore 
potential changes in the mRNA expression levels (and in the case of THP-1 cells in the 
protein secretion levels) of these pro-inflammatory proteins, as well as those of the TNF-
α and IL-1β receptors).  
Knowing that several of the cytokines used to stimulate the ciGEnCs were also 
found to be elevated in the plasma/serum of patients with active LN, serum samples from 
JSLE patients with active and inactive LN and serum samples from paediatric HCs were 
used to stimulate the ciGEnCs for 4 and 24 hours. Additional to the pro-inflammatory 
proteins, potential changes in the mRNA expression of fibrosis-related genes were also 
tested following the serum treatments. The JSLE serum treatments had a moderate to 
low effect in the expression of pro-inflammatory genes such as IL-6 and IL-1β and of 
fibrosis-related genes such as FN and LAMB2 and COL1A1. 
Taking into account that JSLE patient sera may not be as effective on ciGEnC 
activation due to administration of immunosuppressive medications to the patients, the 
ciGEnCs were also treated with conditioned media of previously activated primary 
human neutrophils (TNF-α, IFN-γ, or LPS activation) and macrophages (IFN-γ or LPS 
activation). Additionally, a THP-1 macrophage cell line was used for experiments 
similar to those of primary human macrophages. The rationale behind these experiments 
was that upon renal inflammation, immune cells could infiltrate the glomerulus via the 
glomerular capillaries and once reaching there, they would secrete pro-inflammatory 
factors. Alternatively, immune cell-derived secreted factors could reach the glomerulus 
via the circulation, therefore they could be present in the patients’ plasma/serum. 
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The primary human neutrophils did not particularly affect the ciGEnCs as 
compared to the primary human macrophages, with the latter being considered anyway 
as more potent pro-inflammatory cytokine producers. With the THP-1 cell providing a 
cell line of macrophages much more stable in terms of proliferation and survival 
compared to the primary human macrophages, it was possible to specifically study how 
the potential secretion of TNF-α and IL-1β after THP-1 stimulation could affect the 
human ciGEnCs in vitro. Indeed, blockade of TNF-α (via anti-TNF-α Ab) and IL-1β (via 
IL-1Ra) prior to addition of THP-1 conditioned media to the human ciGEnCs, abrogated 
(completely or partially) the THP-1 media-induced increased expression of IL-6, IL-8, 
IP-10, VCAM-1, TNFR2 and IL-1RII mRNA and secretion of IL-6, IP-10, MCP-1, 
sVCAM-1 and GM-CSF.  
Finally, another important part regarding GEnC interaction with their 
microenvironment was covered via studying the effect of conditioned media from 
cytokine (TNF-α, IL-1β, IFN- α, IFN-γ)/LPS-stimulated conditionally immortalised 
human podocytes and mesangial cells. However, no statistically significant changes 
were observed in ciGEnC pro-inflammatory gene expression. 
The THP-1 macrophage/ciGEnC in vitro model was therefore the one providing 
the most robust and interesting data. 
             The mRNA expression and/or secretion of seven experimentally validated 
urinary biomarkers for LN (AGP, CP, TF, L-PGDS, MCP-1, VCAM-1, NGAL) was 
tested following cytokine/LPS treatments (Chapter 3) and JSLE/HC serum treatments 
(Chapter 4). The ciGEnCs, however, exhibited substantial basal expression/secretion of 
only MCP-1 and VCAM-1 and this was statistically significantly increased only 
following cytokine/LPS treatments but not serum treatments.  
313 
 
It was therefore obvious that the human GEnCs are probably not the main source of 
these potentially novel LN urinary biomarkers. These biomarkers, however, could have 
a profound effect on ciGEnCs in terms of pro-inflammatory activation. For this reason, 
the human ciGEnCs were treated for 24 hours with human recombinant biomarkers 
(apart from VCAM-1) alone or combined all together. The viability of the ciGEnCs and 
the expression and secretion of the pro-inflammatory genes/proteins previously tested 
on Chapters 3 and 4 was then studied. The urinary biomarkers, however, had no 
profound effect on ciGEnC viability or pro-inflammatory activation. 
6.3. Important ciGEnC stimuli identified in this model of LN  
The stimuli with the most profound effect on ciGEnC pro-inflammatory activation 
were the four cytokines (TNF-α, IL-1β, IL-13, IFN-γ), LPS, the THP-1 conditioned 




Figure 6.1 Important ciGEnC pro-inflammatory stimuli as identified in this study. 
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 The most prominent effect of the JSLE serum treatments was the upregulation of 
IL-6 mRNA expression which was mimicked by the ciGEnCs treatments with IL-1β and 
LPS; these led to statistically significantly increased secretion of IL-6. Furthermore, 
conditioned media from untreated THP-1 cells were able to significantly upregulate 
secretion of IL-6 compared to untreated ciGEnCs. When anti-TNF-α and IL-1Ra were 
added onto the THP-1 conditioned media, IL-6 levels were brought down to the levels 
of untreated ciGEnCs. This suggested that the presence of TNF-α and/or IL-1β within 
the JSLE sera could be playing a pivotal role in ciGEnC upregulation of IL-6 production. 
The untreated THP-1 media also significantly increased IP-10 secretion compared 
to untreated ciGEnCs but anti-TNF-α and IL-1Ra addition only partially decreased the 
levels of IP-10, corroborating the finding that IFN-γ and LPS treatments had a robust 
effect on ciGEnCs IP-10 secretion, with TNF-α and IL-1β probably playing a more 
trivial role in IP-10 induction. The IFN-γ THP-1 media induced high levels of secreted 
IL-8 compared to the IFN-γ-treated ciGEnCs but although TNF-α and IL-1β treatments 
of ciGEnCs seemed to promote high levels of IL-8 secretion by the ciGEnCs, anti-TNF-
α/IL-1Ra addition to the IFN-γ THP-1 media did not remarkably decrease IL-8 secretion. 
Therefore, other factors secreted by the IFN-γ-stimulated THP-1 cells could also 
promote IL-8 secretion (for example other members of the TNF superfamily or of the 
IL-1 superfamily). 
Similarly, the IFN-γ THP-1 media promoted the secretion of MCP-1 by the ciGEnCs 
when compared to the IFN-γ-treated ciGEnCs and anti-TNF-α/IL-1Ra addition to the 
media considerably decreased MCP-1 levels, a finding agreeing with the TNF-α- and 
IL-1β-mediated increase of ciGEnCs MCP-1 secreted levels. sVCAM-1 secretion 
induced by the IFN-γ THP-1 media was significantly suppressed by anti-TNF-α/IL-1Ra 
addition to the THP-1 media, a result that supporting the finding that (along with IL-13), 
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TNF-α can promote VCAM-1 expression (and to a smaller extent sVCAM-1 secretion) 
by the ciGEnCs. 
Finally, M-CSF secretion was significantly promoted by the untreated THP-1 media 
and GM-CSF secretion was upregulated by the untreated and IFN-γ THP-1 media. Anti-
TNF-α/IL-1Ra addition to the THP-1 media led to decreased levels of GM-CSF, 
confirming the TNF-α- and IL-1β-mediated effect on elevated GM-CSF secretion by the 
ciGEnCs. 
6.4. Clinical implications arising from these data 
In this study, TNF-α and IL-1β have been identified as the most robust ciGEnC 
stimuli among the four cytokines found to have an effect on ciGEnC activation, leading 
to increased production of the majority of the pro-inflammatory proteins tested.  
Anti-TNF-α antibody and IL-1Ra treatments had the desirable effect in vitro 
(inhibition of NF-κB nuclear translocation and decreased pro-inflammatory protein 
production), either when human recombinant TNF-α or IL-1β were added onto the 
ciGEnCs were directly inhibited or when more complex models were utilised to test their 
efficacy. Conditioned media from untreated, IFN-γ- and LPS-activated THP-1 
macrophages were generated and the presence of TNF-α and IL-1β within these media 
was tested via ELISA. When anti-TNF-α antibody and IL-1Ra were added in these 
media, their pro-inflammatory effect on ciGEnCs was attenuated, providing evidence 
that the use of TNF-α and IL-1β blocking agents could be an efficient patient treatment 
in the future. However, to render human GEnCs into an intra-renal target for kidney-
specific anti-TNF-α and IL-1Ra treatments, more future work is necessary including co-




There are very many subsequent steps to take between an in vitro model that 
includes only one cell type and the development of a human GEnC-based therapeutic 
approach, especially given the mixed outcomes to date of anti-TNF-α usage in lupus 
patient clinics444. Heterozygous mice [NZB × B6, 129 Tnf0)F1 ] exhibiting decreased 
levels of TNF-α production were shown to develop autoimmunity and kidney disease 
with important disease features being aberrant upregulation of anti-nuclear autoantibody 
levels in the mice sera and abnormal expansion of anti-dsDNA-producing B cells490; 
these findings indicated an important role for TNF-α in the suppression of autoreactivity 
and suggested that lack of adequate TNF-α production could contribute to lupus 
development. On the contrary, on C3H.SW mice on which experimental SLE was 
induced via anti-DNA human autoantibody injection, early anti-TNF-α monoclonal 
antibody and pentoxiphylline administration suppressed TNF-α and IL-1β production 
and prevented experimental SLE development491. It has been suggested, that, TNF-α 
dysregulation and decreased production in both murine and human lupus is dependent 
on certain MHC alleles that have been connected to lupus-associated development of 
autoimmunity492,493. To this end, it is important to note that epistatic relationships 
between the TNF-α gene and major histocompatibility complex (MHC) genes can be 
occurring as, in both humans and mice, the TNF-α gene is located and is encoded within 
the MHC gene locus494,495. 
In humans, mixed results regarding TNF-α levels have also been observed in SLE 
patients496,497. In several studies, bioactive TNF-α levels within the sera of active SLE 
patients have been found to be remarkably increased and have been associated with lupus 
disease activity498,499.On the other hand, another study has shown that serum TNF-α 
levels as well as the TNF-α/IL-10 ratio were upregulated in inactive SLE patients 
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compared to active SLE patients and healthy control, indicating a protective role of TNF-
α in SLE patients497. 
In a study where both healthy and SLE blood donors serologically typed and 
genotyped for certain human leukocyte antigen (HLA) alleles (HLA-DR2, HLA-DQwl, 
HLA-DR3, HLA-DR4) were used to evaluate TNF-α production by peripheral blood 
lymphocytes500, some very interesting results were generated. The HLA-DR2- and 
HLA-DQwl-positive healthy donors, often demonstrated low TNF-α levels in contrast 
to HLA-DR3- and HLA-DR4-positive healthy donors who exhibited high TNF-α 
production levels500. Similar to healthy subject, in HLA-DR2- and HLA-DQwl-positive 
SLE patients low TNF-α levels were observed and these alleles were linked to more 
frequent occurrence of LN500. In contrast to HLA-DR2- and HLA-DQwl-positive SLE 
patients and similar to the healthy individuals, the HLA-DR3-positive patients exhibited 
induction of high TNF-α levels and no LN predisposition, whereas the HLA-DR4-
positive patients demonstrated high TNF-α levels with the latter negatively correlating 
with LN development500. It is therefore suggested by these findings that LN 
predisposition could be linked to low TNF-α production and that SLE is not a disease 
with a homogeneous pattern of pathogenic features. On the contrary, it is suggested that 
patients could be divided into two different categories that would consequently 
determine the success of an anti-TNF-α treatment; those who are HLA-DR2/DQwl-
positive, produce low TNF-α levels and are genetically predisposed to LN and those who 
are HLA-DR3/DR4-positive, produce high TNF-α levels and have no genetic 
predisposition to LN development.  
It would therefore be interesting if future laboratory studies on ciGEnCs could also 
focus on further elucidating any potential relationships between production of TNF-α 
and of MHC molecules following pro-inflammatory stimulation. Furthermore, plasma 
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and serum studies of JSLE patients stratified into active LN and inactive LN patients 
with the latter being further subdivided into those with previous renal involvement and 
those with no signs of renal disease could focus onto exploring potential correlations of 
plasma/serum TNF-α levels with the presence of specific HLA alleles (HLA-DR2, HLA-
DQwl, HLA-DR3, HLA-DR4). 
In both SLE and JSLE, IL-1β patient  polymorphisms in the promoter region of IL-
1β gene rendering IL-1β overactive have been  discovered355,501, and therefore this 
finding could open new avenues for therapeutic approaches. Similarly, patient 
polymorphisms in the promoter region of the TNF-α gene being linked to LN 
predisposition have also been discovered502,503.  
Infliximab (a chimeric antibody) and Etanercept (a fusion protein), both TNF-α 
blockers, have been used in rheumatic diseases including rheumatoid arthritis (RA), 
psoriasis, Crohn’s disease, juvenile idiopathic arthritis, but also SLE. However, the 
TNF-α blockers did not only have successful results but have been known to induce 
autoantibody production and lupus-like syndrome in patients suffering from other 
autoimmune diseases than SLE504–506. In an open-label study, SLE patients (with either 
LN or arthritis) refractory to other therapies were treated with infliximab in combination 
with azathioprine or methotrexate and demonstrated decreased disease activity-the 
nephritic patients showed attenuation of proteinuria and the arthritic patients showed 
remission of arthritis-  although some developed urinary tract infections507. A long-term 
follow-up study by the same group, however, showed that long-term infliximab therapy 
-in contrast to short-term therapy- led to serious and severe adverse effects in patients, 
even cerebral lymphoma165. Anakinra, a non-glycosylated form of human IL-1Ra, has 
been widely used in systemic juvenile-onset RA patients445, was also able to improve 
arthritis symptoms in SLE patients with safety and efficacy508.  
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This ciGEnC study mainly focused on testing the effect of anti-TNF-α/IL-1Ra 
treatments as TNF-α and IL-1β treatments promoted the majority of pro-inflammatory 
proteins tested. Nonetheless, IFN-γ was found to significantly promote IP-10 and IL-10 
secretion -with IFN-α potentially contributing in even higher IP-10 and IL-10 levels as 
suggested by the combined cytokine treatments- whereas IL-13 had a specific effect on 
VCAM-1 production. It would therefore be very interesting but also important in terms 
of potential clinical implications, that future in vitro studies test the effect of IFN-γ, IFN-
α and IL-13 blockade/neutralisation in ciGEnC production pro-inflammatory proteins. 
In SLE patients, dose-response intravenous treatments with sifalimumab or 
rontalizumab, anti-IFN-α monoclonal antibodies, induced a dose-depedent reversal of 
the blood and skin type I interferon signature509. Furthermore AMG 811, an anti-IFN-γ 
monoclonal antibody, has been used in Phase Ib clinical trial in SLE patients with or 
without LN with good safety results, although further investigation is required to 
determine the usefulness of this agent in clinic510. In SLE or JSLE, no anti-IL-13 
monoclonal antibody or any other anti-IL-13 treatment has been used yet. It would 
however be interesting if anti-IL-13 antibody treatments were used in vitro to test their 
effect on human ciGEnCs and similarly, future studies could also investigate the effect 
of anti-IFN-α and anti-IFN-γ antibody treatments on ciGEnCs, especially after ciGEnCs 
treatments with pro-inflammatory stimuli-activated conditioned media derived from 
human immune cells, such as macrophages and T cells. 
6.5. STRING analysis for the urinary biomarkers 
In this study, the novel, laboratory-tested human urinary biomarkers for LN 
(AGP or ORM1, L-PGDS or PTGDS, TF, CP, NGAL or LCN2, MCP-1 or CCL2, 
VCAM-1) were not found to have any remarkable effect either on ciGEnCs’ pro-
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inflammatory phenotype or on ciGEnCs’ viability. Furthermore, the ciGEnCs were 
found to substantially express and produce only MCP-1 and VCAM-1.  
For these reasons, and to explore future avenues for in vitro laboratory research 
involving these biomarkers, a STRING network analysis was performed511 to investigate 
potential interactions among biomarkers and interesting pathways into which they could 
be involved. The protein-protein interaction (PPI) p-value was 2.14 x 10-7, indicating a 
strong possibility that real protein-protein interactions exist among the seven biomarkers 
(Figure 6.2).  
Associations traced from curated databases (light blue line), co-expression 
relationships (black line), textmining-derived (co-mentioned in PubMed abstracts) 
interactions (light green line) and  experimentally determined interactions (fuchsia line) 
were found among the biomarkers (Figure 6.2). AGP (or ORM1), NGAL (or LCN2), 
MCP-1 (or CCL2) and VCAM-1 were shown to be involved in immune system-related 
pathways (node colour: green) in contrast to TF, CP and L-PGDS (or PTGDS) that might 
be mainly involved in metabolism-related pathways (Figure 6.2).  
VCAM-1 and MCP-1, the two biomarkers substantially produced by ciGEnCs 
and remarkably modified by pro-inflammatory stimuli, were found to be involved in 
fluid shear stress-related pathways in atherosclerosis (node colour: red) (Figure 6.2). 
Having previously mentioned that fluid shear stress is an important player involved in 
GEnC pro-inflammatory activation30 that requires future investigation, it would be 
interesting to in vitro imitate fluid shear stress conditions; subsequently, potential 
changes in levels of MCP-1 and sVCAM-1 secretion as well as surface VCAM-1 
expression on ciGEnCs could be tested. Similarly, the effect of IL-17 on ciGEnCs, was 
not tested in this study and, yet, IL-17 is a cytokine with an important role in lupus as it 
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is involved in aberrant T cell responses512. In this analysis, MCP-1 (or CCL2) and NGAL 
(or LCN2) were shown to be involved in the IL-17 signaling pathway (node colour: 
purple) (Figure 6.2) and thus future in vitro studies could explore changes in MCP-1 
ciGEnC production following ciGEnC stimulation with IL-17 directly or, potentially, 
with T cell condtioned media (in which IL-17 presence will have been previously 
determined). NGAL was not found to be expressed by the ciGEnCs but it would be 
interesting to test the possibility of IL-17 specifically inducing NGAL expression by the 
ciGEnCs. 
Finally, MCP-1 and VCAM-1 were found to be involved in the pathway of  
advanced glycation end products (AGEs) and their receptor (RAGE) in diabetic 
complications (node colour: fuchsia) (Figure 6.2). More specifically, the AGE/RAGE 
signaling system has been found to to be involved in diabetic nephropathy via inducing 
vasculopathy; AGEs can elicit their effect via interaction with glomerular endothelium-
expressed RAGE, leading to endothelial cell oxidative stress and inflammation and 
activation of pathways such as the NF-κB pathway513–515. Therefore, future work could 
explore the effect of AGE treatments on ciGEnC pro-inflammatory activation whereas 
JSLE patient -with or without LN- plasma and serum samples could be tested for the 
presences of AGEs and/or soluble RAGE. Furthermore, ciGEnC treatment with LN-
related cytokines (such as TNF-α and IL-17) could give interesting results regarding 





Figure 6.2 STRING analysis for the novel urinary biomarkers  
(ORM1=AGP, PTGDS=L-PGDS, LCN2=NGAL, CCL2=MCP-1). 
 
6.6. Study limitations and the importance of specifically studying the human 
GEnCs 
As every in vitro study, this study had several limitations. First of all, an in vitro 
model cannot precisely imitate the procedures occurring within a live human organism 
or the complexity of the human renal structure. Also, only single ciGEnC culture was 
performed and no 2-D or 3-D co-culture models with ciGEnCs-podocytes-mesangial 
cells were developed; these models could be more accurate as cell-cell interactions affect 
and modulate the actions of a cell type along with factors secreted within their 
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microenvironment. Therefore, no cell-cell contact effect either between ciGEnCs and ci 
podocytes/mesangial cells or between ciGEnCs and neutrophils/macrophages was 
studied, which means that only the paracrine effects mediated by secreted factors were 
investigated. Fluid shear stress is another extremely important factor that could affect 
the behaviour of the human GEnCs along with pro-inflammatory stimulation and thus, 
future in vitro models using ciGEnCs should also investigate this parameter. 
With the serum samples, no concentration response was performed due to the 
limited number of samples available from active disease patients and this, together with 
the medications administered to patients, limits the possibilities of observing a strong, 
robust effect mediated by the serum samples. The time-points used in the study were 
also limited at 24 hours and in some cases also 4-hour time-points were used. Time 
response experiments expanding on more acute (1 hour or 2 hours) and more chronic 
time-points (48 hours-72 hours-96 hours-7 days) should definitely be performed in the 
future as LN is a chronic inflammatory disease. 
In a study in which 76 SLE patients (85% were women and 67% had biopsy-
proven LN) were enrolled along with 42 disease controls (having other forms of renal 
disease) and 80 HCs, the serum levels of IgA- anti-endothelial cell antibodies (AECA) 
were evaluated516. AECA had been previously found to cause HUVEC and human 
kidney endothelial cell dysfunction517,518 thus, this study also investigated their effect on 
HUVECs and primary human GEnCs516. The IgA-AECA prevalence in the sera of SLE 
patients with and without LN was 35% and 28% respectively whereas in the disease 
controls and HCs the IgA-AECA prevalence was 2% and 7% repsectively516. 
Furthermore, IgA-AECA levels correlated with disease activity and active renal 
lesions516. The human GEnCs were incubated for 24 hours with 5% sera from AECA-
positive LN patients and their proliferation rates that were measured via confluence 
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assay at both 0 and 24 hours indicated that the IgA-AECA sera could significantly 
decrease the GEnCs’ proliferation rates516. This finding suggests that the IgA-AECA can 
recognise and potentially bind to the human GEnCs and induce GEnC damage.  
It is important to note that the 24-hour use of 5% sera concentration, same time-
point and same serum concentration used for this PhD research project, induced 
significant reduction in the ability of primary human GEnCs to proliferate. The 24-hour 
serum effect on ciGEnC proliferation, however, was not tested in this study and thus, it 
would be very interesting if future studies could investigate a potential LN serum effect 
on ciGEnC proliferation but also ciGEnC death.  
In a recent in vitro study using SLE sera from 25 patients and HC sera from 14 
healthy individuals, HUVECs were in vitro treated with 20% sera (for 6 or 24 hours) to 
detect changes in endothelial NO synthase (eNOS) expression and with 50% sera to test 
changes in HUVEC NO production and in neutrophil migration and adhesion519. The 
SLE sera were able to significantly induce increased eNOS mRNA expression but at the 
same time to reduce NO production519. Furthermore, the SLE sera significantly 
promoted neutrophil migration towards the HUVECs519. With NO production being an 
important endothelial cell function, it would be interesting if future ciGEnC treatments 
with LN sera were performed to assess changes in NO production and eNOS expression. 
In a study testing the effect of uremic damage on human endothelial cells pooled 
human serum from HCs and patients with CKD suffering from uremia was used to treat 
HUVECs520. More specifically, HUVECs were treated with four different groups of 
pooled human sera including, HC sera, pre-dialysis patient sera, peritoneal dialysis 
patient sera and haemodialysis patient sera520. The cells were stimulated for 1, 5 and 15 
minutes with 2% human pooled sera from the four different groups and subsequently, 
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activation of NF-κB and of the p38 mitogen-activated kinase pathway (MAPK) was 
assessed520. The sera from the three groups of CKD/uremic patients were able to 
significantly promote activation p38 MAPK and NF-κB compared to the HC sera at 1 
and 15 minutes520. Similar to the HUVECs, 10% sera from LN patients have been shown 
to significantly enhance neutrophil chemotaxis toward primary human GEnCs compared 
to 10% HC sera521.  
The most notable effect in the activation of these pro-inflammatory pathways 
was attributed to the pooled sera from the peritoneal dialysis patients a finding that 
correlated with increased presence of endothelial damage markers -soluble VCAM-1, 
ICAM-1, vWF, E-/P-selectin and elevated levels of circulating endothelial cells-, 
especially in the plasma of the peritoneal dialysis patients520. It is important to note here 
that use of only 2% serum concentration was able to induce an important effect in the 
activation of important pro-inflammatory pathways in HUVECs in vitro, suggesting that 
the use of pooled sera could have a robust effect in endothelial cell activation. Thus, the 
use of pooled active and inactive LN sera to treat ciGEnCs in vitro, could be considered 
in the future. Serum starvation prior to treatments with HC and patient sera should also 
be considered. 
When human GEnCs, labeled for detection of glycosaminoglycans (GAGs), 
were exposed for 24 hours in 10% plasma from patients with heavy albuminuria or 10% 
plasma from HCs, the GAGs, which are glycocalyx components, were reduced 
following albuminuria patient plasma activation522. The endothelial glycocalyx is a very 
important part of the human GEnCs that was not studied in this project. It would 
therefore be important to elucidate the role and modulation of the endothelial glycocalyx 
composition in lupus renal disease with the in vitro use of human ciGEnCs. 
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When human arterial and human venous endothelial cells were treated for 24 
hours with 20% sera collected from end-stage renal failure patients before and after 
hemodialysis treatment, interesting changes occrurred523. The post-hemodialysis patient 
sera induced significant changes in both arterial and vein endothelial cells compared to 
the pre-hemodialysis sera, but in a completely opposite way523. More specifically, the 
post-hemodialysis patient sera were able to increase the secretion -among others- of IL-
6 and vWF by venous endothelial cells whilst in the same time they significantly reduced 
IL-6 and VEGF synthesis by the arterial endothelial cells523.  
In another study in which HUVECs were in vitro treated for different time-points 
(8-72 hours, depending on the experimental assays) with 5%, 10% and 20% pre- and 
post-hemodialysis sera from patients with CKD the effect of hemodialysis treatment, a 
process that leads to removal of uremic toxins (such as urea) from the CKD patients, 
was highlighted524. In contrast to the post-hemodialysis serum treatments, the pre-
hemodialysis serum treatments induced higher apoptotic HUVEC levels, reduced the 
cell numbers, and decreased the number of migrating endothelial cells in a wound-
healing assay, in a dose-dependent manner524. Furthermore, the pre-hemodialysis 20% 
sera were able to significantly increase the production of ECM-degrading and ECM-
remodeling proteins, such as TIMP1, TIMP2, collagen IV and elastin524. In this research 
project, TIMP1 and COL1A1, COL1A2, COL3A1 and COL4A1 mRNA expression were 
tested, but without revealing intriguing changes following treatments with active LN, 
inactive LN and HC sera. Future work could further investigate the serum effect on 
TIMP2 and elastin mRNA expression as well as on the expression of more types of 
collagen. 
It also has to be noted that not all cytokines involved in JSLE and LN were tested; 
for example, the effect of IL-17A on ciGEnC activation was not investigated. IL-17A 
328 
 
has been shown to be produced by kidney-infiltrating T cells and promotes local renal 
inflammation in lupus disease, via various mechanisms including cytokine and 
chemokine production and immune cell infiltration512,525. Similar to IL-17A, the effect 
of adaptive immune cells and more specifically the effect of T cells on ciGEnCs and 
chronic renal disease was not investigated, although Th17 cells have been observed to 
promote kidney injury in LN526. Instead, only the effect of innate immune cells 
(neutrophils and macrophages) was investigated in this study. Finally, only immune cells 
derived from healthy adult donors and not from JSLE patients were utilised in this study. 
The novelty of data and findings arising from this work lies in the fact that the 
human endothelial cells are not a homogeneous cell population located in a specific part 
of the human body. On the contrary, many different types of human endothelial cells can 
be found in a plethora of tissue microenvironments located in organs such as the heart, 
brain, eye, lungs, skin, kidney, the placenta and other organs. The endothelial cells line 
the lumen of veins and arteries as well as of larger or smaller blood vessels and 
capillaries.  
Thus, although the different types of human endothelial cells share a number of 
signature functions (blood circulation-tissue barrier, angiogenesis, blood flow 
homeostasis and tight regulation of vasodilation/vasoconstriction, response to pro-
inflammatory stimuli and to oxidative stress, fluid shear stress sensing), they can also 
attain relatively altered phenotypes that accommodate the specific requirements of the 
local microenvironment at which they are present. This could mean that depending on 
the origin of each vascular bed, the endothelial cells could exert their commonly shared 
basic functions via exhibiting differential responses to certain stimuli and via using 
differential mechanisms and/or effector molecules. 
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For example, vWF, an important endothelial cell-specific marker involved in 
platelet adhesion and blood co-agulation527, has been shown to be more highly expressed 
in veins compared to arteries and arterioles528. Such differences, have been suggested to 
occur under the influence of certain local microenvironments, such as the cardiac 
mircoenviromnment528. In a study in which endothelial cells were isolated from four 
main human foetal organs –kidneys, liver, heart and lung- vWF protein expression was 
tested529. The heart endothelial cells displayed high vWF expression and the lung 
endothelial cells exhibited in general high vWF levels, comparable to those expressed 
by the heart endothelial cells529. In the liver, the endothelial cells expressed lower vWF 
levels529. Within the kidney, the GEnCs expressed higher vWF levels compared to the 
peritubular microvascular endothelial cells529. Differences in the structure of 
fenestrations among endothelial cells in different organs were also observed529. 
Atherosclerosis leading to vascular lipid deposition and chronic inflammation, 
principally affects the arteries –including the aorta- and not the veins530. For this reason, 
an in vitro study comparing the expression profiles of atherosclerosis-related genes in 
primary human saphenous vein endothelial cells (HSVECs) versus primary human 
coronary artery endothelial cells (HCAECs) was performed530. This study revealed 
striking differences between the HSVECs and HCAECs at both unstimulated and 
oxidative stimuli-induced conditions; in the HSVECs, atheroprotective genes involved 
in cell growth (important for the integrity of the endothelium), oxidoreductase activity, 
extracellular matrix deposition and anti-inflammatory responses were found to be 
significantly upregulated and more highly expressed compared to the coronary artery 
endothelial cells530. Furthermore, genes involved in the NF-κΒ pathway were found to 
be downregulated by the HSVECs530. In contrast, genes involved in adhesion, apoptosis 
330 
 
and cellular proliferation, functions tightly-associated to atherosclerosis, were found to 
be significantly upregulated by the HCAECs530. 
In another in vitro study, neutrophil recruitment following TNF-α and IL-1β 
stimulation under static and blood flow (via shear stress application) conditions was 
compared among HUVECs, human umbilical arterial endothelial cells (HUAECs) and 
human coronary arterial endothelial cells (HCAECs)531. Although under static 
conditions all three types of TNF-α and IL-1β-stimulated endothelial cells were able to 
effectively recruit neutrophils, under shear stress conditions TNF-α and IL-1β-
stimulated HUAECs and HCAECs lost their ability to recruit flowing neutrophils531. On 
the other hand, HUVECs were still able to efficiently recruit neutrophils after IL-1β but 
not after TNF-α stimulation, an effect that could largely be attributed not only to the 
shear stress force but also to the lack of human recombinant basic FGF (that is able to 
bind to the basement membrane) within the HUVEC media (in contrast, FGF was present 
in both HUAEC and HCAEC media)531. Another study using HUVECs has shown that 
under prolonged culture of HUVECs, basement membrane deposition could impair 
TNF-α-mediated neutrophil recruitment532. Furthermore, in bovine aortic endothelial 
cells changes in the subendothelial ECM composition have been shown to influence 
shear stress-induced NF-κΒ activation533. Thus, it seems that under local shear stress and 
changes in basement membrane and ECM composition, the endothelial cells can 
differentially alter their phenotypes. 
The importance of vascular bed-specific flow patterns has also been stressed by 
another in vitro study, using HSVECs and HCAECs534. HSVECs and HCAECs were 
stimulated with TNF-α and were both exposed to either coronary artery flow or venous 
artery flow; the coronary artery flow was physiological for the HCAECs and the venous 
artery flow was physiological for the HSVECs534. Thus, when the TNF-α-stimulated 
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HSVECs were exposed to coronary artery flow, mononuclear cell adhesion was 
increased compared to both TNF-α-stimulated HSVECs and HCAECs exposed to 
coronary artery flow534. This increased mononuclear adhesion was accompanied by 
increased HSVEC secretion of soluble VCAM-1, ICAM-1 and E-selectin compared to 
HCAECs534. In terms of adhesion molecule mRNA expression, only coronary artery 
flow exposure could induce HSVEC VCAM-1 mRNA expression along with ICAM-1 
and E-selectin mRNA expression whereas venous artery flow induced only ICAM-1 and 
E-selectin mRNA expression534. Venous and artery flow exposure had a strikingly 
different effect on TNF-α-stimulated HCAECs (reduced VCAM-1 and E-selectin mRNA 
expression) but coronary artery flow was able to upregulate HCAEC ICAM-1 mRNA 
expression534. 
In the same study that assessed vWF expression in human endothelial cells 
isolated from four principal organs –heart, lung, kidney, liver-529, RNA-sequencing was 
performed using in vitro cultured human heart, lung, kidney and liver endothelial cells, 
to detect potential organ-specific gene expression signatures. All four types of human 
endothelial cells demonstrated a common and high expression of transcription factors 
(and co-factors) involved in vascular development and remodelling as well as in VEGF 
signaling529. At the same time, all four types of human endothelial cells are also 
differentially expressing genes involved in organ-specific growth and development with 
the kidney endothelial cells expressing higher levels of genes involved in 
regionalisation, pattern specification processes, nephron development, embryonic organ 
morphogenesis and hormone secretion and transport (Angpt2, HOXB7, HOXD8, 
HOXA9, HOXB9, EXOC3L2, ZNF366, ZNF503-AS1, ELAVL2, NLGN4X, MMP7)529. 
The homeobox (HOX) transcription factor genes that were particularly enriched by the 
human kidney endothelial cells are highly involved in kidney development and 
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patterning535,536 and thus, modulations in their expression levels/epigenetic pattern under 
inflammatory conditions could be studied in ciGEnCs in the future.  
In this PhD research project, two important adhesion molecules were found to be 
upregulated by the ciGEnCs following pro-inflammatory stimulation; VCAM-1 and 
ICAM-1. The cytokines and LPS tested, had a differential effect on ciGEnC surface 
expression of VCAM-1 and ICAM-1, suggesting that different pro-inflammatory stimuli 
could lead to recruitment of different kidney-infiltrating immune cell populations. IL-13 
had an effect exclusively on surface VCAM-1 expression, only in combination with 
TNF-α. ICAM-1 expression was significantly increased by TNF-α, IL-1β and LPS. 24-
hour ICAM-1 upregulation by TNF-α, IL-1β and LPS has also been confirmed in 
HUVECs385,537. Similar to the human ciGEnCs and in contrast to other types of human 
endothelial cells (carotid, coronary endothelial cells), lack of 24-hour IL-1β- and LPS-
mediated upregulation of surface VCAM-1 has been previously observed in HUVECs 
and human subclavian endothelial cells537. 
Thus, it is important, to highlight that this project is further enhancing the notion 
supported by a variety of previous studies that the local microenvironment into which 
the human endothelial cells are found, can significantly influence and alter their response 
to a range of stimuli.  The human endothelial cells are therefore generally characterised 
by high heterogeneity and by unique phenotypes and no definite conclusions should ever 
be extrapolated from general results of studies using human endothelial cells different 
than those of specific interest. Hence, further human GEnC-specific studies are 
necessary to elucidate and accurately depict their unique phenotype. 
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6.7. Future work: Taking human GEnC research to the next step  
This study was mainly focused on investigating the pro-inflammatory profile of 
human GEnCs in the context of LN. However, the human GEnCs have more than one 
important function. 
Apart from being potent pro-inflammatory mediators of renal pathogenesis, they 
are also an integral part of the GFB and via their glycocalyx and fenestrations they can 
regulate both the GFB net charge and permeabilty signficantly contributing to the highly 
selective filtering capacity of the GFB. It is therefore very possible that these important 
functions of ciGEnCs could be significantly impaired upon renal inflammation. For this 
reason, studying the effect of pro-inflammatory activation on ciGEnC permeability in 
vitro (for example via albumin permeability transwell assays) would be a very important 
step onto elucidating all the different procedures and mechanisms of GEnC involvement 
in renal disease. Cytoskeleton remodelling and changes in fenestration number or 
structure could also generate interesting findings in terms of human GEnC research. 
Furthermore, it is necessary that more chronic models of ciGEnC stimulation 
should be introduced in order to be able to identify potential structural and functional 
changes during the course of the renal disase. To this end, co-culture models with 
podocytes, mesangial cells and both innate and adaptive immune cells derived from 
JSLE patients would be of paramount importance in order to create more realistic in vitro 





6.8. Final Conclusions 
This study aimed to address the hypothesis that the human GEnCs are not just 
passive bystanders but are actively involved in the development and perpetuation of 
renal inflammation in LN. 
This study has demonstrated that: 
1. The human ciGEnCs respond to pro-inflammatory cytokines (TNF-α, IL-1β, IL-13, 
IFN-γ) and LPS via significantly upregulating production of various pro-inflammatory 
proteins and via inducing NF-κB and STAT-1 activation, while retaining their viability. 
2. The human ciGEnCs can be affected by their surrounding microenvironment to 
express pro-inflammatory and pro-fibrotic genes, as shown by serum and THP-1 
macrophage conditioned media treatments. 
3. No ciGEnC pro-inflammatory phenotype induction or apoptotic/necrotic cell death 
occurred following treatments with novel laboratory LN urinary biomarkers. 
Whilst acknowledging the limitations of this study, important results were 
generated, demonstrating that human GEnCs are in fact potent producers of pro-
inflammatory cytokines, chemokines, blood cell growth factors, adhesion and co-
stimulatory molecules. In particular, these are all important factors that have been 
associated with the aetiopathogenesis of LN and/or JSLE itself (Table 6.1 & Figure 
6.1).  
The human GEnCs could therefore be a promising target for kidney-specific 
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